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Summary
Sensitive radioimmunoassays (RIAs) were developed and 
validated for deoxyuridine triphosphate (dUTP) and deoxycytidine 
triphosphate (dCTP), while partial development and validation was 
achieved for RIAs for deoxythymidine triphosphate (dTTP) and 
cytosine arabinoside triphosphate (ara.CTP). Because of a lack of 
complete antibody specificity, pre-RIA separation of these four 
compounds from cross-reacting nucleotides was required. Liquid and 
affinity chromatographic and degradative techniques were optimised 
for this purpose. Antibody specificity was also improved for dUTP 
and dTTP by the use of affinity chromatography to remove a cross­
reacting portion of the immunoglobulin.
The two validated assays have been given initial applications 
in measuring intracellular pool sizes of dUTP and dCTP. dUTP, not 
found in untreated cells and implicated in the toxicity of certain 
anti-cancer agents, was found to occur in increasing, dose-related, 
concentrations in a human lung carcinoma cell line treated with a 
thymidylate synthase inhibitor. dCTP, an endogenous and highly 
successful competitor of ara.CTP, the active form of the anti- 
leukaemic drug, cytosine arabinoside (ara.C), has been measured in 
both ara.C-sensitive and ara.C-resistant human leukaemic cell lines 
and L5178Y mouse lymphoma cells, in order to see if a correlation 
existed between such resistance and raised dCTP concentrations.
These RIAs represent a novel way of measuring compounds which 
were previously difficult to quantify in small numbers of cells - 
(10 ) - due to their presence in very low concentrations. The dUTP 
assay in particular achieves a unique combination of specificity and 
sensitivity, in a validated assay, for the measurement of this 
compound in the presence of dTTP. The dTTP assay, nearing 
validation, will provide similar advantages over other published 
methods, for measuring low concentrations of dTTP in the presence of 
high levels of dUTP. The dCTP and ara.CTP assays may, it is hoped 
be of use where cases of resistance to ara.C occur clinically. It 
is also anticipated that the three assays for the endogenous dNTPs 
will be used for studies on the mode of action of new anti-cancer 
agents both in vitro and in vivo.
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Chapter 1
INTRODUCTION
"Deoxyribonucleotides are situated at the entrance of a one­
way street leading to a dead end, DNA synthesis."
Peter Reichard and Bjorn Nicander 
Current Topics in Cellular Regulation 
(1985) Volume 26, p403.
The four substrates used in the synthesis of DNA are the two 
pyrimidine-based dNTPs, dTTP and dCTP, and the two purine-based 
dNTPs, dATP and dGTP. A fifth endogenous dNTP, the pyrimidine- 
based dUTP, can act as an "unnatural" substrate for DNA synthesis, 
being misincorporated in place of dTTP (Bessman et al., 1958; 
Richards et al., 1984).
For reasons of brevity and simplicity it is the role of the 
pyrimidine-based dNTPs which is emphasised in this thesis.
The structures of the three pyrimidine dNTPs are shown in 
Figure 1.1.
The dNTPs are products of complex biosynthetic pathways over 
which they exert stringent regulatory effects. Because their 
presence in the cell in balanced ratios is necessary for the 
replication of viable cells (Haynes, 1985), the disruption of these 
ratios is often used as a means to kill tumour cells, and a large 
range of drugs has been developed to this end. Abnormal ratios of 
dNTPs have been found in tumour cells prior to drug exposure 
(Fridland, 1984), and it has also been shown that genetic change 
can result from such abnormalities (Kunz, 1982).
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Figure 1.1 The Structures of the Three Endogenous 
Pyrimidine dNTPs - dCTP, dTTP and dUTP
1.1 Regulatory Effects of dNTPs
The dNTPs, and the nucleotides preceding them in their 
biosynthetic pathways, are regulators of the pathways, maintaining 
control over the concentrations of dNTPs and thus controlling DNA 
synthesis, and cell replication.
This regulation is exerted by inhibitory and stimulatory 
effects on metabolic and catabolic enzymes (Harrap & Renshaw, 1980; 
Henderson & Hunting, 1981; Keppler & Holstege, 1982). 
Substrate/enzyme concentrations and activities are carefully 
balanced in the cell throughout its cycle to maintain the pattern of 
replication normal for that cell, and to help to ensure the accuracy 
and stability of replicated DNA.
1.1.1 Changes Throughout the Cell Cycle
Both total cellular pool sizes and compartmentalisation of 
dNTPs within the cell have been shown to change throughout the cell 
cycle, so that the dNTPs are generally present in higher 
concentrations, and are concentrated in the nucleus, at S-phase 
(Harrap & Renshaw, 1980). Different types of cell, however, may 
show different patterns of peak concentration of dNTPs. Human 
thymocytes, for example, have been shown to have a lower dCTP pool 
in S-phase then in G^, although the other three dNTP DNA precursors 
were at their highest concentration in S-phase (Cohen et al., 1983), 
whereas CHO cells showed the highest concentration of all four 
precursors in S-phase (Skoog & Bjursell, 1974).
dNTPs are still synthesised, although only in small amounts, 
when DNA replication is not taking place. Mouse fibroblast 3T6 
cells were shown to continue to synthesize dTTP and dCTP even though 
their replication was blocked by aphidicolin (Reichard & Nicander, 
1985), and resting human peripheral lymphocytes untreated in any way 
were found to have low concentrations of dNTPs (Cohen et al., 1983).
1.1.2 Pyrimidine dNTP Biosynthetic Pathways
The d£ novo pathway to pyrimidine dNTP synthesis in eukaryotes 
is illustrated schematically in Figure 1.2.
The d£ novo pathway can be supplemented or substituted by pre­
formed or salvaged nucleosides, such as Urd, dUrd, Cd, dCd and dTd, 
or their bases, taken from within the cell or from its environment. 
Intracellular bases and nucleosides are mainly derived from the 
breakdown of nucleic acids and specific enzymes exist for their 
metabolism to nucleotides. This use of nucleosides varies among 
tissues, cell lines, species, and also throughout the cell cycle 
(Keppler & Holstege, 1982). Bases such as uracil, orotate, cytosine 
and thymine, can be utilized by the salvage pathways, enzymes being 
present in the cell for their phosphoribosylation, but generally 
they are poor substrates for nucleotide synthesis due to their rapid 
degradation within the cell (Cooper et al., 1972; Keppler & 
Holstege, 1982).
The feedback effects which dTTP and dCTP have been shown to 
exert on enzymes in the pathway are indicated in Figure 1.2, and
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FIGURE 1.2. Schematic Representation of de novo 
Pathways of Pyrimidine Nucleotide 
Biosynthesis
similar regulatory effects are shown by the purine dNTPs, as well as 
by ribonucleotides such as UTP and CTP (Keppler & Holstege, 1982).
dCTP has been shown to act as an inhibitor of the salvage 
pathway enzyme deoxycytidine kinase (EC 2.7.1.74) (Momparler & 
Fischer, 1968; Durham & Ives, 1969). This inhibition is 
reversible where elevated levels of dTTP are present, thus 
maintaining a balance of dCTP and dTTP concentrations (Harrap & 
Renshaw, 1980). dCTP is a positive effector of dCMP deaminase 
(EC 3.5.4.12) (Scarano et al., 1967; Momparler, 1974; Ellims et 
al., 1983A), with the ability to overcome the inhibition of this 
enzyme by dTTP (Scarano et al., 1967; George & Cory, 1979; Ellims 
et^  al., 1983A). The deamination of dCMP to dUMP has been shown to 
be a major source of dTMP and thus dTTP in human lymphocytes and 
Novikoff hepatoma cells (Tyrsted, 1975; Jackson, 1978), and the 
level of activity of dCMP deaminase has been found to correlate with 
tumour growth rate (George & Cory, 1979). dCTP pool size was shown 
to correlate with the rate of DNA synthesis in several cell lines 
and it was concluded that there was a closer correlation between 
these two parameters than has been shown for the other three dNTPs, 
(Thelander & Reichard, 1979). Despite these observations, there has 
been no evidence to show feedback control by dCTP on ribonucleotide 
reductase (EC 1.17.4.1) which reduces UDP and CDP to dUDP and dCDP 
respectively, and which, as it is also involved in the reduction of 
purine nucleotides to dATP and dGTP, has a key regulatory function 
in the route to DNA precursor synthesis. It has, however, been 
demonstrated that dCTP has a role as a positive effector of the DNA
polymerizing enzyme, DNA polymerase a (EC 2.7.7.7.) (Meuth et al., 
1976; Nicander & Reichard, 1981; Newman & Miller, 1985 ) and in 
this way plays an important part in regulating DNA synthesis.
dTTP regulates the salvage of dUrd and dTd by inhibitory 
action on deoxyuridine kinase/thymidine kinase (EC 2.7.1.21) (Maley 
& Maley, 1962; Bresnick et al., 1964; Hashimoto et al., 1972) 
which catalyse the phosphorylation of these nucleosides to dUMP and 
dTMP. The concentration of dUMP can also be regulated by dTTP via 
inhibition of dCMP deaminase (Scarano et al., 1967; George & Cory, 
1979; Ellims et al., 1983A), and via the allosteric inhibition of 
ribonucleotide reductase (Moore & Hurlbert, 1966; Reichard, 1972). 
In the latter case, dCTP synthesis is also inhibited, but can be 
restored by the salvage of cytidine. dTTP only becomes a negative 
effector of ribonucleotide reductase when its levels are abnormally 
elevated. The usual positive and negative effectors of CDP and UDP 
reduction are ATP and dATP (Keppler & Holstege, 1982). A further 
enzyme involved in dTTP synthesis is thymidylate synthase 
(EC 2.1.1.45), which, with the coenzyme 5,10-methylene 
tetrahydrofolate, catalyses the conversion of dUMP to dTMP. The 
regeneration of tetrahydrofolate is in turn catalysed by 
dihydrofolate reductase (EC 1.5.1.3) (Keppler & Holstege, 1982). A 
marked inhibition of thymidylate synthase has been demonstrated in 
cells grown in culture medium supplemented with dTd, suggesting a 
regulation by thymidine nucleotides (Rode et al., 1980). It has 
also been suggested that dTTP is a negative effector of DNA 
polymerase a when present in the cell in excess (Newman & Miller, 
1985).
dUTP has not been shown to exert any direct regulatory effects 
on the biosynthetic pathway. Its importance appears to be 
as a source of dUMP, and therefore indirectly, of dTTP. It has 
been shown to be degraded, in both prokaryotes and eukaryotes, by 
the action of the highly specific enzyme dUTP pyrophosphatase 
(EC 3.6.1.23), to dUMP and pyrophosphate (Greenberg & Sommerville, 
1962; Bertani et al., 1963; Grindey & Nichol, 1971). dUTP is an 
effective substitute for dTTP as a substrate for DNA polymerase 
(Bessman et al., 1958) and its concentration in cells has been 
undetectable by methods available to date, because of the rapid 
degradative action of the pyrophosphatase. The efficient 
maintenance of such low concentrations of dUTP has been postulated 
to be a result of cellular avoidance of its ready misincorporation 
into DNA (Bjursell & Skoog, 1980), such incorporation leading to a 
lack of accuracy in DNA replication or damage to the replicating 
strands due to instability or incomplete repair (Richards et al.,
1984).
1.2 The Consequences of dNTP Pool Imbalance
DNA synthesis has certain requirements in the cell, i.e.:
a suitable supply of dNTPs for polymerization, a polynucleotide
template/primer, DNA polymerase, and an appropriate concentration of
2+
the divalent cation Mg (Haynes, 1985).
Incorrect concentrations and ratios of the appropriate dNTPs 
have been shown to have several important consequences for DNA 
synthesis. They are capable of stopping DNA synthesis altogether,
or of affecting the accuracy and the stability of newly replicating 
strands by base misincorporation. Mechanisms existing within the 
cell for the repair of such misincorporation may either not be able 
to deal adequately with it if its frequency is too great, or may 
themselves be adversely affected by the pool imbalances. Thus 
inadequate repair following DNA damage caused by X-rays, UV light or 
carcinogens, may be a consequence of imbalanced dNTP pools in the 
cell. Such imbalances have also been demonstrated to be capable of 
causing heritable mutagenic changes in DNA, and they can thus cause 
genetic change (Kunz, 1982).
1.2.1 DNA Synthesis
One possible consequence of imbalanced dNTP pools is the 
cessation of DNA synthesis on the critical depletion of any one of 
the precursors (Meuth, 1984). This could occur, for example, on the 
depletion of the dCTP pool when ribonucleotide reductase is 
inhibited by elevated dTTP levels and a further supply of dCTP is 
not available via the salvage pathway.
Working with in vitro pool-altered CHO cells and with mouse 
3T6 fibroblasts, several groups have shown that there is a strong 
correlation between relatively low dCTP pools and a marked decrease 
in the rate of DNA synthesis (Meuth et al., 1976; Nicander & 
Reichard, 1981). This finding has been supported by Newman &
Miller, (1985), who further noted a correlation between enhanced DNA 
synthesis and an excess of dCTP; they proposed that dCTP is a 
positive allosteric regulator of DNA polymerase a activity.
Further, dTTP has been proposed as a negative regulator of 
polymerase a , with inhibition of DNA synthesis appearing to 
correlate with changes in the dTTP/dCTP ratio compared with the 
steady state ratio (Newman & Miller, 1985).
It has also been suggested that control of the activity of DNA 
primase (EC 2.7.7.6) is exerted by dNTPs (Parker & Cheng, 1987).
This enzyme produces a ribonucleotide strand of about ten bases, and 
the 3 '-hydroxyl of this primer is then used by DNA polymerase ot to 
begin DNA synthesis. Perturbation of dNTP pools could inhibit DNA 
primase and thus inhibit DNA synthesis. dTTP and dCTP in particular 
were shown to exert an inhibitory influence on the primase, with a 
lesser inhibitory effect shown by dUTP and dATP.
1.2.2 Genetic Consequences of dNTP Pool Imbalances
Agents or conditions that alter DNA precursor metabolism are 
capable of causing genetic change (Kunz, 1982; Barclay et al., 
1982). In vitro experiments with a number of DNA synthesis systems 
have shown the strong correlation that exists between the 
presence of correctly balanced concentrations of dNTPs in the 
reaction mixture and the replicational fidelity of DNA (Kunz, 1982; 
Das et al., 1985).
It has been shown both in prokaryotes and eukaryotes, in vitro 
and in vivo, that unbalanced precursor pools can cause a wide range 
of effects, including loss of cell viability, DNA strand breakage 
and degradation, chromosome breaks, exchanges and structural
alterations, oncogenic transformation, mutagenesis and the 
enhancement of mutagenesis by agents such as Brd Urd and EMS, and 
also altered sensitivity to UV light and X-rays (Kunz, 1982).
Thymidine in particular has been implicated in genetic damage 
to cells, either when they are starved, or given an excess,of dTd 
(Meuth, 1984A). dTd nucleotide deprivation was demonstrated to 
cause chromosome and chromatid breaks in human bone marrow cells and 
human lymphoblasts (Jensen, 1967; Ryan et al., 1965), and in mouse 
oocytes (Hansmann, 1974). DNA strand breaks and degradation were 
shown to occur following depletion of dTTP pools in prokaryotes such 
as Escherichia coli (Buick & Harris, 1975) as well as in human 
fibroblasts, T-cells, and promyelocytic leukaemia cells (Sedwick ^t 
al., 1981; Richards et al., 1985). Human fibroblasts and HeLa 
cells have also undergone mutagenesis following dTd deprivation 
(Dimnik & Hoar, 1981), as have mouse embryo fibroblasts (Landolph & 
Jones, 1982), and prokaryotes such as Salmonella typhimurium (Holmes 
& Eisenstark, 1967). Oncogenic transformation has been found to 
follow dTd starvation in mouse embryo fibroblasts (Jones et al., 
1976).
It has been shown that uracil misincorporation may account for 
the strand breaks found in DNA following induced dTd deprivation, or 
when cells are deficient in dUTP pyrophosphatase (see section 
1.2.3). Incorporation of uracil into DNA has been demonstrated to 
occur in the presence of depleted dTd pools in bacteriophage A and 
B. subtilis (Hays et al., 1981; Makino & Munakata, 1978), and also 
in human lymphocytes (Goulian et al., 1980) following exposure to
the dTd depleting drug MTX. Short fragments of DNA have been found 
to occur in mutants of Ej^  coli deficient in the dUTP degradative 
enzyme dUTP pyrophosphatase (Tye et al., 1977).
Excess dTTP has been found to cause mutagenesis in mouse 
lymphoma cells (Anderson, 1975), and to give rise to chromosome 
breaks and aberrations in CHO cells (Anderson et al., 1981). The 
known mutagenicity of physical and chemical agents such as UV light, 
X-irradiation and monofunctional alkylating agents has been shown to 
be altered after exposure of cells to excess dTd. However, Meuth 
(1984) showed that the mutagenicity of UV to CHO cells was 
significantly decreased by a 20-fold increase in dTTP pools over 
dCTP pools, while Booth et al., (1987) showed that a similar induced 
increase in dTTP in X-irradiation resistant cells caused a 
significant increase in the level of resistance. However, the 
toxicity and mutagenicity of the alkylating agent EMS to CHO cells 
and Chinese hamster V79 cells was enhanced by the presence of 
excess dTTP pools, as demonstrated by Brennand et_ al•, (1981) and 
Meuth (1981). It is clear therefore, that a variety of effects of 
excess dTTP, some paradoxical, have been demonstrated in different 
cell types by different groups of workers.
Excess dCTP has not so far been implicated in such a wide 
range of damaging actions to DNA, but was shown to be mutagenic in 
CHO cells and mouse S49 T-lymphoma cells (Meuth et al., 1979; 
Weinberg et al., 1981), and chromosome aberrations were found to 
occur in CHO cells and mouse lymphoma cells following the addition 
of excess dCd to the culture medium (Anderson et al., 1981). High 
levels of dCTP have also been shown to be implicated in the enhanced
mutagenesis of Brd Urd in hamster melanoma cells (Davidson &
Kaufman, 1978), as have enhanced pool sizes of dATP and dGTP 
(Kaufman & Davidson, 1979). Raised pool sizes of these two purine 
nucleotides have given rise to chromosome aberrations and breaks in 
rodent cells (Anderson et al., 1981) and human leucocytes (Kihlman, 
1963).
DNA damaging effects such as those described above have been 
ascribed to changes in one dNTP pool or another, but a change in the 
pool size of one dNTP will almost certainly cause alterations in 
other NTP and dNTP pools. For example, excess dTd will cause dCTP 
pool depletion by feedback inhibition of ribonucleotide reductase, 
so that it may be alterations in pool ratios rather than in the 
absolute size of one pool, which influence the effects on DNA.
dNTP pool imbalances are thought to facilitate replication 
errors. Many in vitro studies using imbalanced mixtures of dNTPs 
and purified DNA polymerases ("pool bias experiments"), have found 
that the error frequency of various DNA polymerases was partly 
dependent on the dNTP composition present (Kunz, 1982). Errors 
increased with an increase in the concentration of the incorrect 
nucleotide or with a decrease in concentration of the correct 
nucleotide (Seal et al., 1979; Loeb et al., 1981; Das et al.,
1985). Mutation frequency was directly proportional to the 
concentration of the incorrect nucleotide, and misincorporation of 
the biased nucleotide was demonstrated.
Misincorporation of dNTPs into the RNA primer for DNA is 
another means by which a lack of accuracy could arise in newly 
replicated DNA. It has been shown that this occurs, as well as a 
shortening of the primer, where dNTP pools are expanded so that 
their ratio to NTPs is abnormally increased (Eliasson & Reichard, 
1979; Tseng & Goulian, 1980).
1.2.3 Secondary DNA Structure and Base Misincorporation
Both base composition and sequence have an effect on DNA 
secondary structure. Thus base sequence affects parameters within 
the helix such as the tilt of the plane of the base pair relative to 
the helix axis, and the roll of the planes of adjacent bases into 
one another (Lumonossoff et al., 1981; Patel ejt al., 1982).
Base stacking interactions are important to the overall 
stability of nucleic acid conformation, as they make an important 
energy contribution to the structure (Richards et al., 1984). 
Misincorporation of e.g. uracil, causes structural problems for DNA 
helices. Although thymine and uracil have almost equal hydrogen 
bonding strengths, the stacking interactions of thymine are about 
50% greater than those of uracil. Synthetic polynucleotides 
containing thymine melt at higher temperatures than isomeric 
polynucleotides containing uracil (48°C compared with 35°C) (Gill et^ 
al., 1974) and it is suggested that structural instability also 
occurs under physiological conditions (Richards et al., 1984).
An unstable DNA molecule could result in instability of the 
chromatin, as the bonds giving DNA its stable three-dimensional 
configuration are shared with the various proteins which are 
associated with DNA, such as the histones and DNA and ENA 
polymerases (Watson et al., 1987). Thus, an unstable DNA helix 
could lead to major difficulties for the cell in e.g. replication 
and transcription.
1.2.4 DNA Repair Mechanisms
Damage to DNA can be corrected by enzymatic mechanisms present 
in the cell to repair damage by environmental mutagens or from 
spontaneous lesions. The enzymes repair or by-pass such damage by 
mechanisms including base and nucleotide excision, strand break 
ligation, replicative by-pass of damaged bases, and post-replication 
recombinational repair.
For example, uracil in DNA, either following the post­
insertion deamination of cytosine, or following dTd starvation, can
•)
be excised by uracil-DNA glycosylase (EC 3.2.2 .), which catalyses 
cleavage of the glycosyl bond between the deoxyribose and uracil 
moieties in DNA, leaving an apyrimidinic site. This enzyme has been 
isolated from plant, bacterial, viral and animal sources (Richards, 
1984). Apurinic-apyrimidinic endonucleases (EC 3.1.25.2) then 
excise the apyrimidinic sites in DNA, and exonucleases open up the 
site for DNA repair synthesis by polymerase. The process of repair 
is completed by a ligase, which joins the repaired-segment to the 
original strand (Richards, 1984). Under conditions of dTd
starvation, reiterative uracil insertion and excision would occur, 
with dUTP being reinserted by polymerase into the repair patches. 
Such incomplete and frequent episodes of repair would generate many 
single-strand breaks or gaps in DNA (Barclay et al., 1982).
There is some evidence that dNTP pool imbalances may play a 
role in the inhibition of these repair mechanisms. In human 
fibroblasts, the excision repair of UV induced damage to DNA was 
inhibited by depletion of purine dNTPs (Snyder, 1985), and in human 
lymphocytes abnormally high dATP pools significantly reduced the 
efficiency of repair to single strand breaks (Cohen, 1986). Work 
with radiation sensitive strains of Ustilago maydis has indicated 
that induced low dTTP pools may reduce the efficiency of repair 
processes (Holliday, 1985). A recent study by Katz & Sirover (1987) 
has however indicated that in human skin fibroblasts in vitro, UV 
excision repair processes were not affected by the hydroxyurea- 
induced ten-fold reduction in dTTP pool sizes in these cells.
1.3 Variations in the Normal Pyrimidine Biosynthetic Pathways
Found in Tumour Cells
Tumour cells have frequently been shown to possess 
abnormalities of the purine and pyrimidine biosynthetic pathways. 
These are manifested as altered enzyme levels or activities, with 
accompanying changes in substrate concentrations, and loss of normal 
feedback control.
Most work to date has focused on the measurement of enzyme 
levels and activities, but abnormal pool sizes of NTPs or dNTPs, or 
abnormal ratios of DNA precursors, have been demonstrated in tumour 
cells in some studies.
1.3.1 De Novo Pathway Abnormalities
UDP kinase (EC 2.7.4.6) and CTP synthase (EC 6.3.4.2) which 
respectively catalyse the conversions of UDP to UTP, and of UTP to 
CTP, have been found to be markedly more active in rat hepatoma 
cells than in normal or regenerating rat liver (Weber, 1980). CTP 
synthase has been found by other workers to have elevated activity 
in rat hepatomas and transplantable kidney tumours, and also in 
primary renal cell carcinomas in man (Williams et al., 1978). CTP 
syntlietase activity has been suggested as a biochemical marker of 
the clinical aggressiveness of malignant lymphoma in man, as it was 
found that raised activity correlated with aggressiveness of the 
disease, being lowest in the more favourable cases (Ellims et 
al., 1983B). This study also found differences in the levels of 
this enzyme in leukaemic cells from patients with different forms of 
lymphatic leukaemia; cells from cases of ALL having up to seven­
fold the activity of normal lymphocytes, while in case of CLL the 
activity was within the normal range.
Elevations in ribonucleotide reductase activity have also been 
associated with neoplastic cells, and with an increased growth rate 
of tumours. Very fast growing rat hepatomas were found to have a 
two hundred-fold difference in the activity of this enzyme when
compared with slow growing hepatomas, while no activity was found in
normal rat liver cells, or in liver cells from tumour bearing rats
(Elford et al., 1970). In another study, proliferating hepatoma
cells had a twenty-three-fold increase of activity of ribonucleotide
reductase over that found in "resting" hepatoma cells, while the
r
catabolic enzyme of dTd and dUd-, dihydropyrimidine dehydrogenase
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(EC 1.3.1.2) had activity decreased by about 40% in the neoplastic 
cells (Weber et al., 1980). Increased ribonucleotide reductase 
activity in mutant human leukaemic cells in vitro, was found to give 
rise to two- to eight-fold elevations in the dNTP precursor pools in 
these cells (Fridland, 1984).
Thymidylate synthase in both rat and human malignant liver 
cells was found to be many times more active than in corresponding 
normal tissue, and once more heightened activity correlated with 
increased tumour growth rate. These malignant cells also showed 
significantly raised (ten-fold) activity of dTMP kinase (EC 2.7.4.9) 
over that of normal adult liver (Cummins & Balinsky, 1980). Human 
colon and breast carcinomas were also found to have increased 
thymidylate synthase levels, twice as high as in biopsies of normal 
liver taken from the same individuals as the tumour tissue (Spears 
et al., 1984).
1.3.2 Salvage Pathway Abnormalities have been frequently reported in 
tumour cells.
Uridine kinase (EC 2.7.1.48), which catalyses the conversion 
of Urd and C; d to UMP and CMP respectively, was found to have
elevated activity in rat hepatoma cells, which also showed a marked 
reduction in the activity of the catabolic enzyme, dihydropyrimidine 
dehydrogenase (Weber et al., 1978). Other workers have found 
elevations of uridine kinase activity in solid tumours of rats, such 
as renal, pancreatic and mammary carcinomas, but this group did not 
find any such elevations in a fast-growing rat hepatoma (Herzfeld & 
Raper, 1979). Human solid tumours of the colon, breast and kidney 
were found to have both adult and embryonic forms of this enzyme, 
while leukaemic cells had only the adult form. Tumours of the same 
tissue origin from different individuals showed a wide range of 
activity of the enzyme, for example, colon carcinoma activities 
varied six-fold and breast carcinomas five-fold (Otal-Brun & Webb,
1979).
Thymidine kinase which has been found in multiple forms with 
different kinetic and physical properties in neoplastic tissues 
(Moore & Hurlbert, 1966; el Assouli, 1985), has been demonstrated 
to have strongly enhanced activities in malignant cells such as 
those of rat hepatoma, but showed no increased activity in human 
liver cancer cells (Cummins & Balinsky, 1980). It has been found in 
elevated levels of up to six-fold in peripheral lymphoid cells of 
children with ALL (Russo et al., 1987).
The activity of deoxycytidine kinase (EC 2.7.1.74), which 
phosphorylates dCd to dCMP (Durham & Ives, 1969) has been shown to 
be elevated three- to eighteen-fold over comparable normal tissue, 
in transplantable rat hepatomas (Jackson & Harkrader, 1981). The
highest activity of this enzyme in normal rat tissue was found to be 
in the thymus, and this level of activity was exceeded, in a range 
of tumours investigated, only in L1210 leukaemic cells (Cooper et 
al., 1972). The activity of dCd kinase appears to correlate with 
proliferative activity, as shown by a study performed on normal and 
leukaemic human granulocytes, where fifteen-fold higher than normal 
levels were found in cells from patients with AML. However on 
separation of these cells into mature and immature populations, the 
proliferation-linked incidence of enzyme activity was evident in 
normal, as well as in tumour cells (Coleman et al., 1975). These 
workers, and others working on human nucleated bone marrow cells 
(Tattersall jBt al., 1974), have found a wide (up to twenty-fold) 
individual variation of dCd kinase activity to occur. The latter 
group found similar variations between the activities of the enzymes 
cytidine deaminase (EC 3.5.4.5) and dCMP deaminase (EC 3.5.4.12) in 
AML patients, with smaller variations occurring among normal 
subjects. There was considerable overlap of normal and tumour cell 
levels of these enzymes. The four normal DNA precursors were also 
measured and two to three times the normal concentrations were found 
in leukaemic marrow cells of AML patients. There was also an 
alteration of the pool balance, from dATP being the largest pool in 
the normal cells, to dTTP forming the largest pool in all the 
leukaemic individuals.
Another salvage pathway enzyme, cytidylate kinase 
(EC 2.7.4.14), which is responsible for the phosphorylation of CMP, 
dCMP, UMP and dUMP, has been isolated from normal and leukaemic 
human granulocytes, and has been found to have almost a two-fold 
increase in activity in tumour cells compared with normal cells 
(Hande & Chabner, 1978).
In summary, heightened activity of many of the anabolic 
enzymes in the purine and pyrimidine pathways can be seen to exist 
in tumours, often with correlations between activities and rates of 
proliferation. Decreased activity of catabolic enzymes has also 
been demonstrated in tumours. It is, however, clear that wide 
variations occur within tumours of the same type obtained from 
different individuals.
1.4 The Chemotherapy of Tumours with Antimetabolites
Drugs which interfere with the processes of purine and 
pyrimidine biosynthesis, and hence ultimately with the synthesis of 
normal DNA, are known collectively as antimetabolites. They may 
directly inhibit enzymes in the pathways, frequently being synthetic 
analogues of natural substrates, and they may require metabolism to 
active forms. These active forms may also compete with dNTPs for 
incorporation into nucleic acids. This class of drug is most active 
in the S-phase of the cell cycle, but some agents, such as the 
pyrimidine base and nucleoside analogues 5FU and ara.C (Fig.4-.l.), 
have been shown also to have cell-killing ability in the or G^ 
cell cycle phases (Karon & Shirekawa, 1969; Moore, 1981; Bertino,
1984).
Some points of action of antimetabolites on purine and 
pyrimidine pathways are indicated in Figure 1.3.
Because of their interference with cell replicative 
processes, these drugs can be highly toxic to rapidly dividing 
normal tissues, such as the bone marrow and the gut mucosa. Most 
normal tissues however, are relatively unharmed by exposure to 
antimetabolites, and even the bone marrow and gut lining cells
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Figure 1.3 Some Points of Action of Antimetabolites
on the Purine and Pyrimidine Pathways
recover quickly when the drug is withdrawn, thereby showing a 
relative lack of sensitivity to these drugs (Harris, 1985A). Normal 
tissues could be said to have an innate resistance to chemotherapy 
where they lack responsiveness, although normal tissues which show 
some sensitivity, such as the bone marrow, do not acquire resistance 
on prolonged or repeated exposure to the drugs (Zajicek, 1986).
Antimetabolites are designed to exploit two commonly occurring 
features of tumour cells; firstly, frequent cell divisions and, 
secondly, the raised activity of many of the purine and pyrimidine 
biosynthetic pathway enzymes described in Section 1.3. In this way, 
it is hoped that normal tissues will be spared the toxic effects 
which will kill the tumour cells. However, as pointed out in 
Section 1.3, not all tumours possess the desired raised enzyme 
activities to preferentially metabolize or utilize the 
antimetabolite substrates, and they are also not composed of a 
homogeneous population of cells (Whitehouse, 1984; Dexter & Leith, 
1986; Nicolson, 1987). Tumours contain cells which are distributed 
throughout the cell cycle, so that at the time of drug exposure 
there will be many cells in the tumour that are not in the 
susceptible S-phase (Whitehouse, 1984). Differences in cell 
biochemistry leading to differences in drug sensitivity may also be 
present within a tumour, along with differences in other 
characteristics such as morphology, doubling time and ability to 
metastasize (Henderson, 1984). Sensitive cells also would be 
expected to be selected out by the drug treatments given, leaving 
only those that are resistant (Tattersall jet» a]*?1974 ).
1.4.1 Resistance to Antimetabolites
Resistance to antimetabolites may not only be innate, it may 
be acquired by genetic change after repeated exposure to the drugs. 
As noted in Section 1.2, altered dNTP pool ratios, often caused in 
cells by antimetabolite action, can cause mutations, some of which 
may be favourable to the cell in combating the action of the 
antimetabolite. Spontaneous mutations also occur in cells, despite 
the elaborate mechanisms which exist to ensure the accuracy of 
replicated DNA (Haynes, 1985). Tumour cells, with their inherent 
tendency to instability of the genome, particularly may acquire 
genetic changes favourable to their survival (Nowell, 1976). Many 
documented instances exist of resistance to antimetabolites being 
induced iri vitro in tumour cell lines, and in vivo instances are all 
too common clinically (Whitehouse, 1984), although in the clinical 
setting it is impossible to know if resistance is acquired or has 
arisen from innately resistant clones within the tumour.
There are several mechanisms by which cells can acquire 
resistance to antimetabolites. Reduced drug uptake has been 
implicated where the agents utilize a specific carrier-mediated 
transport mechanism. This may be due to changes in the carrier 
mechanism or to an increase in intracellular concentration of 
endogenous competitors of the drug (Harrap & Jackson, 1978; Sobrero 
et al., 1985). Reduced conversion of prodrugs to active forms 
because of deficient levels of anabolic enzymes has been noted in 
tumour cells (Drahovsky & Kreis, 1970; Ardalan et al., 1980), as 
has inactivation of the active form by increased activity of
catabolic enzymes (Abe et al., 1982; Fernandes & Cranford, 1985).
An increased preference for d_e novo over salvage pathways has been 
documented in cells resistant to a nucleoside analogue requiring 
salvage pathway metabolism to an active form (Karle et al., 1984). 
Altered target enzyme affinity for the drug substrate has been 
reported to occur (Tanaka & Yoshida, 1982; Liu et al., 1983), and 
gene amplification leading to overproduction of the target enzyme to 
be inhibited has been described in resistant tumour cells (Bertino, 
1984; Berger et al., 1985; Hahn et al., 1986). Abnormally high 
concentrations of endogenous nucleotides competing with the prodrug 
for both activating enzymes and sites on a target enzyme, have been 
described in resistant cells (de Saint Buttin et al., 1980;
Kaufman, 1984). It is also possible that repair pathways could be 
activated or induced to deal with damaged DNA, although no evidence 
so far exists to support this theory in the case of resistance to 
antimetabolites (Harris, 1985B).
1.4.2 Enzyme Inhibitors
This type of antimetabolite blocks the production of normal 
DNA precursor pools at some point in the purine and/or pyrimidine 
biosynthetic pathways.
Drugs which prevent the formation of dTTP are among the most 
successful antimetabolites clinically. These include MTX, a
4-amino-10 methyl analogue of folic acid, an inhibitor of 
dihydrofolate reductase, which in turn inhibits thymidylate 
synthesis. It also interferes with purine ribonucleotide synthesis 
by depleting the levels of one-carbon carrying tetrahydrofolates
(Harrap & Renshaw, 1980). Other enzyme inhibitors which stop the 
production of dTTP are the nucleoside analogues 5FU and
5-fluorodeoxyuridine which, after metabolism to the mononucleotide 
form, 5-fluorodeoxyuridine 5 ’-monophosphate, inhibit thymidylate 
synthase (Hartman & Heidelberger, 1961; Houghton & Houghton, 1984).
Enzyme inhibitors acting at other points in the synthesis of 
dNTPs, and used with varying success clinically, include: 
hydroxyurea, which prevents purine dNTP production by scavenging the 
tyrosyl free radical of ribonucleotide reductase, thus inhibiting it 
(Bjursell & Skoog, 1980; Bianchi et al., 1986): and
PALA (N-(phosphonoacetyl)-L-aspartate), which inhibits aspartate 
carbamoyltransferase (EC 2.1.3.2) bringing about a reduction of UTP 
and CTP and thus reducing the pyrimidine dNTP pools (Keppler & 
Holstege, 1982). 6-azauridine and pyrazofurin, after 
phosphorylation to their 5 ’-monophosphate forms, can effectively 
inhibit UMP synthetase - the multienzyme complex for the pathway 
from carbamoyl phosphate to UMP - and thus give rise to a depletion 
of UTP and CTP (Keppler & Holstege, 1982). 3-deazauridine, after 
conversion to the 5 ’-triphosphate form, is a potent competitive 
inhibitor of CTP synthetase, leading to a depletion of cytidine and 
deoxycytidine phosphates (Brockman et al., 1975).
1.4.3 Competitors of dNTPs for Incorporation into Nucleic Acids
Suitably metabolized to triphosphate forms, some
antimetabolites have been shown to be incorporated into RNA and DNA, 
giving rise to miscoding which may produce irreversible damage.
5FU has been demonstrated, after conversion to 5-FUTP, to be 
incorporated into RNA in place of UTP (Herrick & Kufe, 1984; Akazawa 
et al., 1986), and after conversion to 5FdUTP, to be 
incorporated into DNA in place of dTTP (Ingraham et al., 1982;
Major et al., 1982), both events leading to cell death. 5FdUTP has 
also been shown to be incorporated into the oligonucleotide primer 
for DNA synthesis, potentially blocking DNA replication (Sawyer et 
al., 1984).
Ara.C, an arabinose-sugar analogue of Cd or dCd, is effective 
as a cytotoxic agent after its metabolism to the 5 ’-triphosphate 
form, ara.CTP. It is thought to act by competing with dCTP for 
sites on DNA polymerase a , although it is a weak competitive 
inhibitor of this enzyme (Momparler, 1982). It has been shown to be 
incorporated into DNA in place of dCTP, bringing about damage to the 
newly forming strands which is not always reversible and may lead to 
cell death (Zahn et al., (1972); Kufe et al., 1984).
1.4.4 Mutagenic Effects
Another means by which antimetabolites may cause cell death, 
is by genetic damage (Crowther et al., 1985). All the anti­
metabolites give rise to imbalances in NTPs and dNTPs, and are thus 
potential mutagens, (see Section 1.2), whose lethal effects may not 
become apparent until the passage of several generations.
1.4.5 Drug Synergy and Biochemical Modulation
Cancer chemotherapy usually involves treatment protocols using 
several drugs in combination, which are chosen because they act as 
cytotoxic agents at different sites in the cell, or modulate and 
enhance each other’s effects.
Combinations of agents acting at different sites in the cell 
include antimetabolites with: activators of free radicals and DNA
intercalators (antitumour antibiotics, e.g. adriamycin, bleomycin);
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DNA cross-linking agents (nitrosureas, alkylating agents, cis- 
platinum compounds, e.g. BCNU, cyclophosphamide, cisplatin); drugs 
binding to microtubular proteins (vinca alkaloids, e.g. 
vincristine); drugs affecting the DNA nick-closing enzyme, 
topoisomerase (podophyllotoxin derivatives, e.g. VP16); and cell- 
growth regulators (steroids or steroid analogues, e.g. tamoxifen, 
prednisolone).
Antimetabolites are successfully used on their own against a 
very limited number of tumours, e.g. MTX has been used successfully 
as a single agent against choriocarcinoma and head and neck cancer 
(Aitken et al., 1979; Jain et al., 1979). It is more usually 
combined in treatment protocols with other drugs such as 
vincristine, 5FU, ara.C, and the purine analogue 6-thioguanine, 
against a range of neoplasms such as ALL, osteosarcoma, breast 
tumours and small cell lung cancer (Jolivet et^  al., 1983). Many 
drug combinations like this have been used to good effect against
tumours, although their combination, dosage and scheduling have 
often been arrived at empirically, and the reasons for their 
effectiveness are unknown. Much effort has however, been expended 
on devising, in vitro, drug combinations whose synergistic or 
modulating effects are understood. Some of these combinations have 
shown clinical promise.
Ara.C for example has shown limited clinical usefulness as a 
single agent, but it is indispensable, in combination with other 
drugs, against AML (Freireich, 1987). Resistance to ara.C, either 
on initial treatment or at relapse, is common, and the easy 
accessibility of leukaemic cells and cell lines derived from them 
has led to the accumulation of a large body of work on ara.C 
resistance mechanisms, (see Chapter 4) and attempts to overcome 
them.
1.4.5.1 Modulation of ara.C Action with Nucleosides has been 
investigated with a view to increasing the amount of active drug, 
ara.CTP, relative to dCTP, the endogenous inhibitor of both its 
activation and its activity.
(1) Modulation with dTd: an accumulation of dTTP in cells
has an inhibitory effect on ribonucleotide reductase, resulting in 
reduced levels of dCTP. Elevated dTTP can also overcome the 
inhibitory action of dCTP on dCd kinase, which phosphorylates ara.C 
to ara.CMP. In vitro, increased sensitivity to ara.C was seen 
following combined dTd and ara.C treatment in Novikoff hepatoma 
cells (Plagemann et al., 1978), in several leukaemia cell lines
(Harris et al., 1979), and in L1210 cells (Grant et al., 1980; 
Kinahan et al., 1981). Clinical trials of dTd/ara.C combinations, 
carried out up to Phase III in cases of refractory, heavily pre­
treated leukaemia, have shown inconclusive results (Van Echo et al., 
1981; F r a m ^ a l . ,  1983; Blumenreich, 1984; Zittoun et al., 1985; 
1 0 ’Dwyer et al., 1987).
(2) Modulation with Urd was reported by Saslow et al., (1968), 
who showed a potentiation of ara.C action against L1210 leukaemia in 
mice when Urd was co-administered. Following Urd administration, 
the UTP pool increases, providing a more efficient phosphate donor 
for dCd kinase phosphorylation of ara.C than the usual donor, ATP 
(Kessel, 1968). It has also been shown that the K^ . of dCTP for dCd 
kinase is significantly greater when UTP is the phosphate donor as 
compared to ATP, and this reduced inhibition of dCd kinase /favours 
ara.C phosphorylation (Kowal & Grindey, 1981).
(3) Modulation with dGu and dAd was shown to increase ara.C 
activity against rat hepatoma cells, a human leukaemia cell line 
(K562) and marrow blast cells from AML patients (Harkrader et^  al., 
1981; Akman et al., 1982 and 1985). Both nucleosides, after 
conversion to dGTP and dATP, reduced dCTP levels in the cells. This 
was thought to be as a result of inhibition of CDP reductase 
activity of ribonucleotide reductase, and, in the case of dGTP, of 
the simultaneous activation of ADP reductase, leading to a rise in 
dATP levels and further blockade of CDP reductase (Harkrader ejt al.,
1981).
(4) Modulation with THU: ara.C is rapidly deaminated, and 
thus inactivated, in man by the action of cytidine deaminase. A 
reduced pyrimidine nucleoside (l-(6-D-ribofuranosyl)-4~ 
hydroxytetrahydro-2(lH)-pyrimidinone), THU is a potent and specific 
inhibitor of this enzyme, and it was found to be relatively non­
toxic in dogs, monkeys (Camiener, 1968), and man (Ho et al., 1978). 
THU with ara.C has given significantly prolonged therapeutic levels 
of ara.C in the CSF of monkeys (Riccardi et_ al., 1982) and has 
significantly lengthened the half-life and raised the peak 
concentrations of ara.C in the plasma of human subjects (Kreis et 
al., 1988). A Phase I study of a THU/ara.C combination showed 
limited success, with 8 of the 9 leukaemic patients treated having a 
reduction in peripheral disease, but bone marrow remissions were 
absent (Wong et al., 1979). Some types of leukaemic cell have low 
cytidine deaminase activity (Ho et al., 1980) and THU will possibly 
therefore only show beneficial effects where there is a high 
activity, i.e. in AML (Schilsky et al., 1981). A recent study using 
a THU analogue, 2 ’-deoxytetra-hydrouridine, has shown that it is 
effective in inhibiting the deamination, and inactivation, of 
ara.CTP in a leukaemic cell line, (Fridland & Verhoef, 1987).
1.4.5.2 Modulation of ara.C Action by Other Antimetabolites
(1) Ara.C and 5FU: the rationale behind this combination is
that as 5FU inhibits thymidylate synthetase and dTTP levels fall, 
the inhibition of dCMP deaminase by dTTP is removed, and dCTP levels 
then fall as this enzyme in activated. Grant & Cadman (1982) showed 
this to be an active combination of drugs in L1210 cells.
(2) Ara.C and hydroxyurea: reductions in dCTP levels,
presumably due to the action of hydroxyurea on ribonucleotide 
reductase, were noted in HL60 and L1210 cells treated with these two 
agents (Rauscher & Cadman, 1983), which was also active against 
other leukaemic cell lines (Walsh et al., 1980; Streifel & Howell,
1981). This combination also gave rise to an elevation of ara.CTP 
levels in CCRF-CEM lymphoblastic leukaemia cells (Tanaka et_ al.,
1985), and a five-fold increase in the amount of ara.C incorporated 
into the DNA of LoVo colon carcinoma cells normally resistant to 
high concentrations of ara.C (Robichaud & Fram, 1987).
(3) Ara.C and PALA: enhancement of ara.C activity with this
combination was seen against ara.C-refractory Lewis lung carcinoma 
cells and in a mammary carcinoma line. PALA, by acting as an 
inhibitor of de novo pyrimidine synthesis, lowers intracellular 
pyrimidine pools (Martin et al., 1981). Riva et al., (1986) found 
that dCTP was lowered and ara.CTP increased after L1210 cells were 
exposed to these two drugs.
(4) Ara.C and MTX together have been shown to give an 
enhancement of ara.C activity with appropriate dose levels and 
timing. MTX modulates for ara.C by the same mechanism as 5FU, 
causing dTd starvation and therefore lowering the dTTP pool, thus 
removing inhibition of dCMP deaminase and leading to a reduction of 
dCTP pools (Cadman & Eiferman, 1979). Ara.C on its own has been 
reported to give rise to elevations in dCTP, which may be attenuated 
by MTX (Roberts & Peck, 1981). Nobori et al., (1985) have found 
also that ara.CTP levels in L1210 cells are elevated when ara.C/MTX 
combinations are used.
1.4.5.3 Modulation of ara.C by Drugs Acting at Different Sites
in the Cell
(1) Ara.C with cisplatin: Bergerat et al., (1981) and 
Schulz et al., (1987) have demonstrated apparent synergy between 
these two drugs when used against colon and ovarian carcinoma cell 
lines, and the results of early studies using this combination were 
reported to be encouraging (Schilsky et al., 1984; Markman &
Howell, 1987). The mode of action of the synergy is not known, but 
it has been speculated that ara.C enhances cisplatin-induced DNA 
strand cross-linking, or it inhibits the repair of damage to DNA 
(Bergerat et al., 1981).
(2) Ara.C with adriamycin: this combination, with the 
addition of the purine analogue 6-thioguanine, is widely used to 
induce remission in AML patients (Freireich, 1987). The DNA 
intercalating effects of adriamycin have been shown to be 
significantly enhanced when combined with ara.C against L1210 cells. 
It was postulated that intercalation was facilitated by changes in 
the DNA chromatin complex including a reduction in H^ histone 
content (Minford et al., 1984).
(3) Ara.C with VM26: VM26 is a podophyllotoxin derivative
which has been used to great effect with ara.C, in the treatment of 
refractory ALL (Rivera ejt al^., 1980; Sanz et^  al., 1986). Ara.C in 
conventional doses is not normally effective against ALL, possibly 
because of low ara.C uptake by ALL cells (Wiley e_t al., 1982). VM26
may affect the carrier mediated mechanism used by ara.C to get into 
cells, although inhibition rather than augmentation of its uptake by 
high concentrations of VM26 into Erlich ascites cells and human 
leukaemic blasts was shown by White et al., (1985). It is also 
possible that the repair of DNA strand breaks caused by VM26 may be 
slowed by ara.Cfs inhibitory effect on DNA polymerase a.
1.4.5.4 Miscellaneous Means of Enhancing Antimetabolite Drug 
Activity
These include the delivery of active forms of prodrugs 
e.g. ara.CTP, encapsulated in liposomes (Mayhew et al., 1978); the 
prevention of drug efflux from cells by the use of an inhibitor of 
cell membrane transport systems, e.g. ara.C or 5FU entrapment in 
cells treated with dipyridamole (Grem & Fischer, 1986; Chan, 1987); 
and the protection of normal tissues from the toxic effects of high 
doses of S-phase specific drugs, by the use of agents which, it has 
been reported, can cause cell cycle arrest in normal cells but not 
in tumour cells, e.g. cycloheximide (Slapak et al., 1985) and L- 
histidinol (Warrington et al., (1987).
1.5 dNTP Assay
The importance of dNTPs, as described above, is indisputable 
and well-proven. There is still however much work to be done in the 
fields of DNA replicational fidelity and repair, which have 
important applications in investigations of environmental mutagens 
and in the chemotherapy of tumours. The development of new anti­
cancer drugs which it is hoped will have an improved therapeutic 
index, or be effective in drug resistant tumours, continues. Many 
of these are antimetabolites, with immediate effects on dNTPs. 
Modulation of the actions of existing anti-metabolites also shows 
some clinical promise. The monitoring of dNTP concentrations and, 
in appropriate situations, of active drug forms like ara.CTP, is 
therefore of importance in understanding drug actions and 
interactions. The development of RIAs for the three pyrimidine 
dNTPs and for ara.CTP was undertaken with these applications in 
mind, and to provide assays of greater sensitivity and specificity 
than those already available.
Chapter 2
Methods Used in the 
Determination of dNTP Concentrations
Chapter 2
METHODS USED IN THE DETERMINATION OF dNTP CONCENTRATIONS
The determination of dNTP concentrations in cells has involved 
a number of basic techniques such as careful cell harvesting and 
extraction, often followed by the removal of interfering compounds 
by chromatographic and/or chemical means, and quantification by such 
techniques as microbiological assay, UV absorbance or enzymatic 
assay (Hauschka, 1973; Hunting & Henderson, 1982). Although the 
experimental induction of antibodies to nucleic acids and their 
constituents has been described by many workers (Stollar, 1980), no 
use has been made of antibodies to dNTPs in order to quantify these 
compounds in cell extracts by RIA.
2.1 Cell Harvesting
Cultured cells are most commonly harvested for dNTP assays by 
centrifugation or filtration (suspensions), or are scraped off or 
extracted in situ after removal of the medium by suction 
(monolayers). Cells in medium have also been layered over a 
suitable density oil (e.g. silicon oil, density 1.040 (Reiss et al., 
1984) which in turn is layered over an acid extractant; the cells, 
but not the medium, are then centrifuged through the oil into the 
acid.
Blood cells can be separated into their component groups by 
layering defibrinated or anticoagulant-treated blood over a 
commercially available polymeric erythrocyte aggregating agent such
as Ficoll. Low speed centrifugation results in the formation of 
layers containing different cell types. Erythrocytes, aggregated by 
the Ficoll, form the bottom layer; granulocytes are in the layer 
immediately above the erythrocytes, as at the osmotic pressure of 
the Ficoll solution they attain a density great enough to migrate 
downwards. Lymphocytes, with a lower density, are at the interface 
between the plasma and the Ficoll, with other slowly sedimenting 
particles such as platelets and monocytes, which can be washed off 
the lymphocytes using balanced salt solutions (Boyum, 1968).
Washing cell pellets has been found to significantly reduce the 
recovery of dNTPs (Tyrsted, 1975; Kinahan et al., 1979). It has 
been strongly recommended that such washings be kept to a minimum, 
or better, not done at all (Hauschka, 1973; Hunting & Henderson,
1982). Scraping cells from monolayers rather than extracting them 
in situ was also found to result in a loss of about 50% dNTPs (Adams 
et al., 1971) as was trypsinisation of the cells before extraction 
(Booth, 1985). Pieces of tissue for dNTP analysis should be rapidly 
frozen in liquid nitrogen, then pulverized for extraction.
2.2 Extraction
Extraction of dNTPs from cells is a necessary pre-requisite 
for their quantification. Enzyme activities must be stopped as soon 
as possible after cell harvesting to inactivate phosphatases and 
kinases in the dNTP metabolic pathways. Extraction procedures 
should be carried out using ice-cold reagents to minimize the 
breakdown of dNTPs, and the extractant chosen must be compatible 
with procedures to be followed later.
2.2.1 Acid Extraction
PCA and TCA have been used extensively to extract dNTPs 
because of their ability to inactivate enzymes, being potent and 
rapid protein precipitating agents. PCA has been shown to give the 
highest yield of dNTPs, while TCA generally gives less reproducible 
yields (Hauschka, 1973). Formic and acetic acids have been used 
also, but show lower recoveries of dNTPs than PCA and TCA (Bagnara & 
Finch, 1972).
The acid extract is most commonly either neutralized with a 
concentrated solution of KOH (Bagnara & Finch, 1972), or dNTPs and 
NTPs are extracted from it with a water insoluble amine dissolved in 
a water immiscible organic solvent, e.g. tricaprylyl tertiary amine 
in 1,1,2-trichloro-l,2,2-trifluoroethane, (Khym, 1975), or with a 
solvent such as ether (Arezzo, 1987). Chlorate ions, which 
interfere with most of the procedures used to quantitate dNTPs, are 
removed by these methods, being precipitated or extracted out.
2.2.2 Extraction with Aqueous Alcohol
Ethanol and methanol have commonly been used in 60-70% 
concentrations to extract dNTPs, and have the advantage of being 
readily lyophilised. It has however been suggested that certain 
degradative enzymes remain active following this method of 
extraction (North et al., 1980; Hunting & Henderson, 1982; Fuller
2.3 Pre-Quantification Treatment of Extracts
Because dNTPs are present in very low concentrations, and are 
also in the presence of one hundred-fold or greater concentrations 
of NTPs which interfere with some methods of quantification, 
extracts may be treated to concentrate-up dNTPs, or to separate them 
from NTPs before the quantification step.
2.3.1 Concentrating dNTPs (and NTPs) may be achieved by 
lyophilisation, or by co-precipitation with calcium fluoride (Kukko 
£t_ al., 1983; Harmenberg et al., 1987). Kukko et^ al. showed that 
compounds such as dNTPs containing a terminal or linear 
pyrophosphoryl group were specifically complexed with calcium 
fluoride.
2.3.2 Separation of NTPs from dNTPs may be achieved by means 
of the destruction of NTPs by periodate oxidation and amine 
degradation, or by borate complexing of NTPs, or by chromatography, 
or by a combination of these methods.
2.3.2.1 Periodate/Amine Degradation of NTPs
The ability of periodate to oxidise adjacent cis-diol groups 
such as those at 2 f and 3 ’ on ribosides, to yield aldehydes, has 
been used for many years to investigate the structure of natural and 
synthetic compounds (Brown & Lythgoe, 1950; Khym & Cohn, 1960). 
Periodate and ribose compounds react quantitatively within 15
-4
minutes at room temperature at periodate concentrations of 10 M, or
faster at higher concentrations, in a pH range of 3-9. Deoxyribose 
compounds are unaffected by the reaction. Degradation of the 
oxidised ribose product by bases such as ammonia and glycine, or, 
for more complete reactions, a primary amine such as methylamine, 
can then be carried out at room temperature in a pH range of 5-9. 
This proceeds via the formation of an addition compound and yields 
inorganic pyrophosphate and the aglycone residue (Khym & Cohn,
1961). These reactions are shown schematically in Figure 2.1.
2.3.2.2 The Use of NTP : Borate Complexes
The ability of borate to form complexes with adjacent cis-diol 
groups has been widely used in work with polyhydroxy compounds such 
as vitamins, co-enzymes and polysaccharides (Zittle, 1951).
Boronates react readily under mild conditions with a range of polar 
functional groups if they are oriented in the proper geometry. 
Adjacent trans hydroxyl groups such as those in ara.C are not 
complexed to boronate, whereas 2 f,3f cis hydroxyls in the rigid 
five-membered furanoid ring of NTPs are easily complexed, and dNTPs 
cannot form such complexes (Khym, 1967; Bergold & Scouten, 1983). 
Phenylboronic acid is commonly used as the complexing agent, and a 
cyclic ester complex, shown in Figure 2.2.(a), is formed. The use 
of other boronates such as potassium tetraborate can lead to a 
variety of species being formed in solution such as those shown in 
Figure 2.2.(b) (Khym et al., 1957). The borate complexes formed are 
usually anionic at neutral pH (Bergold & Scouten, 1983). Cohn 
(1955) demonstrated the use of tetraborate to separate CTP and dCTP 
on an anion exchange resin column. dCTP eluted from the column, 
which was set up in 0.1M formate with 0.05mM tetraborate, earlier
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and well separated from CTP, which was eluted off with formate 
alone. The borate complexes are easily disassociated by a reduction 
in pH. Khym (1974) and Pal (1978) used borate complexation to 
separate NTPs from nucleosides and bases, and deoxynucleosides from 
nucleosides, on polyacrylamide gel and on cation exchange resin 
respectively.
Boronate ligands immobilized onto solid supports provide a 
convenient way to separate NTPs and dNTPs. Matrices most commonly 
used, and requiring activation before coupling on the boronate 
ligand, are cellulose, agarose, polyacrylamide gel and glass. 
Polymers with boronic acid integrated into the polymer backbone are 
also used (Bergold & Scouten, 1983). Boronate affinity adsorbents 
are commercially available, and, though costly, with the right 
treatment are re-usable over a long period (A Hardcastle, personal 
communication).
2.3.2.3 Chromatography
Thin Layer Chromatography has been widely used, especially to 
effect group separations of bases, nucleosides and nucleotides, or 
to separate compounds with different groupings on the base ring such 
as UTP and CTP (Randerath & Randerath, 1967; Bols & Mosser, 1982). 
Systems commonly used were e.g. cellulose plates with organic mobile 
phases composed of solvents such as n-butanol, acetone, acetic acid, 
water and ammonia. Periodate and borate treatments have been 
applied to improve resolution (Hauschka, 1973).
Ion Exchange Resins have been used to effect group separations 
of bases, nucleosides and nucleotides which differ on the basis of 
charge, and simultaneously to separate dNTPs and NTPs using borate 
complexing as described above in Section 2.3.2.2. (Pal, 1978).
High Performance Liquid Chromatography. This technique has 
become the chromatographic method of choice for the resolution of 
NTPs and dNTPs, utilizing reversed-phase or anion exchange columns, 
with isocratic or gradient elution. Ion-pairing has been used with 
some success with reversed-phase systems. The great advantage of 
HPLC over other methods of chromatography is its capability for 
excellent resolution of complex mixtures of compounds, which can be 
achieved in a relatively short time. Problems associated with this 
method are the short life of HPLC columns, especially when using 
high molarity buffers; interference of gradient "noise" with the UV 
signal generally employed for quantification (see Section 2.4); 
interference by ribosides and ribotides with the much smaller dNTP 
peaks; interference by the products of periodate oxidation with 
early eluting peaks; and periods of time-wasting and expensive 
break-down of the equipment, particularly where strong buffer 
solutions are used.
Column life has been prolonged by careful washing, while the
problem of gradient "noise" has been found to be improved by running
the gradient buffers prior to use through columns packed with the
same materials as the analytical column to remove impurities (Reiss
et al., 1984). Interfering ribosides and ribotides can be removed
2+
by pre-analytical treatment of the extract on a Cu -loaded metal 
chelate column (Brown et al., 1982), or a silica cartridge (Lothrop
& Uziel, 1980), or a boronate affinity column (Payne & Ames, 1982). 
Interference by products of periodate oxidation can also be removed 
by passing the extract through an anion exchange cartridge before 
the analytical column (Harmenberg et al., 1987). The problem of 
equipment breakdown, not alluded to in the literature, can be 
greatly helped by avoiding the use of gradient elution involving 
strong buffers.
The ion exchange mode of HPLC was a direct development from 
earlier ion exchange separations on resins. Microparticulate silica 
matrix anion exchangers were developed in the early 1970s, and have 
been used with the gradient elution, by increasing molarity 
phosphate solutions, of mono-, di- and triphosphates of purines and 
pyrimidines. These are eluted on the basis of their increasing 
negative charge. The time taken to achieve separation of dNTPs 
using this method is from 90 to 120 minutes (Zakaria & Brown, 1981), 
but a radial compression column gave good separations in 30 minutes 
(Reiss et al., 1984), and Arezzo (1987) reported an isocratic 
elution system giving good resolution in 60 minutes. Some 
separations are difficult, so that two anion exchange columns in 
series or reversed-phase separation following anion exchange, have 
been used to resolve heterogeneous peaks (Ritter & Bruce, 1979;
Brown et al., 1982). The time required to re-equilibrate the column 
to the starting conditions is however an unavoidable drawback of the 
use of gradients.
Reversed-phase and ion-pairing techniques have been 
successfully used with the microparticulate, chemically bonded 
reversed-phase packing materials developed in the 1970s. They have
a short equilibration time, and elution is usually by an isocratic 
system such as 0.2M ammonium phosphate with low % (e.g. 5% v/v) 
methanol. Because of their negative charge, NTPs and dNTPs are not 
retained for long in reversed-phase systems, and elute early, often 
not resolving well (Taylor et^  al., 1981; Martinez-Valdez et al.,
1982).
Hoffman & Liao (1977) first reported the use of an ion-pairing 
reagent (tetra-n-butylammonium) with a reversed-phase system, to 
successfully separate mono-, di- and triphosphates of purine and 
pyrimidine nucleosides. These ions are positively charged and on 
pairing with the phosphates, retard their elution depending on the 
number of ion-pairs formed. This principle has been used by Au et 
al., (1982) to separate 5PU and its phosphorylated metabolites, 
while Knox & Jurand (1981) used another ion-pairing reagent, 11- 
amino -undecanoic acid, to separate purine nucleotides.
Another method used is the combination of anion exchange and 
reversed-phase columns to separate pairs of compounds e.g. UMP and 
dUMP, CTP and dCTP, which, after co-eluting from the ion exchange 
column, are hydrolysed by acid phosphatase to the nucleoside forms, 
and separated by reversed-phase chromatography (Maybaum et al.,
1980), or by cation exchange chromatography (Jackson et al., 1983).
2.4 Quantification of dNTPs
2.4.1 Microbiological Assay
This assay, introduced in 1957, is based on the principle that
some organisms, such as Lactobacillus acidophilus, require 
deoxyribonucleosides or their monophosphates for growth. The assay 
is specific but sensitivity, at 0.5 nmole, is not very great, so 
that a large amount of test material is required. Standard curves 
are constructed by plotting cell number or turbidity after 
incubation against the amount of standard in the culture (Hunting & 
Henderson, 1982).
2.4.2 Enzymatic Assay
This was originally developed by Solter & Handschumacher 
(1969), and has been widely used with many improvements and 
modifications. The general principle is that DNA polymerase I will 
catalyse the incorporation of dNTPs into DNA, which is both the 
template and the primer for the reaction. Three of the 
triphosphates are present in excess, and one of the three is 
radioactive. At the completion of the polymerization reaction the 
amount of radioactivity in DNA will be proportional to the amount of 
the fourth, limiting triphosphate that was originally present.
Solter & Handschumacher1s original assay had a lower limit of 
sensitivity of 100 pmole, and they found no interference by cell 
extracts with the assay. They used calf thymus DNA as the primer 
template and E. coli polymerase I as the polymerization enzyme. 
Lindberg & Skoog (1970) improved the assay by the use of synthetic 
alternating polymers, higher specific activity radiolabelled dNTPs 
and by mercuric ion inhibition of phosphatase activity in the
polymerase YeParati°n * The synthetic polymers were poly [d(I-C)],
N
used for dGTP and dCTP assays, and poly [d(A-T)] used for dATP and 
dTTP assays. They had the advantages of being more readily soluble 
than DNA, they polymerized faster, and, because of the alternating 
dNTP sequence, they incorporated labelled and unlabelled nucleotide 
in exactly equal amounts and also required only two substrates for 
the reaction. With these improvements an assay sensitivity of 
0.2 pmole was reported. However, a possible source of error 
recognised by Munch-Petersen et al., (1973) was dilution of the 
labelled dNTP and hence reduction of its specific activity, by high 
levels of its endogenous counterpart. Where poly [d(A-T)] was used 
this would lead to erroneously low levels of e.g. dTTP, where dATP 
levels were high, and mathematical factors were devised by these 
workers to correct for this dilution.
Other problems encountered included some background 
incorporation of the labelled dNTP, due probably to the terminal 
addition of the label to the primer template, and 3 ’-5* exonuclease 
activity in the polymerase preparations used. A correction factor 
for the former, and the use of an inhibitor for the latter, have 
been described by Hunting & Henderson (1982), who also found some 
contamination by phosphatases which interfered with the assay.
There have also been reports of interference by cell 
extractants with this assay. Methanol extracts can give 
artificially high results (North al., 1980), while dCTP 
measurements in particular were found to be affected by methanol 
(Tyrsted, 1985) and by PCA (Booth, 1985). In the latter case,
complete removal of KCIO^ precipitated from the neutralized extract 
by a second extraction, into 60% methanol, was found to circumvent 
the problem. Fuller et al., (1982), however, found that low 
recovery of exogenously added dNTPs occurred when MeOH/PCA 
extraction was used. These workers also emphasised the variable 
quality of the commercial reagents available for the dNTP enzyme 
assay, having found some lots of polymerases and the synthetic 
polymers to be unsatisfactory.
2.4.3 UV Absorbance
The dNTPs all absorb light maximally when in solution at 
wavelengths in the UV range between 260nm and 280nm. This 
characteristic has been employed frequently to quantify 
concentrations of dNTP in fractions from HPLC or other chromato­
graphic columns (Cohn, 1955; Zakaria & Brown, 1981). The 
sensitivity of this method of quantification is not very great - in 
the nmole range - but quantification of pmole amounts measured by UV 
absorbance with highly sensitive spectrophotometers following HPLC 
has been reported (Danks, 1982; Arezzo, 1987).
2.4.4 Radioimmunoassay
Yalow and Berson first used the term "radioimmunoassay" in 
1959 in their description of the measurement of plasma insulin 
levels, and since then the technique has become widely used to 
quantify a range of compounds such as peptides, drugs, steroids,
etc. (Yalow, 1987). Its success lies in the great sensitivity which 
it can achieve and in the possibility of rapidly processing large 
batch numbers.
There are many reports of high avidity antibodies to nucleic 
acids or their components, the antibodies often showing considerable 
specificity (Stollar, 1980). Sensitive RIAs have been reported for
carcinogen induced pro-mutagenic bases in DNA, such as N -
£
substituted 5 f-AMP (Bredehorst et^  al., 1981) and 0 -substituted 
butyl-guanosine (Saffhill et al., 1982), while Steiner et al.,
(1972) and others have described RIAs for cyclic nucleotides. 
Antibodies to purine and pyrimidine di- and tri-nucleotides and to 
compounds such as dAMP have been described by many workers, 
including Wallace et al., (1971), Bonavida et al., (1972), and 
Humayun & Jacob (1973), while RIAs for plasma nucleosides were 
reported by Dudman et al., (1981).
2.4.4.1 Principles of RIA
Reagents essential for RIA are: a pure form of the substance
to be measured, which is known as the antigen (Ag), a radiolabelled 
form of the antigen (Ag*), and an antibody to the antigen (Ab). A 
fixed amount of antibody is present in assay tubes, so that a 
limited number of binding sites are present, and the technique 
exploits the ability of the unlabelled and labelled antigen, (the 
latter also added in a fixed amount), to compete for these limited 
sites. The following equation (Marks, 1981) represents the reaction
that occurs:
k l V
Ag Ab Ag
Ab + Ag + Ag* — +
\ k
2 Ag* Ab Ag*
Antibody Unbound 
bound or "free"
antigen antigen
where and k£ are the association and dissociation constants for 
the reaction (Landon, 1971). At the low concentrations used the 
antigen-antibody complexes do not precipitate and chemical or 
physical means must be employed to separate the free and bound 
fractions - "phase separation".
As more unlabelled antigen is added, it will increasingly
t
compete with the labelled antigen thus displacing more of the latter 
from the antibody binding sites, so that a standard curve for 
antigen concentration can be constructed. This standard curve is 
then used to calculate the concentration of antigen in samples.
The antibody should be both specific for, and have a high 
affinity for, the antigen. Affinity is the energy with which the 
combining sites of the antibody bind the antigen, and avidity is the 
mean affinity of a polyclonal antiserum (Morris, 1988).
2.4.4.2 Production of Antibodies for RIA
"The Maharajah also made two animals available, one of which, 
a work elephant at the edge of the jungle, was willing to lie
down on command of his mahout. After several attempts the 
elephant was injected through its massive ear vein and the 
thin skin behind the ear with a few grams of human gamma 
globulin which I had brought along, thinking an antiserum to 
it might be of use in India. When we went for a bucket of 
blood some days later, the mahout and forester in charge 
would only let us draw about 5cc, fearing we might kill the 
animal and the mahout would be jobless! - - - Anyhow, the 
5cc sufficed to show that one elephant, at least, was a good 
producer of anti-human globulin."
Michael Heidelberger, Annual Reviews of Biochemistry 
1979. Vol.48, pl9.
It is known that compounds of a molecular weight of less than 5000, 
and especially less than 1000, are not generally immunogenic (Aherne 
& Marks, 1979), and must be conjugated to a large molecule of known 
immunogenicity, such as a foreign protein, to elicit antibodies in 
immunised animals. Thus dNTPs, which have a molecular weight of 
about 500 or less, require conjugation to proteins to confer 
immunogenicity. The low molecular weight antigen in these 
circumstances is known as a "hapten", and the hapten-protein 
conjugate as an "immunogen".
Conjugation methods involve using chemical reactions which 
couple the hapten to residues on the carrier protein such as lysine, 
carboxylic acid, serine etc. (Aherne & Marks, 1979). The method 
should be chosen so that chemical groupings on the hapten which are
required for recognition by the immune system for good antibody 
specificity are not masked by it by being linked onto the protein or 
by being too close to the point of linkage.
On completion of the chemical reaction of conjugation, 
unconjugated hapten is removed by extensive dialysis or gel 
filtration, and the number of molecules of hapten conjugated to one 
molecule of protein - the degree of derivatisation - is calculated. 
This can be done by the incorporation of a radioactive tracer in the 
reaction mixture, or by spectrophotometric quantification of the 
unconjugated hapten in the dialysates, or if the hapten and protein 
absorption spectra are sufficiently different, by spectrophoto­
metric scans of the conjugate itself (Aherne & Marks, 1979).
The optimal degree of derivatisation for immunogenicity has 
been controversial, some workers obtaining the best results from 
conjugates with a low degree of derivatisation (Taylor & Iverson, 
1971) with others claiming the best results from highly derivatised 
conjugates (Spector, 1973; Hurn, 1974). It is however generally 
agreed that a molar incorporation of between ten and thirty moles of 
hapten to one mole of protein is optimal, and the relative molar 
quantities in the reaction mixture can be adjusted to obtain this 
degree of derivatisation (Aherne & Marks, 1979).
Because of the wide variation in the molecular size of 
proteins, the "density of incorporation", i.e. the number of moles 
of hapten per one thousand molecular weight of protein, has been 
found to be of importance in correlating the degree of
derivatisation with immunogenicity (G W Aherne, personal 
communication). For example, if thyroglobulin (M.W. of dimer =
669.000) had only ten moles of hapten incorporated per mole, it 
would probably compare unfavourably as an immunogen with an 
ovalbumin conjugate of the same molar ratio (M.W. of ovalbumin =
45.000).
Two conjugation methods were used in the course of this 
project, and they are outlined below.
(1) The use of water soluble carbodiimides as coupling
agents for nucleotides and proteins was first described by 
Halloran & Parker (1966). Carbodiimides are of the general 
formula R T-N=C=N-R and can be used to couple many types of 
functional groups such as carboxylic acids, amines, 
phosphate, alcohols and thiols (Goodfriend et^  al., 1964). The 
carbodiimide used here was l-ethyl-3-(3-dimethylamino-propyl) 
carbodiimide hydrochloride (EDC) and the structural formula is 
shown by:
The reactions take place at a neutral or slightly basic pH, in 
aqueous solution, the reactants being simply stirred together 
for a time period to be optimized for each hapten to be 
coupled. Possible reactions of nucleotides with proteins in 
the presence of EDC, as postulated by Halloran & Parker 
(1966), are shown below.
H
Cl
0 0
_0 — P— Ch2OCH'"0
PROTEIN"0 ■►v 0
COOH
OH
Purine or 
Pyrimidine
CH
•• N H  CH—
NH
NH
p—  OCH
NH — * P —  CH
OH
OH
Possible Reactions of Nucleotides with Proteins 
in the Presence of Carbodiimides (adapted from 
Halloran & Parker, 1966)
(2) The use of'the periodate oxidation reaction for coupling
nucleosides to proteins was described by Erlanger & Beiser 
(1964). The adjacent hydroxyl groups at 2 f and 3* on 
ribosides are first oxidised by the action of NalO^ yielding a 
dialdehyde (Khym & Cohn, 1960). The excess periodate is 
destroyed by the addition of ethylene glycol, and the reaction 
product then couples to the amino groups of a protein at 
pH9-9.5 in aqueous solution. The linkage between the haptenic 
group and the protein must be stabilized by reduction with 
NaBH^ (Erlanger & Beiser, 1964). The reactions are shown 
schematically below:
I
10,
P — c
II I I
H OH OH H
C C — CHUR­
H H J
C c —  0
I II H
0 0
-9.5 ,R’NH2
CH OR 
2
NaBH,H H
P — H?“  CH2O R ^ m .  P
N
I
R'
0
COH HOC  q1
N
CH2OR
R'
Stable Unstable in Acid
P = Purine or Pyrimidine 
OH
P /
R = H or ||N 0H 
0
R T = Protein backbone i.e. the
N is supplied by the lysine 
residues.
Conjugation of Riboside to Protein
(adapted from Erlanger &. Beiser (1964)
Immunisation procedures
The immunogen gives rise to antibodies more effectively if it 
is injected in a slow-release formulation formed by mixing it to a 
stable emulsion with an adjuvant composed of a detergent and a 
mineral oil, e.g. Freund's adjuvant. This particulate immunogen is 
apparently phagocytised more readily then a soluble one (Robinson, 
1975). The ulceration often caused by such adjuvants is painful to 
the animal, and does not appear to enhance the immunogenic effect 
(Aherne & Marks, 1979), therefore another adjuvant, "non-ulcerative 
Freund's adjuvant" (Guildhay Antisera Ltd) described by Marks et_ 
al., (1974), has been used in this project. This is a mixture of a 
detergent - Arlacel A, with a highly refined pharmaceutical mineral 
oil - Marcol 52. The immunogen, in an aqueous medium, is 
homogenised by vigorous mixing with the adjuvant, in a ratio of 
1 part immunogen to 2 parts adjuvant (v/v).
The initial, or primer, immunisation generally includes a 
known immunogen such as killed Mycobacterium butyricum or BCG, which 
is not normally included in booster injections. Deciding on the 
optimal frequency of boosters, and also the optimal route of the 
injections - whether sc., im. or id., is very difficult, as
I
individual variation between animals is so great, and no clear rules 
are indicated in the literature (Marks, 1981). Where only small 
quantities of immunogen are available, multi-site id. injections 
appear to give good results (Morgan et_ al., 1978), though this is a 
very unpleasant procedure for the animals, and should be avoided 
where possible. If boosts are too frequent or contain relatively
large doses of antigen, both the titre and the avidity of the 
antibody produced in response to the boosts are poor. At high 
concentrations of antigen immunological tolerance may occur (Roitt 
et al., 1986).
Choice of animal species for immunisation is usually dictated 
by available space and funds, but the larger the animal, the more 
blood can be expected to be obtained at one time - Dr Heidelberger's 
"Indian experience" was unusual in all respects - thus reducing the 
need for time consuming bleeding and antiserum assessment 
procedures.
Animals are bled from a convenient vein, e.g. the jugular vein 
for sheep or the marginal ear vein for rabbits, at suitable 
intervals after immunisation from nine days onwards, and the titre 
and characteristics of the antiserum are assessed.
2.4.4.3 Characterisation of Antibodies for RIA
This includes measurement of the titre, avidity and 
specificity of the antibody.
Titre is generally defined as the dilution of antiserum that 
binds 40-50% of the radiolabelled antigen added in the absence of 
unlabelled antigen. Doubling dilutions of antiserum are incubated 
with the same amount of labelled antigen, and after equilibrium has 
been reached - (an arbitrary time for incubation to equilibrium has
to be used when antisera to new antigens are being assessed) - the 
free and antibody bound fractions are separated (Section 2.4.4.5), 
and the dilution of antiserum binding 40-50% of the maximum label 
bound by the antiserum is calculated from an antiserum dilution 
curve (Figure 2.3) where the y axis represents the percentage of 
total radioactivity bound, and the x axis represents the dilution of 
antiserum.
Determination of antibody avidity can be made by a number of 
methods (Scatchard, 1949; Steward & Petty, 1972; Muller, 1980) but 
in each procedure the antigen and antibody are allowed to come to 
equilibrium: [Ab] + [Ag] [AbAg]. The quantities of free and
antibody complexed antigen are then measured without disturbing the 
equilibrium, and the data obtained is analysed by application of the 
Law of Mass Action equation:
[AbAg]
K = _________ in litres/mole
[Ab][Ag]
where K is the association constant, and [AbAg], [Ab], and [Ag] are 
molar concentrations of the antibody bound antigen, free antibody 
and unbound antigen, respectively. It follows that when half the 
antibody binding sites are occupied by antigen, [Ab] = [AbAg] and 
therefore K = l/[Ag]. Thus a high avidity antibody only requires a 
low antigen concentration to achieve binding of antigen to half its 
binding sites (Roitt et al., 1986).
Assumptions made by this equation are: that equilibrium has
been reached, that there are single binding sites on the antigen and 
antibody, and that the labelled and unlabelled antigen have the same
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reactivity with antibody (Chard, 1971). Normal polyclonal antibody 
populations are however heterogeneous, containing antibodies of 
differing affinity for the antigen, so that equilibrium may not be 
achieved for the whole population when data for the calculation of K 
is obtained (Roitt et al., 1986), thus making precise determinations 
of K difficult (Muller, 1980).
A knowledge of the antibody specificity is vital for an
accurate RIA. Cross-reacting compounds, when they are known, can be
removed from the test sample by chemical or chromatographic means, 
or attempts can be made to remove cross-reacting antibodies by 
affinity purification of the antiserum.
The specificity of an antiserum is the result of the sum of 
actions of antibodies within the total population, each of which 
reacts with a different part of the antigen molecule and possibly 
with different parts of the same determinant (Roitt et al., 1986). 
Antigen/antibody reactions can be highly specific when the binding 
sites of the antibodies are directed against determinants on the 
antigen which are not shared by another antigen. When some of the
antigenic determinants are shared by a second antigen, the
antibodies will react with both antigens, thus cross-reacting. This 
is shown diagrammatically in Figure 2.4. Where there are numerous 
compounds within a test sample sharing possible antigenic 
determinants, such as in a cell extract containing a mixture of NTPs 
and dNTPs, there will be varying degrees of cross-reactivity between 
the antibodies being assessed and the compounds in the sample. Thus 
for this project, it was assumed that antibodies raised to one dNTP
SPECIFIC REACTION CROSS-REACTION NO REACTION
AgBAgA AgC
IMMUNIZING
ANTIGEN
DETERMINANT Y 
SHARED
NO SHARED 
DETERMINANT
INDIVIDUAL ANTIBODY MOLECULES (ANTI-X, ANTI-Y and ANTI-Z)
WITHIN A POPULATION ARE DIRECTED AGAINST DIFFERENT DETERMINANTS 
(XYZ) ON THE ANTIGEN MOLECULE (AgA). A SHARED DETERMINANT (Y) 
ON AgB RESULTS IN CROSS-REACTIVITY, WHILE THERE IS NO CROSS- 
REACTION WITH AgC WHICH HAS NO SHARED DETERMINANTS.
FIGURE 2.4. Diagrammatic Representation of
Specificity and Cross-reactivity-- of 
Antibodies and Antigens.
(Adapted from: Roitt et. al., 1986)
would almost certainly display cross-reactivity with NTPs and other 
dNTPs, so that pre-RIA treatment of cell extracts to remove cross­
reactants would be required.
Where there are stereochemical differences between antigens, 
even where a number of chemical groupings, i.e. possible 
determinants, are shared, it has been shown that antibodies do not 
cross react significantly (Piall _et al., 1979; 1986). Moreover, 
Roitt e£ al. (1986) envisaged that antibodies are directed against 
specific three-dimensional electron cloud shapes rather than 
specific chemical structures, so that the antibody recognises the 
overall configuration of the antigen.
The removal of antibodies by affinity purification of 
antiserum has been described by many authors, (Lowe, 1979). This 
technique involves first attaching either the antigen of interest or 
the cross-reacting antigen - (known in this technique as the 
"ligand") - to an inert support such as agarose. The IgG fraction 
of the antiserum can then be separated from other serum proteins by 
adsorption onto DEAE discs or by ammonium sulphate precipitation, 
when after extensive dialysis it is applied to a column filled with 
the prepared ligand-Sepharose. Antibodies are separated on the 
basis of their differing specificity for the ligand, those not 
binding to it being collected in the mildly basic aqueous column 
eluant. Antibodies binding to the ligand can be disasssociated with 
an acid buffer e.g. pH 2.5, (Lowe, 1979). There is however evidence 
that this degree of acidity may damage the antibodies (K Beyzavi, 
personal communication), and it is therefore preferable to have the
antibodies of interest elute straight off the column having attached 
the cross-reacting antigen to the agarose as the ligand.
2.4.4.4 Radiolabelled Antigens
The labelled and unlabelled antigens should be as similar as 
possible to each other in order to have the same reactivity with the 
antibody. The labelled compound should have a high specific 
activity, as the addition of a large mass of labelled antigen to the 
assay tube would result in reduced assay sensitivity, a relatively 
large concentrations of unlabelled antigen being required to compete 
successfully for antibody binding sites.
Stability of the radiolabel on storage is a great practical 
advantage. [^H], [^C] and ]are the most commonly used
3
isotopes for RIA (Aherne & Marks, 1979). The incorporation of [ H] 
14
and [ C] into molecules causes very little structural change and
usually results in a stable product, which may however have a low
14
specific activity, especially in the case of [ C] substituted 
compounds. The relatively low energy emitted by these beta-emitting 
isotopes also means that samples to be assayed require special 
sample preparation for liquid scintillation counting, which is both 
expensive and time consuming. Counting time is also relatively long 
per sample - 3 minutes or more.
[ I], a high energy gamma-emitter gives high specific
activity labelling and requires no special sample preparation for 
counting, which can be achieved in the short time of about 10 - 30
seconds per sample. Its disadvantages are its short half-life of 60 
days, and the large size of the iodine atom, which on incorporation 
into a small molecule can alter it to such an extent that its 
antigenic properties are lost or severely diminished. It is often 
necessary to iodinate a derivative of the antigen, as direct 
substitution is not possible, thus further reducing its antigenicity 
(Aherne & Marks, 1979). In the case of the pyrimidine NTPs and 
dNTPs such as dCTP, however, halogenation at position 5 on the base 
ring is straightforward, so that direct substitution at this 
position is possible.
Radiolabelled dNTPs, of very high specific activity, labelled 
3 125
with either [ H] or [ I], are available commercially.
2.4.4.5 Separation of Antibody Bound and Free Antigen
This is a very important step in the RIA procedure, as 
complete separation of these two phases, without disruption of the 
binding reaction, is vital for precise and reproducible assays.
This is difficult if low avidity antibody is used, and where there 
is a high concentration of protein, such as in unextracted serum or 
plasma samples, interference may occur. The most commonly used 
methods used are: adsorption, fractional precipitation, double
antibody precipitation and the use of solid-phase immuno-adsorbents 
(Ratcliffe, 1974).
Adsorption is widely used especially for small molecular 
weight antigens, because it is simple, fast, effective and cheap.
It is usually the free fraction which is adsorbed onto particulate 
materials in suspension such as charcoal or silicates. Factors 
needing careful optimisation for this type of method are the 
concentration of competing proteins, and the temperature and time of 
exposure to the adsorbent (Binoux & Odell, 1973). Optimum 
conditions for this type of separation are generally found to be a 
ten to fifteen minute exposure to the adsorbent, which is added ice- 
cold to cold samples. The binding reaction may be disrupted if the 
separation is carried out at ambient temperature and/or over a 
longer time period, and this method is generally considered to be 
suitable only where high avidity antibody is being used.
Fractional precipitation with neutral salts or organic 
solvents, such as ammonium sulphate or ethanol, precipitates 
immunoglobulins, leaving the free fraction in solution. Protein 
concentrations heavily influence this method, and scintillation 
counting may be adversely affected by the salts or solvents (Aherne 
& Marks, 1979).
Double antibody precipitation employs a second antibody which 
precipitates the antigen-antibody complexes formed in the first 
antibody reaction. It is widely used, but is expensive and the 
introduction of a second immunological reaction can cause 
difficulties (Ratcliffe, 1974).
The use of solid phase immunoadsorbents gives good precise 
results, and utilizes antibody coated discs, tubes, or finely 
divided solid phases such as Sephadex or dextran (Ratcliffe, 1974).
However, large amounts of antibody are needed, making this method 
expensive.
2.4.4.6 Assay Diluent
The choice of an assay diluent is usually confined to a medium 
of a physiological nature, i.e. having a pH close to neutral and a 
low molar concentration (0.05 - 0.1M). Buffered salt mixtures such 
as potassium and sodium phosphate, containing sodium chloride (0.6g% 
w/v) and a protein (0.1g% w/v) are commonly used. This type of 
diluent is chosen to promote optimal antibody/antigen binding 
reactions. Alteration of conditions such as pH, salt constituents, 
and molarity of the medium can have a profound effect on antibody/ 
antigen binding reactions however, and should be optimised for new 
RIAs.
2.4.4.7 RIA Procedure
A standard curve must be set up with each assay, preferably 
in duplicate. Its range should, if possible, cover the 
concentration range expected in the samples. Blank assay tubes, 
containing label and diluent only, incubated together, are set up 
each time to assess the non-specific binding of the label to the 
tube or the diluent solutes; they are known as "non-specific 
binding" or "NSB" tubes. An increase in the percentage of label 
non-specifically bound is usually an early sign of a deteriorating 
label. Each standard curve must have "zero-binding" tubes set up; 
these contain radiolabel and antiserum, but no antigen, and are a 
measure of the maximum label bound by the antiserum in the absence
of antigen. Other standard curve points are calculated as a 
percentage of this zero binding value (Aherne & Marks, 1979).
The accuracy of the RIA should be assessed by the recovery of 
added antigen, or antigen added to samples. Precision should be 
measured by calculating the standard deviations and coefficients of 
variance of results from multiple standard curves performed on the 
same day ("intra-assay variation") or on several consecutive days 
("inter-assay variation"). Coefficients of variance for both intra- 
and inter-assay variation should preferably not exceed 10%.
Assay sensitivity is in practice often taken as the amount of 
antigen which causes a 10% drop in binding from zero binding. 
However, the figure for assay sensitivity which is generally quoted 
in reporting RIAs, is derived from a calculation of the standard 
deviation at zero binding divided by the gradient of the slope of 
the curve at zero binding (Albano & Ekins, 1970; Feldman & Rodbard, 
1971).
A description of the development of RIAs for four dNTPs 
follows in Chapters 3 and 4. Pre-RIA treatment of extracts using 
procedures referred to in Section 2.3.2 is also described.
Chapter Three
Radioimmunoassay for dUTP and dTTP
Chapter 3
RADIOIMMUNOASSAYS FOR dUTP AND dTTP
The development of RIAs for dUTP and dTTP was undertaken 
specifically to measure concentrations of these dNTPs in cells 
exposed to antifolates or thymidylate synthase inhibitors such as 
N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl) methyl) prop-2- 
ynylamino) benzoyl) -L-glutamic acid, (CB3717) (Jones et al., 1981). 
The structure of CB3717 is shown schematically below:
CO—NK—CH—COOH
CH«—CH«— COOH
A human lung carcinoma cell line, A549, has been cultured and 
exposed in vitro to CB3717, in order to measure the effect of the 
drug on dUTP and dTTP concentrations in these cells, and also to 
assess the modulation of these effects by biochemical means (Curtin 
& Harris, 1988). Cell extracts from such experiments have been 
provided for dNTP measurements.
3.1 Inhibition of de novo Thymidylate Synthesis
Inhibition of thymidylate synthase by disruption of normal 
folate metabolism, leading to thymidylate deprivation, can be a 
highly successful method of bringing about tumour regression. The 
folic acid analogue MTX acts in this way by inhibiting dihydrofolate 
reductase (Jackson, 1984), thus causing a depletion of the coenzyme 
tetrahydrofolate, which is essential for de novo thymidylate 
synthesis as its 5,10-CH2 adduct is the methyl donor for dTMP 
synthesis from dUMP. Tetrahydrofolate is also essential for purine 
biosynthesis, so that purine precursors of DNA are suppressed as 
well. The thymidylate synthesis cycle is shown below:
FH0 + dTMPthymidylate
synthase
dUMP + CH0-FH
Gly NADPH
dihydrofolate
reductase
serine
hydroxymethyl-
transferase
^ NADP+Ser
FH
Thymidylate Synthesis Cycle 
(adapted from Huennekens et^  al., 1987)
FH 2  = 7,8-dihydrofolate FH^ = 5,6,7,8-tetrahydrofolate
The clinical usefulness of MTX is limited by the occurrence of 
acquired resistance to the drug, which can take several forms 
including reduced drug uptake and the amplification of the gene 
coding for dihydrofolate reductase, which is then overproduced 
(Sirotnak, 1987). In an attempt to introduce a clinically useful
antifolate which would overcome these forms of resistance while 
still acting as an efficient inhibitor of thymidylate synthase, the 
drug CB3717 was synthesized and found in animal experiments to be 
effective against tumour cells (Jones et al., 1981). CB3717 acts in
competition with 5,10-methylenetetrahydrofolate, and thus inhibits 
thymidylate synthase activity. This is its sole mode of action, 
which can be completely reversed in vitro and jln vivo by thymidine 
rescue (Jackson et al., 1983). Resistance to CB3717 has been noted 
in L1210 cells, by virtue of increased thymidylate synthase levels 
and activities (Jackman et_ al., 1986). The drug has been tested in 
Phase I and II clinical trials, and was found to have activity 
against breast and ovarian cancer and in cases of hepatoma and 
mesothelioma (Cantwell et al., 1986; Calvert et^  slL., 1987;
Cantwell et_ al., 1988). However toxicity, including hepatotoxicity, 
malaise and dose-limiting nephrotoxicity, was such that no Phase III 
trials have been undertaken (Cantwell ej: al., 1988). The poor 
solubility of CB3717 at physiological pH may have contributed to 
these toxicities, and a series of analogues some with improved 
solubility, a more rapid plasma clearance and greater tumour cell 
toxicity has recently been tested in mice (Newell et^  al., 1988).
One of these compounds - an analogue substituted at C 2  by a CH^ 
group - also appears to act solely as a thymidylate synthase 
inhibitor, as thymidine rescues exposed cells (Jackman et al.,
1988).
It has been shown that there is a build-up of dUMP in cells 
which are exposed to drugs blocking the jle novo formation of dTMP 
and this is probably partly due to the reduction of dTTP inhibition
of dCMP deaminase (Jackson, 1987). Jackson et al., (1983) have 
shown that dUMP is increased in human lymphoblastoid cells by 
thirty-fold following treatment with MTX, and forty-fold following 
exposure to CB3717. They also noted a simultaneous six- to eight­
fold decrease in dTTP concentrations. dUDP was increased by more
than twenty-fold, and dUTP, not measurable in control cells, was
£
detectable at low levels of 1-2 pmoles/10 cells after exposure to 
these drugs. dUTP has been detected in human lymphoblasts treated 
in vitro with MTX (Goulian et al., 1980A) and with the antifolate 
metoprine (DDMP) (Sedwick et al., 1981), but not in control cells. 
The incorporation of uracil into DNA following the appearance of 
dUTP in cells has been discussed as a possible mechanism of 
antifolate toxicity (Richards e_t al., 1984; Jackson, 1987), and it 
has been shown to occur in human lymphoblasts treated with MTX or 
DDMP (Goulian et al_., 1980B; Sedwick et al., 1981) while Ingraham et 
al., (1982) have demonstrated the incorporation of FdUTP into DNA in 
the same cell type following treatment with the thymidylate synthase 
inhibitor, 5FdUr. It is not yet known whether uracil incorporation 
into DNA occurs after treatment with CB3717.
3.2 The Development of a Sensitive RIA Specific for dUTP
The two essential requirements for this assay are great 
sensitivity and specificity for dUTP. It has been shown by Goulian 
et al. (1980A) and by Jackson et al., (1983) that dUTP 
concentrations can be as low as 2 pmole or less per 10 cells 
following antifolate exposure, and it was known that this was
approximately the number of cells which would be available for dUTP 
quantification from each experiment in vitro, and also possibly from 
biopsy material at a later date. Specificity for dUTP was obviously 
required, and it was particularly important that there should be no 
significant cross-reactivity of anti-dUTP antibody with dTTP. dTTP 
could be present in normal actively dividing cells in concentrations 
of 50 pmole or more per 10 cells (Goulian et al., 1980A; Jackson 
et_ al., 1983). It was realised that complete antibody specificity 
for dUTP was impossible, due to both the masking of some antigenic 
determinants on the dUTP molecule by the conjugated protein, and to 
the presence of antigenic determinants shared with NTPs and other 
dNTPs. However, it was expected both from the literature and from 
previous experience that a compound such as dTTP, with the altered 
base ring substituent of a methyl group at 5, would not be 
recognizable to antibodies produced to dUTP, (Humayun & Jacob, 1973; 
Stollar, 1980; Piall et^  al., 1986).
3.2.1 Standard dUTP was purchased from the Sigma Chemical
Company or from Pharmacia. The Pharmacia preparation (catalogue 
number 27-1997) was used for most of the work presented here, and 
was the potassium salt, purity 100% by spectral analysis. Other 
dNTPs and NTPs for cross-reactivity studies were obtained from 
either of these two sources. Crystalline standards were stored as 
recommended by the suppliers at -20°C with a desiccant. They were 
discarded after 3 months and replaced with fresh material. A stock 
standard solution, lOOpg/ml in distilled water, was made up and kept 
frozen at -40°C in approximately 200pl aliquots until needed for 
dilution in the assay.
3.2.2 Production of Antibodies to dUTP
3.2.2.1 Conjugation of dUTP to ovalbumin was accomplished by the 
carbodiimide reaction reported by Halloran & Parker (1966) and 
described in Section 2.4.4.2. 20mg dUTP, 60mg ovalbumin and 60mg 
EDC (Sigma Chemical Co.) were stirred together overnight at 4°C in 
2ml of 0.05M phosphate buffer, pH 7.4. The mixture was then 
dialysed against two changes of one litre of distilled water, whilst 
at 4°C. The absorbance of the dialysates at 260nm was measured and 
read off a dUTP calibration curve to calculate the concentration of 
unconjugated dUTP. The mixture containing conjugated dUTP:ovalbumin 
was then diluted in phosphate buffer to a concentration of 5mg 
protein/ml and freeze-dried in 0.5ml aliquots for storage at -20°C. 
Two such conjugates have been made, and the degree of derivatision 
as calculated from the amount of dUTP remaining in the dialysed 
mixture, and assumed therefore to be conjugated, was 10.1 and 9.6 
moles dUTP per mole ovalbumin respectively. Each of these 
conjugates was stored for a period of two years, and remained
immunogenic as evidenced by giving rise to high titre dUTP antiserum
in a rabbit (Section 3.2.2.3.).
3.2.2.2 Immunisation Schedule
Three Half-lop and three New Zealand White rabbits, and two
Suffolk-cross and one Soay sheep, were immunised with 
dUTP:ovalbumin. The freeze-dried conjugate was reconstituted in 
0.5-1.0ml water, and BCG (IOOjjI of standard vaccine) was added for 
the primer injection. Sheep received 5mg proteinthapten and rabbits
2.5mg protein:hapten in the primer, and half this amount, with no 
BCG, at subsequent immunisations. The reconstituted conjugate was 
mixed vigorously into two volumes of non-ulcerative Freund’s 
adjuvant (Section 2.4.4.2), and, after a pre-immunisation bleed of 
the animal, was injected as a stable emulsion into im. sites in the 
back legs and also into sc. sites in the back in sheep and across 
the neck in rabbits. The number of sites was arbitrarily chosen, 
but was never less than six. Blood was taken from the animals at 
9-10 days after injection, and was centrifuged to separate the 
serum, which was stored undiluted at 4°C, with 0.1% (w/v) sodium 
azide as a preservative. If antibodies were present in sufficient 
titre, the animals were bled again at intervals until the titre was 
too low to be of use. Booster injections were given at three 
monthly intervals, but later the one good antibody responder was 
boosted at approximately six-monthly intervals to preserve the 
production of high affinity antibodies. (Sections 2.4.4.2 and 
3.2.2.3).
3.2.2.3 Assessment of Antiserum Titre and Results of
Immunisation
The assay protocol used for obtaining antiserum dilution curves and 
calculating antiserum titre is shown in Table 3.1.
Table 3.1 Protocol for Assessment of Antiserum Titre
Total Non-Specific Antiserum
9*1) Binding (NSB) Dilution
( P D Curve (jil);
Diluent 600 oOO 400 1
Label 100 100 100
Antiserum - - 100
Dextran
Coated - 100 100
Charcoal
Aliquot for
Scintillation 500 500 500
Counting
The assay was set up in duplicate in plastic tubes (LP3, 
Luckham Ltd). The assay diluent used at first was 0.4M K^PO^, 
pH 4.5, but this was later changed to 0.7M Kt^PO^., pH 4.5 (Section
3
3.2.4). Antiserum and [ H] dUTP (Section 3.2.3) were added diluted
in water. After vortex-mixing, the tubes were incubated in ice for
3
two hours. The unbound [ H] dUTP was then adsorbed onto ice-cold 
dextran-coated charcoal (Section 3.2.4), which was added from a 
rapidly stirred suspension. After vortex-mixing, and standing in 
ice for ten minutes, the tubes were centrifuged at 1500g for 10 
minutes at 4°C, and 500pl aliquots of the supernatant were taken for 
liquid scintillation counting in 4ml of "Ultrafluor" scintillant 
(New England Nuclear - Section 3.2.4.). Samples were counted for 3 
or 4 minutes each.
Results were meaned and calculated as a percentage of the 
counts recorded in the Total tubes. NSB was taken into account by 
subtracting it from specific bound counts. Where low antiserum 
dilutions were employed at the early stages of antiserum production, 
e.g. 1/5 to 1/40, the binding shown by the same dilutions in pre­
immunisation serum from the animal was subtracted. High NSB due to
the presence of large amounts of protein was thus accounted for. A 
typical dUTP antiserum dilution curve obtained from a rabbit is 
shown in Figure 3.1. The titre was taken to be the dilution of 
antiserum binding 40% of the maximum counts bound.
The highest titres obtained following the immunisation 
programme for dUTP antibody production are summarized in Table 3.2.
Table 3.2 
Highest Anti-dUTP Titres Obtained 
in Animals Immunised with dUTP:Ovalbumin Conjugates
G/R/8 G/R/9
Anin
G/R/10
lal ( 
G/R/21
R = Rab 
G/R/22
bit S 
G/R/23
= She 
S17
ep)
S1427 S1428
Highest
titre
obtained
1/90 1 /2. 8K 1/30 NIL NIL 1/10 1/5 1/30 1/10
One New Zealand White rabbit - G/R/9 - has produced 
consistently high titres of anti-dUTP antiserum, and this has been 
used throughout for the dUTP assay. This animal’s response to 
booster immunisations with dUTP:ovalbumin is shown in Figure 3.2. 
Because of the low volume of serum obtainable from a small animal 
like a rabbit at one time, sera were pooled where appropriate.
Three of the rabbits died early on in the immunisation programme and 
immunisation of the remaining animals was discontinued as they 
failed to respond sufficiently to a prolonged programme of 
immunisation (four to seven boosts).
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3.2.2.4 Assessment of Antiserum Avidity and Specificity
for dUTP, and Sensitivity of the RIA
Antiserum avidity was determined from standard curve data, and 
the standard curve assay protocol, used also for samples, is shown 
in Table 3.3.
Table 3.3 Standard Curve Assay Protocol
Total
C/l)
NSB
(/l)
Zero binding
(/I)
Standard or 
Sample (^ il)
Diluent 600 500 400 400 (containing 
standard or sample)
Label 100 100 100 100
Standard - - - up to 400 made up 
in diluent
Antiserum 100 100
Dextran
Coated
Charcoal
100 100 100
Aliquot for
Scintillation
Counting
500 500 500 500
One or two appropriate dilutions of standard dUTP were made 
from the stock solution, and varying aliquots of these were added in 
a total of 400jil of diluent in duplicate to plastic LP3 tubes 
(Luckham Ltd). Samples were assayed in duplicate either as whole 
(400pl) fractions from chromatography columns (Section 3.2.7.2) or 
as aliquots of fractions made up to 400jil with diluent. Assay 
conditions for standard curves were the same as those for antiserum
dilution curves. The addition of accurate and precise amounts of
R
all reagents was made either by use of a Dilutrend Diluter 
(Boehringer) or of B.C.L. repeating pipettes (Boehringer).
The calculation of data in order to construct a standard curve 
was performed by taking the mean of duplicates, then subtracting NSB 
(calculated as a percentage of the total). Standard samples were 
calculated as a percentage of the zero binding. Standards were 
plotted as % bound/% bound at zero on the y axis, versus amount dUTP 
added on the x axis. A typical standard curve fur dUTP is shown in 
Figure 3.3.
Data reduction using spline fitting (LKB software) was 
routinely used in day to day assays to minimise errors in reading by 
eye.
The NSB using the conditions described was between 2-3% of 
total counts, but when the label deteriorated on storage, this 
figure rose consistently to 5% or above. Fresh label was then 
purchased. Zero binding was between 40 and 50% of total counts, and 
the standard curve range was chosen so that the lowest concentration 
would give a 10-15% reduction and the highest about a 90% reduction 
in binding from zero binding.
The determination of antibody avidity was made by using the 
method of Muller (1980) which takes into account the heterogeneity 
of the polyclonal antibodies used in this assay (Section 2.4.4.3.). 
The molar concentrations of the tracer and the inhibitor at 50% 
inhibition of tracer-antibody binding (l^ .) in the RIA and the molar
-J  _ ___________I_______  _J________
20 50 100
pg dUT-P added
FIGURE 3-3. Standard Curve for dUTP Using G/R/9 
Unpurified Antiserum
_J___________  I
500
amount of tracer bound in the absence of inhibitor (T ) need to be
known in order to calculate the average affinity constant, K, of the
dUTP antibody population. Tracer and inhibitor should be the same
chemically and the assay should have reached equilibrium. The
equation applied to the data is:
K = 8
3 (111 3) “ [Tt]
Substituting data generated by a typical dUTP standard curve,
K =  8 K = 8 = 7.97 x 10^ litres/
3(.292+.0638)-.0638 1.0674 - 0.0638 mole
Theoretical sensitivity of the RIA was calculated using the
expression _____ 2 x S.D. at zero binding (Feldman and
gradient of the slope at zero binding Rodbard, 1971)
Ten zero binding tubes were set up for the calculation of S.D.
Sensitivity = 3.06 = 0.64 pg added
4.78
= 1.06 pg/ml
= 2.26 fmole/ml
The specificity of G/R/9 antiserum for dUTP is shown in Figure
3.4, and is summarised in Table 3.4.
Table 3.4 Cross-reactivity of G/R/9 Antiserum Following Boost No.4
Compound Amount added to give 
50% inhibition of B/Bo
% Cross-reactivity
dUTP 76.0 pg 100.00
UTP 2.5 ng 3.04
dUMP >2.0 ng <3.80
dUDP 180.0 pg 42.20
dTTP 18.0 ng 0.42
dCTP > 100.0 ng <0.08
This degree of cross-reactivity showed that both periodate 
oxidation to remove UTP, and chromatography to remove dUMP and dUDP, 
would be necessary treatments for cell extracts before RIA 
quantification. Later batches of antiserum following further boosts 
have continued to show the same degree of cross-reactivity with 
dUMP, dUDP and UTP. However, it was noted that following boost 
number 5 (Pool II), cross-reactivity with dTTP had markedly 
increased to 12.0% on days 14-23 after boosting (high titre 
antisera), falling off to 5.5% on day 44. The reason for this was 
not known, but the possibility of the presence of contaminating dTTP 
in the dUTP standard used to make the immunogen was considered. 
dTTP was obtained from a new source (Pharmacia) and a fresh 
ovalbumin conjugate was made with it for the next and all subsequent 
boosts. Maximum cross-reactivity with dTTP following a boost with 
the new dTTP:ovalbumin conjugate fell to 4.5%, and it has remained 
at this level after later boosts. However, cross-reactivity curves 
with dTTP continued to show a significant decrease in binding from 
zero when only low concentrations of dTTP were added, (Figure
3.4.) and the removal of dTTP cross-reacting antibodies by affinity
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chromatography was thus considered to be an essential step before 
the RIA could be used for samples.
3.2.2.5. Purification of G/R/9 Antiserum by Affinity 
Chromatography
This technique has been described briefly in Section 2.4.4.3. 
Agarose was chosen as the matrix for attachment of the ligand, and 
in particular activated CH-Sepharose 4B (Pharmacia). This was 
known to be stable over the wide pH range which would be used, to 
have a high binding capacity for ligands, and very low non-specific 
binding properties. CH-Sepharose 4B has free carboxyl groups at the 
end of 6-carbon spacer arms which can be used to couple ligands 
containing primary amino groups using a carbodiimide reaction. 
Activated CH-Sepharose 4B is a reactive derivative with an active 
ester group for spontaneous covalent coupling of ligands with 
primary amino groups, using mild conditions suitable for labile 
ligands such as dTTP. The structure of the spacer arm and ester 
grouping is shown schematically below:
0
Sepharose-NH-(CH_)_-C0-0-N
0
Spacer arm and ester grouping on the agarose 
Activated CH-Sepharose 4B
(from: Affinity Chromatography: Principles & Methods, Pharmacia).
dTTP was first conjugated to a protein which provided the 
primary amino groups for coupling, using the carbodiimide method of 
Halloran & Parker (1966). Thyroglobulin was used instead of 
ovalbumin, to avoid possible interference from anti-ovalbumin 
antibodies in the antiserum. lOmg of fresh dTTP (Pharmacia) was 
stirred overnight at 4°C with lOmg thyroglobulin and 20mg EDC. 
Following dialysis against three changes of 400ml of water, the 
conjugate was freeze-dried and stored at -20°C before coupling to 
the Sepharose. The absorbance of the dialysates was measured at 
267nm and the amount of free dTTP in the dialysates was calculated 
using a calibration curve for dTTP at this wavelength. 4mg of dTTP 
remained undialysed and was presumed to be coupled to thyroglobulin, 
thus the degree of derivatisation was calculated as 449.7 moles of 
dTTP coupled per mole of thyroglobulin.
Meanwhile the IgG fraction was precipitated by the gradual 
addition while stirring of 26ml saturated (NH^^SO^ to 52ml of 
antiserum (G/R/9 Pool III). After centrifugation at 1800g for 20 
minutes at 4°C, the IgG pellet was solubilised in 10ml 0.1M NaHCO^, 
pH 8.2, and was then dialysed against three changes of 1 litre of 
this buffer. By the absorbance at 280nm (E 1%/lcm at 280nm = 13.6) 
the concentration of protein was determined to be 26.5mg/ml.
The preparation of the Sepharose and coupling of the ligand 
were accomplished using the suppliers1 instructions accompanying the 
gel. 4g of Activated CH-Sepharose 4B was first swollen in 
lm M HC1 (there was practically instantaneous swelling to about 3ml 
for each gram of gel), and was washed slowly under gentle vacuum
with a further litre of the ice-cold acid. It was washed thoroughly 
with 0.05M phosphate buffer*, pH 7.4, which was also used to re- 
solubilise the freeze-dried ligand. Ligand and gel were then gently 
mixed together in 20ml of phosphate buffer on a roller-mixer for 1 
hour at room temperature. Phosphate buffer was used to wash off any 
excess uncoupled ligand. The wash was kept to determine the 
concentration of uncoupled ligand by absorbance measurements at 
267nm. By this method none was found to be uncoupled in any 
preparation made. Any reactive groups on the Sepharose remaining 
after coupling were blocked by gently mixing the gel with 20ml 0.1M 
Tris-HCl, pH 8.0, on a roller-mixer for 1 hour at ambient 
temperature. The product was washed four times alternately with 
0.1M sodium acetate buffer, pH 4.0, and 0.1M Tris-HCl, pH 8.0, each 
in 0.5ml NaCl, ending with the Tris buffer, and followed by three 
washes with 0.1M NaHCO^, pH 8.0, in 0.5M NaCl.
2ml (0.67g) of the gel was poured, in the bicarbonate buffer, 
into each of four disposable plastic columns of 2ml capacity with a 
5ml reservoir, (Amicon). The flow rate was extremely slow, so that 
several short columns were more convenient than one long one. Each 
ml of gel was calculated to have 670ug dTTP coupled onto it (4mg 
dTTP/4g gel).
*
0.1M NaHCOg, pH 8.0, in 0.5M NaCl was used instead of phosphate 
buffer in some preparations.
It was thought that an absolute maximum of dUTP-dTTP 
antibodies in the IgG preparation would be 10% of total IgG 
(26.5mg/ml). 2ml of IgG solution was applied to each 2ml of gel, 
and the first 1ml of eluant was discarded. Non-associated
antibodies were eluted with 3ml bicarbonate buffer followed by a 2ml
wash, and collected for characterisation. Antibodies binding to the 
dTTP ligand-were disassociated by washing the gel with about 10ml of 
0.05M glycine in 0.2M HC1, pH 2.2. The gel was then re-equilibrated 
in bicarbonate buffer for re-use. Storage of the gel was at 4°C 
with 0.1% azide as preservative.*
The titre of each batch of G/R/9 IgG purified in this way
dropped very significantly following affinity chromatography, e.g. 
the titre of pool III IgG (adjusted for dilution factors) fell from 
1/1200 to 1/48 demonstrating the removal of large numbers of anti­
bodies. K for the purified IgG calculated by the method of Muller
9
(1980) was 7.99 x 10 l/mole. Cross-reactivity with dTTP fell from 
11% to <1.9% for pool II, from 4.5% to 0.2% for pool III and from 
5.9% to 0.027% for pool IV. Figure 3.5 shows cross-reactivity of 
G/R/9 pool IV IgG with dTTP before and after affinity purification.
*Some ligand/Sepharose preparations were found to be more stable 
than others - the reason for this was not known. It was found to be 
advisable to use the preparations as quickly as possible after 
making them - one preparation had lost its ability to bind antibody 
after one week.
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Although a calculation of cross-reaction by the usual method (the 
amount of dUTP causing a 50% drop from zero binding divided by the 
amount of dTTP causing 50% inhibition) gave a satisfactory result in 
terms of percent cross-reaction (0.027%), the shape of the dTTP 
curve still gave cause for concern as low concentrations of dTTP 
(90pg) caused a 25% inhibition in binding even when purified IgG was 
used. However, extracts of actively dividing sub-confluent cells, 
which would be expected to have high dTTP levels with no competing 
dUTP present, when assayed using this G/R/9 pool IV purified IgG, 
have shown no immuno-reactivity (Tables 3.10, 3.11, "control 
cells"). Thus the purified IgG was considered suitable for assaying 
dUTP in the presence of dTTP.
3.2.3 Radiolabel
Radiolabelled dUTP was obtained from Amersham International
(TRK 351), specific activity 20 Ci/mmole. It was tritiated at the 5
position on the base ring, and thus was minimally different to the
unlabelled antigen. An aliquot was diluted 1:100 in 50% ethanol-
water (v/v) and both the stock and the diluted label (sub-stock)
were stored at -20°C. A working dilution was made fresh for each
RIA by further diluting the sub-stock in distilled water so that
3
53.2 pg (O.llpmole)) of [ H] dUTP was added in lOOpl to each assay 
tube. The total counts tubes contained approximately 2000 counts 
per minute.
The stock label stored well for at least one year, while the 
sub-stock was discarded every two months and replaced by a fresh 
dilution.
3.2.4 Other RIA Components
3.2.4.1 Assay Diluent
0.4M KH^PO^, pH 4.5, was used early in assay development 
because the samples were in this medium after chromatography, and 
therefore needed no further treatment before RIA quantification. 
Using this diluent good results were obtained and no other diluent 
was tried until a change was made in the method of chromatography 
used (Section 3.2.7.2) so that the samples were in 0.7M IQ^PO^, 
pH 4.5. It was found that even in this high molarity phosphate 
diluent, results were satisfactory, but a higher zero binding, with 
a desirable higher count rate, was obtained if the radiolabelled 
antigen and the antiserum were added diluted in water, rather than 
in 0.7M K^PO^. Thus the molarity of the diluent was reduced in the 
assay tubes to 0.46M.
3.2.4.2 Assay Incubation Conditions
Because of the instability of dUTP at ambient temperature in
very dilute solutions such as those being used in this assay, the
RIA was from the beginning set up and incubated in ice, and no
3
comparison with results at room temperature was made. [ H] dUTP and 
standard solutions were always kept in ice for as short a time as 
possible before addition to the assay tubes and the antiserum was 
diluted just before addition. So-called "equilibrium assay" 
conditions were used where the reagents were added one immediately 
after the other. Incubation times for standard curves of 1 or 4
hours were compared, and the results are shown in Figure 3.6. The 
curves were superimposable, so that any time between 1 or 4 hours 
could be chosen for incubation. Zero binding at 4h was however 
significantly higher (70% compared to 52% at lh), so that a 
desirable higher count rate was obtained. In practice, 2h 
incubation time was generally used, as this had practical 
advantages in organising the working day.
3.2.4.3 Separation of Free from Antibody Bound Antigen
Although there are a large range of free and bound phase 
separation techniques available, such good results have always been 
obtained using the simple, quick and cheap method of charcoal 
adsorption of the free fraction (Section 2.4.4.5) that this was 
adopted from the beginning. As satisfactory results were obtained 
no comparison was made with other methods.
To avoid disruption of the binding reaction, charcoal is 
usually coated with dextran to reduce the adsorptive capacity to an 
acceptable level (Binoux & Odell, 1973). This preparation is known 
as dextran-coated charcoal or D.C.C. 2.5g% (w/v) charcoal (Sigma 
activated charcoal) was coated with 0.25g% (w/v) Dextran T-70 
(Pharmacia) and suspended in 0.05M phosphate buffer, pH 7.4*. After
*The use of 0.05M, pH 7.4, phosphate buffer (a mixture of Na2HP0^ 
and H^PO^) as a diluent for the charcoal - and not a KH^PO^ 
solution of acid pH as used for the RIA diluent - came about because 
this was used by other members of the research group, and was tried 
initially as a "starting-point" phase separator with such success 
that no changes in its composition were made.
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stirring overnight at 4°C, the mixture was centrifuged at 1500g for 
10 minutes at 4°C. The supernatant, containing extremely fine 
particles of charcoal, was poured off, and the coated charcoal was 
resuspended in phosphate buffer. It was stored at 4°C and added to 
all RIA tubes (except total tubes) from a briskly stirring 
suspension while still ice-cold. The contents of the tubes were 
vortex-mixed, stood in ice for 10 minutes, and then centrifuged at 
1500g for 10 minutes at 4°C. Antibody-bound antigen, labelled and 
unlabelled, remained in the supernatant, and 500pl aliquots were 
taken for liquid scintillation counting.
3.2.4.4 Liquid Scintillation Counting
3
Energy emitted by beta isotopes such as [ H] is of a 
relatively low order of energy and is quantified by a beta-counter 
("liquid scintillation counter") by means of the translation of the 
emitted energy into fluorescent emissions. These are then measured 
by two photo-multipliers in coincidence in the beta-counter, and are 
registered as "counts per minute". The translation of the emitted 
energy into fluorescence is accomplished by the use of suitable 
chemical mixtures added to the radioactive sample. These mixtures 
("liquid scintillation cocktails") - which can be obtained 
commercially - contain organic solvents and fluorophores which boost 
the fluorescence so that it is registered with greater efficiency. 
They may also contain detergent, to keep the sample 
being quantified - generally an aqueous sample - evenly suspended 
over a period of several hours while in the beta-counter. If the 
sample comes out of this even suspension a drop in counting
efficiency occurs, and a lack of comparability across a set of 
samples might also result. Thus the choice of a suitable liquid 
scintillation cocktail is important for assay precision and 
accuracy. Counting efficiency is defined as the percentage of 
disintegrations per minute in the sample, which are registered by 
the beta-counter as "counts per minute".
Aliquots from the dUTP assay for scintillation counting
contained a high salt concentration, which was difficult to get into
an even and stable suspension with scintillation counting
"cocktails". It was found that the addition of 4ml "Ultrafluor"
(National Diagnostics) to a 500j l i1 sample aliquot resulted in a
suitably stable suspension, and this was used throughout. An
evaluation of different scintillants tried in order to obtain
3
efficient counting of [ H] in high salt solutions is to be found in 
Section 4.2.4.4.
3.2.5 Assay Precision
Intra-assay and inter-assay variation was measured. Five or 
six standard curves were set up on the same day for intra-assay 
comparison and the data from five or six standard curves performed 
on consecutive days was used for inter-assay comparison. The 
standard deviation and coefficient of variance at each point on the 
curve (including zero binding) were calculated.
Results of intra-assay precision for the dUTP RIA using 
unpurified G/R/9 antiserum are shown in Table 3.5, and in Figure 
3.7. Inter-assay precision using affinity-purified IgG from G/R/9 
is shown in Table 3.6 and in Figure 3.8.
At the bottom of the standard curve, where the count rate is 
low, small errors are magnified and the efficiency of counting is 
diminished, the desirable coefficient of variance of less than 10% 
is often exceeded, an indication that this region is unreliable for 
the calculation of samples.
Table 3.5 Assay Precision Using G/R/9 Unpurlfied Antiserum.
Intra-Assay Variation - 5 Standard Curves Set up on 
the Same Day
% B/Bo at amount dUTP added (pg)
0% B/T 7 15 22 36 51 73 109 146 218 364
27.5 87.0 79.7 70.4 61.3 52.9 41.4 27.5 24.1 17.1 9.7
26.8 88.6 82.2 77.9 61.6 55.6 40.1 30.5 22.9 14.2 6.5
25.9 91.3 79.7 77.4 61.6 54.9 45.6 33.6 28.2 15.8 9.8
24.3 94.1 82.2 80.7 66.1 60.9 49.5 37.6 24.7 15.1 8.5
26.4 89.1 85.8 70.4 61.8 54.2 45.3 30.0 23.3 16.5 8.0
mean
26.2 84.7 81.9 75.4 62.5 55.7 44.4 31.8 24.6 15.8 8.5
S.D
1.20 3.63 2.50 4.69 2.03 3.07 3.73 3.88 2.10 1.09 1.36
c.v.%
4.5 4.3 3.1 6.2 3.1 5.5 8.4 12.2 8.6 6.9 15.9
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FIGURE 3-8 dUTP Standard Curve - Mean of 6 Inter-Assay 
Curves ('jrS.D.) Using Purified G/R/9 IgG
Table 3.6 Assay Precision Using G/R/9 Affinity Purified IgG
Inter-Assay Variation - 6 Consecutive dUTP Standard 
Curves Set up on Different Days
% B/Bo at amount dUTP added (pg)
0 (% B/T) 22 51 74 147 221 367 514 1103
48.8 86.0 74.2 68.1 47.0 36.2 27.0 21.0 11.0
42.2 81.6 76.7 72.1 46.1 37.7 28.9 20.0 14.4
44.5 87.4 77.9 69.4 48.3 41.5 30.2 22.5 14.8
42.2 83.0 73.9 66.0 46.6 36.6 24.2 23.7 10.1
47.2 83.8 69.6 65.5 48.9 39.5 24.6 17.6 9.2
45.8 83.6 72.2 63.5 46.7 42.5 26.4 22.3 10.8
Mean
45.1 84.2 74.1 67.4 47.3 38.9 26.9 21.2 11.7
S.D.
2.67 2.10 3.00 3.07 1.09 2.65 2.35 2.17 2.32
c.v.%
5.9 2.5 4.1 4.6 2.3 6.8 8.7 10.2 19.8
3.2.6 Assay Accuracy
Assay accuracy is normally assessed by the recovery of the 
compound to be measured when added to RIA assay tubes as if it were 
an "unknown" sample. Where serum or urine samples are to be 
quantified, standard material is added to them in a known concen­
tration, and the samples are then treated as normal in the RIA e.g. 
they may be diluted with assay diluent or extracted. In this way, 
any interference from sample constituents such as protein or urea, 
or inaccuracies in dilution, are accounted for. In the dUTP assay, 
cell samples go through a multi-step procedure before RIA
quantification, and this has been taken into account in recovery 
studies where dUTP of known concentration has been taken throughout 
the entire procedure (Section 3.2.9). It was considered that the 
addition of dUTP to RIA tubes was an inappropriate way to assess the 
accuracy of this assay, as a recovery sample measured in this manner 
was in effect only another standard curve point.
3.2.7 Extraction of dUTP
It has been concluded in a review of the methodology available 
for dNTP quantification (Hunting & Henderson, 1982), that the 
highest and most reproducible recoveries for dNTPs were obtained 
following the extraction procedure described by Bagnara & Finch 
(1972). As time did not allow other extraction procedures to be 
evaluated for this project, this method was adopted and used 
throughout. Cells were extracted into ice-cold 0.4M PCA with 
vigorous vortex-mixing to ensure the break-up of the cells, and the 
rapid inactivation of enzymes. The extract was then allowed to 
stand in ice for 30 minutes before centrifugation at 4°C and 1500g 
for 20 minutes. Aliquots of supernatant were taken into ice-cold 
tubes containing 0.5 vol of ice-cold 0.72M KOH in 0.16M KHCO^* and 
vigorously vortex-mixed. KCIO^, precipitated out of the extracts, 
which were kept in ice for 1 hour, with a further vortex-mix after 
20-30 minutes. Centrifugation followed, using the conditions 
already described, and the supernatant was carefully removed to cold 
tubes, to be frozen at -40°C for storage, or to be taken immediately 
through a further step in the assay procedure.
*Bagnara & Finch found that this K0H/KHC0o mixture resulted in 
maximum precipitation of chlorate ions, which interfere with many 
assay procedures, and that it also buffered the extract close to a 
neutral pH.
The recovery of standard dUTP "extracted" from water following 
the procedure above, was measured after following other steps in the 
assay procedure (Section 3.2.9).
3.2.8 Pre-RIA Treatment of Cell Extracts
3.2.8.1 NalO^ Oxidation of UTP was carried out, because although
the degree of cross-reactivity of the antibody with UTP was low 
(2.6%) the high concentrations of this NTP present in cells relative 
to dUTP made its elimination necessary (Garrett & Santi, 1979). The 
simple and effective method of NalO^ oxidation of NTPs followed by 
degradation of the resultant aldehydes using CH^N^ (Section 
2.3.2.1) was employed. The procedure was a modification of one 
described by Garrett & Santi (1979).
0.5ml extract was treated by the addition of 20jil 0.5M NalO^, 
followed by vortex-mixing. After 5 minutes at ambient temperature, 
25jil of 4M methylamine CH^NI^ pH 7.5*, was added and mixing was 
repeated. Incubation was for 15 minutes at 37°C, after which the 
tubes were plunged into ice, and then either stored at -40°C or 
taken through the next assay step on the same day.
The recovery of dUTP and UTP after this procedure, and using 
different incubation conditions, was evaluated. 10ng UTP 
(approximately 20pmol) and lOOpg, 200pg and lng of dUTP (0.25, 0.5
*pH adjusted to 7.5 by the slow addition of concentrated PCA 
(60% w/w)while stirring in ice.
and 2.0pmol approximately) were placed in tubes in KOH/KHCO^- 
treated 0.4M PCA ("blank extract"). The tubes were then treated 
with NalO^. and CH^NI^ as described above, and three different 
incubation conditions were compared, namely 37°C, 15 minutes; 37°C, 
30 minutes and ambient temperature (R.T.), 15 minutes. RIA of the 
recoveries with a standard curve set up containing NalO^/CH^NH^” 
treated "blank extract" to account for any effect of this addition 
on the shape of the curve, gave the results shown in Table 3.7.
Table 3.7 Recovery of UTP and dUTP After NalO^/CH^NHp Treatment 
Under Different Incubation Conditions
Compound Amount % Recovery Following Incubation at:
Added 37°C, 15 min 37°C, 30 min R.T., 15 min
dUTP lOOpg 100 96 102
200pg 95 100 100
lng 92 88 93
UTP lOng None None None
detected detected detected
No UTP remained detectable, showing that degradation of the 
NTP was complete under the conditions used. There was no 
significant difference in the % dUTP recovered following any of the 
incubation conditions tried, and it was decided to incubate the 
samples at 37°C for 15 minutes for this procedure.
3.2.8.2 Chromatography of Extracts
Following exposure of cells to CB3717, relatively high 
concentrations of dUMP and dUDP could be expected (Jackson et^  al, 
1983). Because of the significant cross-reaction of the antibody
with these two compounds, a chromatographic step to separate them 
from dUTP was essential, and anion exchange chromatography (Section
2.3.2.3.) was finally adopted for this purpose.
Initially HPLC was used. A Varian LC 5000, with a Rheodyne 
loop injector, and a 25cm x 4.6mm Partisil 10 SAX anion exchange 
column (Whatman Ltd) was set up, and standard mixtures of dUMP, dUDP 
and dUTP were applied. Elution was by isocratic 0.4M KI^PO^, pH 
4.5, with a flow rate of 2ml/minute, 70 atmospheres pressure (470 
p.s.i.). Detection of peak positions was made by collecting 
fractions of eluate from the column into plastic tubes (LP4, Luckham 
Ltd), by means of an LKB "Redirac" 2112 fraction collector, and 
assaying the fractions by RIA. The relatively insensitive method of 
UV absorbance was not used for detection as it was thought that the 
high concentrations of uridylates (yig quantities) required for 
detection would cause contamination of the HPLC apparatus and 
injection loop.
Using this system, dUMP eluted with the solvent front, with 
2 minutes retention time, followed by dUDP at 2.5 minutes and dUTP 
at 10 minutes. Although the resolution and recovery of 2pmol dUTP 
applied to the column was adequate (mean 87.8%, S.D. 9.27, 
c.v. 10.6%, n = 10), difficulties of leaking pumps, injector loops 
and tubing joints in the HPLC became acute, causing so much wasted 
time and expense, that it was decided to abandon the use of HPLC in 
favour of LC.
LC was adopted, using the following conditions: QAE Sephadex
(Pharmacia) was kept swollen in 0.3M KH^PO^, pH 4.5, containing 
0.002% (w/v) chlorhexidine (Aldrich Chemical Company) as a 
preservative. 5ml (2g) was poured into plastic K9/15 columns fitted 
with 50ml reservoirs (Pharmacia) filled with the same buffer. 
Standards or extracts were applied to the column, and after the 
passage of 10 column volumes of 0.3M K^PO^, a change was made to 
0.7M IQ^PO^, pH 4.5. After discarding the first 2.5ml, appropriate 
fractions were collected, removed immediately to ice, and either 
stored frozen at -40°C or quantified the same day by RIA. Fractions 
were collected into plastic tubes using the fraction collector, and 
were either 400jil or 800jil in volume. Thirty 400jil or fifteen 800^il 
fractions were collected for assay. The former could be assayed 
direct by RIA while the latter could be aliquoted as smaller 
volumes, to be made up to AOOjil for quantification. This latter 
method was advantageous where high concentractions of dUTP were 
expected, and where 400jil fractions might contain more dUTP than the 
highest standard curve concentration, thus necessitating repeat 
chromatography. A further reason for collecting larger fractions 
was the co-elution with dUTP in this system of dTTP, which could 
then be assayed in the same fractions after aliquoting (Section 
3.3).
The elution positions of dUMP, dUDP and dUTP following 
the addition of standard mixtures to the column and ascertained by 
RIA, are shown in Figure 3.9. Very high concentrations (lOOpmole of 
dUTP and dUDP and lnmol of dUMP) were applied, partly because of the 
low cross-reactivity of dUMP with the antibody, and partly because
ng
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FIGURE 3-9. Elution Profile of dUMP, dUTP and dUMP 
from a 5nil QAE A _ Sephadex Column
information regarding any "tailing,,-effect of peaks was required. 
Because even a small overlap from a dUDP "tail" would be detected as 
dUTP, and high dUDP levels were possible (Jackson et al., 1983), a 
large elution volume was allowed before 0.7M KH^PO^ was applied.
Two extracts of treated A549 cells were checked for their 
level of dUDP following treatment with 10 or 30jiM of CB3717 by 
collecting fractions from the entire eluant for the RIA. These 
samples both had high dUTP levels (88 and 127pmole/ml extract 
respectively) but on RIA of all the fractions from the LC columns, 
only a trace of immunoreactive material was detected at the dUDP 
elution position (Figure 3.10).
To ascertain the elution position of dUDP in a cell extract, a 
sample extract was chromatographed alone and also after the addition 
of lOpmole of either dUDP or dUTP standard. The results of dUTP 
assay of all the fractions are shown in Figure 3.11, and demonstrate 
clear separation of dUDP from dUTP. The early eluting peak is 
almost certainly dUMP.
The time required to elute one sample in the fashion described 
was about 1 hour, but several columns at different stages of elution 
could be run at once, so that about twenty samples could be 
chromatographed in one day. The effect of column eluant on the 
RIA was studied by collecting ten fractions from fresh QAE A25 for 
evaluation of its effect on NSB and zero binding. The NSB of these 
fractions was 3.5% (standard curve NSB = 3.4%), and zero binding 
using the column effluent was 104% of the standard curve zero
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binding. It was concluded that there was no interference from fresh 
QAE A25 using the assay conditions described above. However, if the 
Sephadex was re-used several times, despite being thoroughly washed 
before re-use with a minimum of 5 volumes of 0.7M KH^PO^ and then 
re-equilibrated with 5 volumes of 0.3M IQ^PO^, it was noted that 
some immunoreactive materials accumulated, particularly around the 
area of the dUTP peak. Values obtained for individual blank 
fractions eluted from re-used QAE A25 ranged from 24-43pg (mean = 
32.6pg) and when totalled would contribute significantly to the 
calculated dUTP concentration of a sample. It was concluded 
therefore that fresh QAE A25 must be used for each chromatographic 
separation to avoid this contamination.
3.2.9 Summary of dUTP Assay and Recovery of dUTP Through the
Entire Procedure
A summary of the entire dUTP assay is depicted in Figure 3.12. 
Twenty samples can be taken through the entire procedure in about 
four days.
Figure 3.12 dUTP ASSAY PROCEDURE
EXTRACTION 
\
Ice cold 0.4M PCA 
30 min in ice
I
Centrifuge
Supernatant + 0.5 vol 0.72M KOH/0.16M KHCO^ 
| lh in ice
Centrifuge
Supernatant 
/  ^/ Freeze at -40°C
* sNalO^/CHoNH0 *
DEGRADATION OF UTP
20jil 0.5M NalO^/0.5ml extract 
5 min, R.T.
25ul 4M^CHqNH9, pH 7.5 
' 15 min, 37°C
iIce to cool
/  ^/ Freeze at -40°C
CHROMATOGRAPHY ^
TO SEPARATE dUMP and dUDP
♦
Aliquot applied to 5ml QAE A25 
in 0.3M KH2P04, pH 4.5
Discard 50ml
0.7M KH2P0,, pH 4.5 
Discard 2.5ML
▼
30 x 400^1 or
15 x 800jil fractions (aliquoted)
1
Freeze at -40°C
S
QUANTIFY BY RIA
The recovery of dUTP standard, extracted and taken through the 
whole assay procedure is shown in Table 3.8.
Table 3.8 Recovery of Standard dUTP Extracted Treated with
NalO^/CH^NH^, Chromatographed and Quantified by RIA
dUTP ng (pmole) % recovered mean S.D. c.v.%
1.46 (3.11) 37.1, 32.8, 38.9 36.2 3.13 8.7
3.67 (7.84) 69.9, 64.9, 73.9 69.6 4.51 6.5
7.33 (15.66) 59.8, 57.5, 61.7 59.7 2.10 3.5
14.66 (31.32) 62.6, 61.0, 62.5 61.1 1.80 3.1
It can be seen that the recoveries are reproducible, but not 
quantitative at any concentration. Standards of 3.11 and 7.84pmole 
dUTP applied directly to the chromatography column gave mean 
recoveries by RIA of 68.1% and 86.9% respectively (n = 3). Small 
losses probably occur at each step, and may in part be due to the 
instability of dUTP. To further assess recovery from this assay, 
three sample extracts were "spiked" with lng dUTP just prior to 
chromatography, and 109, 93 and 88.7% of added dUTP was recovered 
from these samples respectively.
The reproducibility of the assay has been tested in two 
extracts of CB3717-treated cells, which were chromatographed and 
quantified five times in one day, and once on two other occasions. 
Good reproducibility was obtained both within and between assays, 
and the results are shown in Table 3.9. It should be noted this is 
a test only of the precision of the chromatographic and RIA steps, 
as extraction and NalO^, treatment were performed only once on each 
sample.
Table 3.9 Reproducibility of dUTP Assay in Two Extracts
of CB3717 Cells
Sample number Day of assay dUTP pmole/ml extract
235 1 145.2, 122.8, 130.7, 123.3, 112.4
2 126.7
3 108.7
239 1 90.3, 93.0, 84.4, 86.9, 85.1
2 80.1
3 72.6
The results from Day 1 give mean values of 126.8 and 87.9 
pmol/ml extract respectively. The S.D. of results from Day 1 is 
12.13 (c.v. 9.5%) for sample 235, whilst the S.D. is 3.65 
(c.v. 4.1%) for sample 239. If the mean is established for all the 
results for each sample, then sample 235 had an overall mean of
120.7 pmole dUTP/ml extract (S.D. = 10.42, c.v. = 8.6%), while 
sample 239 had a mean dUTP of 80.2 pmole/ml extract (S.D. = 7.65, 
c.v. = 9.5%).
3.2.10 Results of Sample Assay
The culture and experimental exposure of cells to CB3717 in 
order to determine its effects, if any, on dUTP concentrations, was 
conducted by Dr Nicola Curtin of the Cancer Research Unit, Newcastle 
Royal Victoria Infirmary. The cells were human lung carcinoma 
cells, A549, grown in multiwell dishes in monolayers in RPM I 1640, 
supplemented with 10% heat inactivated foetal bovine serum, 500
i.u./ml penicillin and 500ug/ml streptomycin. The serum was
dialysed to decrease endogenous thymidine thus reducing the use of
the salvage pathway by the cells. When the desired density was
reached - but before the culture was confluent - the medium was
replaced with medium containing CB3717 and/or other compounds
depending on the design of the experiment. Cell counts per well
£
were usually about 1.0 x 10 at the start of the experiment. Dr 
Curtin extracted the dNTPs into PCA, following the protocol 
described previously, but in this case flooding the monolayers with 
lml cold PCA after removing the medium by aspiration. The cells 
were detached from the dish with a cell scraper for transfer to a 
chilled tube. On completion of the extraction procedure, each 
extract was aliquoted into two tubes and stored frozen in liquid 
nitrogen until despatch in dry ice for dUTP estimations.
(a) A Dose Response Curve was obtained for CB3717 and dUTP in A549 
cells. The cells were exposed to 3, 10 or 30pM CB3717 for 24 hours. 
Control cells were also cultured. Four such experiments were 
performed by Dr Curtin on different days, and the results of dUTP 
assay are shown in Table 3.10 and in Figure 3.13.
Table 3.10 dUTP Pool Sizes Following Exposure of A549 Cells 
to Different Doses of CB3717 for 24 h.
£
Dose of dUTP pmole/10 cells Mean dUTP±S.D.
CB3717 Expt.l Expt.2 Expt.3 Expt.4
Control None None None None None detected
detected detected detected detected
3jiM 
10jiM
30uM
3.47 0.8 1.9 1.6 2.62 ±1.48
3.58 2.2 5.5 1.9
134.9 126.1 85.4 122.2 133.9 ± 31.7
193.1 120.1 128.8 161.7
655.8 376.5 144.6 354.4 372.7 ±177.1
605.1 332.4 210.4 302.3
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(b) dUTP Concentrations After Exposure of A549 Cells to CB3717 and
Dipyridamole. The cells were exposed for '2^ h to doses of 3 or 30pM 
CB3717 either alone, or combined with 1 or IOjiM of the nucleoside 
transport inhibitor dipyridamole, and were extracted for dUTP assay. 
Control cells either untreated, or exposed to IOjiM of dipyridamole 
were also extracted. Identical experiments were run on two 
different days. The results of dUTP assay in these extracts are 
shown in Table 3.11 and in Figure 3.14.
Table 3.11 The Effect of Dipyridamole (DP) on dUTP Concentrations 
in Control and CB3717 (CB) Treated A549 Cells 
(24 hour Exposure)
£
Treatment dUTP pmole/10 cells
Experiment 1 Experiment 2
Control 
IOjiM DP 
3}iM CB
3pM CB + l^ iM DP 
3jjM CB + lOuM DP 
30>iM CB
30jiM CB + lpM DP 
30;iM CB + IOjiM DP
None detected 
None detected
33.7
161.1
323.6
313.6
578.6
1233.2
None detected 
None detected
52.5
103.8
275.1
296.2
103.9
396.2
50.7
84.5
330.1
238.2
167.2
351.5
The poor correlation of results between Experiments 1 and 2 
following treatment with 30pM CB3717 and dipyridamole was 
inexplicable and dUTP assays on other replicates from these 
experiments and on samples from fresh experiments are being 
undertaken to confirm the results. The results after 3jiM CB3717 
exposure are however in agreement between the two experiments, and 
it is clear that 3 p K of drug, when combined with IOjiM dipyridamole, 
is as toxic as far as the dUTP concentrations generated are 
concerned, as is 30jiM of drug alone.
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3.2.11 dUTP RIA - Discussion
This RIA has required pre-quantification treatment of cell 
extracts with both NalO^/CHgN^ and with chromatography in order to 
obtain specific results using a suitably purified IgG. Recoveries 
through the entire multi-step procedure are not quantitative at any 
concentration tested, but good reproducibility has been obtained, so 
that for comparison of dUTP levels following different drug 
treatments of cells, this assay is adequate. The trace levels of 
dUDP in extracts of A549 cells contrast with the high 
levels found by Jackson et al., (1983) in human lymphoblasts. It is 
probable that these two different cell types differ in their 
accumulation rates of deoxyuridylates. In view of the low 
concentrations of dUDP in A549 cells, the elution volume of 0.3M 
KE^PO^ can be safely reduced to about 30ml when extracts from these 
cells are being assayed. However, before assaying dUTP in other
cell types, the dUDP concentrations would have to be ascertained so
that 0.3M EQE^PO^ elution volumes could be suitably adjusted.
The results described in Section 3.2.10 show that there is a
significant dose-response curve effect between doses of CB3717 and 
dUTP concentrations in A549 cells. The effect of dipyridamole in 
increasing the toxicity of CB3717 was investigated by Curtin &
Harris (1988), who showed that the efflux of deoxyuridine was 
inhibited by dipyridamole, which they concluded might lead to an 
expansion of deoxyuridine nucleotide pools. The preliminary results 
in Section 3.2.10 show that there is indeed considerable enhancement 
of dUTP levels following the simultaneous exposure of A549cells to 
CB3717 and dipyridamole.
3.3 The Development of a Sensitive RIA Specific for dTTP
Because dTTP is present in normal untreated cells,
particularly those undergoing active division, in relatively large
£
concentrations, e.g. about 50pmole/10 cells (Hunting & Henderson, 
1982), no difficulty has been experienced in measuring it by methods 
available to date. It was however, decided to attempt to develop a 
specific RIA for dTTP because of the difficulties already described 
in distinguishing it from dUTP by HPLC or enzymatic incorporation 
(Section 3.2). Also, as dUTP levels increased after exposure of 
cells to CB3717, it was expected that dTTP concentrations would 
simultaneously decrease to a point where an assay of great 
sensitivity would be required. It was clearly desirable to measure 
dUTP and dTTP in the same extracts which had also received the same 
assay treatment, so that the protocol for this assay deliberately 
followed the same pattern as that for dUTP. The results presented 
here are preliminary, as the assay has not yet been fully validated.
3.3.1 Standard dTTP was purchased from Pharmacia (catalogue 
number 27-5800-02), and was the sodium salt, 98% pure by spectral 
analysis. Conditions for storage of the crystalline and standard 
solutions were the same as for dUTP standard (Section 3.2.1).
3.3.2 Production of Antibodies Specific for dTTP
3.3.2.1 Conjugation of dTTP to Ovalbumin was achieved following 
the method of Halloran and Parker (1966). 20mg of dTTP was 
stirred overnight in the cold with 60mg EDC and 60mg ovalbumin in
2ml 0.05M phosphate buffer, pH 7.4. This was dialysed twice against 
one litre of distilled water, and measurement of unconjugated dTTP 
in the dialysate was made by comparing the absorbance of the 
dialysate at 267nm with a calibration curve for dTTP at this 
wavelength. Three conjugates have been made, and the degree of 
derivatisation was 13.5, 9.6 and 10.0 moles dTTP/mole ovalbumin 
respectively. After dilution to 5mg protein/ml, the conjugate was 
divided into 0.5ml aliquots and freeze-dried for storage at -20°C.
3.3.2.2 Immunisation Schedule
Four Half-lop White rabbits, two Soay and two Suffolk-cross 
sheep were initially immunised. The preparation of the immunogen 
for injection, and the immunisation schedule followed the same 
procedures as those used for dUTP (Section 3.2.2.2).
3.3.2.3 Assessment of Antiserum Titre and Results of 
Immunisation
The protocol followed for measuring antiserum titre has 
already been described in Section 3.2.2.2. Immunisation resulted in 
a positive response in all eight animals, however this response was 
of a low order of titre except in one Suffolk-cross sheep, G/S/1524. 
These results are summarised in Table 3.12.
Table 3.12 Maximum dTTP Antibody Titres Obtained Following
Immunisation with dTTP:Ovalbumin Conjugates
Animal % Bound/Total Titre
Number of 
Preceding 
Boost
G/S/C33 33 1/5 3
G/S/C34 35 1/5 3
G/S/1524 40 1/500 2
G/S/1525 40 1/10 2
G/R/14 24 1/5 3
G/R/15 35 1/40 3*
G/R/16 18 1/10 2
G/R/17 10 1/5 1*
*Animal died before further boosts could be given
All the animals showed a decline in their dTTP antibody titre 
following further boosts. It was thought that the conjugate may 
have deteriorated on storage, so that a fresh one was made for the 
next boost (boost number 4), but no improvement in the titre was 
achieved with its use. Immunisation of all animals except G/S/1524 
was then abandoned and further assay development has used antiserum 
from this sheep. The response of G/S/1524 to dTTP:ovalbumin boosts 
is shown in Figure 3.15. The highest titre bleed obtained from this 
sheep, following boost number 2, was designated "G/S/1524 IIB", and 
was used throughout for further work on this assay.
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3.3.2.4 Assessment of Antibody Avidity and Specificity for dTTP
The protocol used for the standard curve and sample assay 
was the same as that shown in Table 3.3 and described in Section
3.2.2.4. The standard curve range using unpurified antiserum was 
from 28 to 1409 pg dTTP added (0.05 to 2.57 pmole), and a typical 
standard curve is shown in Figure 3.16.
The NSB was between 4.5 - 6.0% of total counts. Zero binding 
was between 35 - 40% of total counts in order to achieve the 
standard curve sensitivity shown.
To calculate the affinity constant, K, analysis of standard 
curve data obtained using unpurified antiserum was performed using 
the method of Muller (1980).
K = 8
3(0.676 + 0.0107) - (0.0107)
= 3.903/10^ litres/mole
The cross-reactivity of G/S/1524 IIB antiserum with 
structurally related dNTPs and UTP is shown in Table 3.13, and in 
Figure 3.17.
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Table 3.13 Cross-Reactivity of G/S/1524 IIB Antiserum
Compound Amount giving 50% B/Bo % Cross-Reactivity
dTTP 195pg 100
dTd > lOOng <0.19
dTMP > lOOng <0.19
dTDP 220pg 88.6
dUTP 4.2ng 4.64
dUMP > lOOng <0.19
dUDP 2.5ng 7.8
dCTP > lOOng <0.19
dATP > lOOng <0.19
dGTP > lOOng <0.19
UTP 65 ng 0.3
These results closely resemble those obtained for G/R/9 
antiserum in that the diphosphate form of the hapten is recognised 
by the antibody to a highly significant degree (88% cross-reaction) 
with the monophosphate showing no significant cross-reactivity.
There is also no significant recognition of the purine dNTPs or of 
dCTP, but there was slight cross-reactivity with UTP (0.3%) and a 
disappointingly significant cross-reaction with dUDP and dUTP (7.8% 
and 4.64% respectively). UTP could be degraded by the NalO^/CHgNi^ 
reaction with the extracts, and chromatography would remove dTDP and 
dUDP, but cross-reaction with dUTP once more indicated the need to 
affinity purify this antiserum, in this case to remove antibodies 
binding dUTP.
3.3.2.5 Antibody Purification
Purification of G/S/1524 IIB antiserum was undertaken by 
carrying out the procedure used successfully for G/R/9. 5g of 
activated CH-Sepharose 4B was prepared for attachment of the ligand
as described in Section 3.2.2.5. The ligand was a conjugate of dUTP 
to thyroglobulin made by stirring lOmg dUTP, lOmg protein and 20mg 
EDC together overnight at 4°C in 2ml of 0.05M phosphate buffer, pH
7.4. After dialysis against two changes of 500ml distilled water, 
the degree of derivatisation of the conjugate was calculated by the 
measurement of unconjugated dUTP in the dialysates at 260nm 
absorbance, and 450 moles dUTP were found to be conjugated to 1 mole 
of thyroglobulin (4.45mg dUTP/lOmg protein). The coupling of this 
conjugate onto Sepharose using the conditions described in Section
3.2.2.5 was assumed to be complete, as no dUTP was found as measured 
by absorbance at 260nm of the wash collected directly after the 
coupling procedure.
G/S/1524 IIB IgG was prepared by the addition of 47ml of 
saturated (NH^^SO^ to 95ml of whole serum while stirring, 
and the IgG pellet recovered after centrifugation was solubilised in 
120ml 0.1M NaHCOg, pH 8.6. After extensive dialysis against three 
changes of 1.5Z 0.1M NaHCO^, pH 8.6, the IgG was stored at 4°C with 
0.1% sodium azide as a preservative.
A 10ml column of the prepared Sepharose/ligand was poured in 
0.1M NaHCOg in 0.5M NaCl, pH 8.6. 10ml of solubilised IgG was 
applied (90.7mg/ml protein as determined by absorbance measurements 
at 280nm), and the first 5ml eluant was discarded. 15ml of 0.1M 
NaHC0^/0.5M NaCl was used to wash off antibodies not binding to the 
dUTP ligand, which were collected and evaluated for titre and 
specificity. The immobilised antibodies were disassociated from the 
ligand by washing with 30ml glycine/HCl buffer (pH 2.2) and the
Sepharose was re-equilibrated in 0.1M NaHC0^/0.5M NaCl as described 
previously (Section 3.2.2.5) for storage at 4°C. Severe 
deterioration in the ability of this Sepharose/ligand preparation to 
bind antibodies was found after re-use for the fourth time over a 
period of six days.
Before affinity chromatography, the titre of the IgG was 
1/330, and after eluting it in 15ml, there was a dilution factor of 
1/1.5 (titre therefore by dilution would equal 1/220). However, the 
titre after chromatography had fallen to 1/48, demonstrating that 
antibodies had been removed by binding to the dUTP ligand.
The affinity constant, K, was calculated for the purified IgG 
using the method of Muller (1980) applied to standard curve data.
K = 8
3(1.54 + 0.0085) - (0.0085)
= 1.72 x 109 1/mole
The effective standard curve range using purified IgG was from 
66 to 2800pg added, and a typical standard curve is shown in Figure 
3.18.
Cross-reactivity of this purified IgG with dUTP was assessed 
by comparison of the amounts of dUTP and dTTP required to displace 
50% of antibody binding at zero standard added. The results and a 
comparison with unpurified IgG are tabulated below in Table 3.14 and 
are shown in Figure 3.19.
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Table 3.14 Cross-Reactivity of Purified and Unpurified
G/S/1524 IgG with dUTP
Amount giving 
50% B/Bo
% Cross-Reactivity
Unpurified IgG 180pg dTTP 100
3.2ng dUTP 5.6
Purified IgG 300pg dTTP 100
6.4ng dUTP 4.7
As these results showed a disappointing similarity in the 
degree of cross-reactivity with dUTP in purified and unpurified IgG, 
it was decided to apply the purified fraction once more to the 
affinity column, in the hope that a distinct population of 
antibodies recognising only dTTP would be separated from this more 
dilute antibody solution. The purification procedure was carried 
out as described above, and the now twice-purified IgG assessed for 
its titre and cross-reaction with dUTP. The titre had fallen to 
1/15 (after allowing for a small dilution factor of 1.13 times this 
showed that more antibody had been bound to the ligand), but cross­
reactivity with dUTP was unchanged at 5.1% (9.4ng dUTP caused a 50% 
drop in B/Bo compared with 480pg dTTP).
It was therefore concluded that G/S/1524 IIB antibodies were
probably all immunoreactive with dUTP, but the possibility remained
that the antibody population was mixed in terms of its avidity for
dUTP, and that only those antibodies with a low avidity for the 
cross-reactant remained after purification. This could best be 
tested using the twice-purified IgG to assay dTTP in extracts of
cells which had a known high dUTP concentration, and comparing the 
results with those obtained using unpurified IgG. In this way, any 
competitive effects of dUTP and dTTP for antibody binding would be 
seen.
Three extracts from A549 cells treated with CB3717 were 
assayed for dTTP in aliquots from fractions collected after ion 
exchange chromatography and assayed also for dUTP. The unpurified 
and twice-purified G/S/1524 IIB IgG was used. Results are shown 
below in Table 3.15.
Table 3.15 Comparison of dTTP Concentrations in A549 Cell
Extracts with Known dUTP Concentrations Using Two 
G/S/1524 IIB IgG Preparations
Sample
No.
Dose CB3717 
(24h Exposure)
dUTP pmole/ml 
extract
dTTP pmole/ml extract 
Unpurified Twice Purified 
IgG IgG
235 30jiM 127 27.7, 23.8 8.9, 5.0
239 ltyiM 88 25.0, 27.9 17.7
215 3jiK 1.04 39.8 32.5
These results showed that where there was low dUTP (sample 
215), the dTTP level was not significantly different when quantified 
by either IgG preparation. However, when high dUTP was present 
(samples 235, 239) significantly lower dTTP concentrations were 
measured using purified IgG. In sample 235 where the dUTP level was 
higher, the dTTP level was lower when using the purified antibody
than in sample 239. This would be expected following a more 
complete blockade of thymidylate synthase resulting from exposure to 
a higher concentration of CB3717. Thus it appeared from these 
results that the avidity of the purified IgG for dTTP was sufficient 
to overcome competition from dUTP for the same binding sites, even 
when the latter was present in a high concentration ratio compared 
with dTTP (18:1 for sample 235). The dTTP levels for samples 235 
and 239 using unpurified IgG were practically identical, despite the 
difference in the amount of dUTP available for competition, and 
despite the different dUTP:dTTP ratio (5:1) in sample 239.
It appears that where mixtures of compounds compete in 
different ratios for binding sites on antibodies with varying 
degrees of avidity for those compounds, simple cross-reactivity 
standard curves are not a valid way of assessing antibody ability to 
distinguish one compound from another. Indeed, it is difficult to 
know how to express antibody cross-reactivity with dUTP in this 
case, and it can only be concluded from the results described above 
that despite the apparently unchanged cross-reactivity with dUTP of 
the IgG with dUTP after purification as measured by comparing 
displacement curves, antibodies with high avidity for dUTP had been 
removed. It is not known however, if some dUTP was still being 
measured in these samples.
The recovery by RIA of standard dTTP in mixtures with standard 
dUTP in ratios similar to those in samples 235 and 239, using 
purified and unpurified IgG, gave the results shown in Table 3.16.
Table 3.16 Recovery of dTTP in the Presence of dUTP Using
Two Preparations of G/S/1524 IgG
G/S/1524 IIB % dTTP Recovered at
Ratio dUTP:dTTP
4:1 20:1
Unpurified 174 225
Purified 155 138
Although recovery of dTTP was closer to 100% when using 
purified rather than unpurified IgG, the recoveries of 155% and 138% 
showed that a considerable degree of antibody recognition for dUTP 
remained•
Two other batches of antiserum, taken after later boosts, were 
tested for their cross-reactivity with dUTP, but showed similar 
results (batch IIIA cross-reacted by 3.1% and batch VA by 4.4%).
It was decided to immunise new animals with a dTTP:ovalbumin 
conjugate in the hope of obtaining a high avidity antiserum with 
less cross-reaction for dUTP. Three Half-lop White rabbits were 
primed, but have not yet been boosted.
3
3.3.3 Radiolabel was dTTP-tetrasodium salt (methyl- H)
obtained from New England Nuclear (NET 221x) with a specific 
activity of 80Ci/mmole. It was diluted and stored as described for
3
[ H] dUTP in Section 3.2.3, and was diluted for the RIA in water so 
that 18pg (0.032pmole) was added to each assay tube. Total counts 
tubes contained approximately 1500 counts per minute.
3.3.4 Other RIA Components such as assay diluent, incubation
conditions, phase separation and liquid scintillation counting were 
identical with those used in the dUTP RIA (Section 3.2.4).
3.3.5 Assay Precision was not evaluated fully as the
establishment of final conditions for the RIA was not complete, e.g. 
the antiserum preparation to be used was not decided upon. However, 
some preliminary inter-assay data is shown in Table 3.17 and in 
Figure 3.20 where the mean results from three consecutive standard 
curves obtained using whole unpurified antiserum and the purified 
IgG fraction from G/S/1524 IIB are compared.
It can be seen that standard deviations were high, 
particularly for the unpurified antiserum, and that there was a loss 
of standard curve sensitivity when the purified IgG was used. Both 
these factors are probably a result of low affinity antibody/antigen 
binding.
3.3.6 Assay Accuracy was also left for full evaluation until
complete establishement of assay conditions, but some preliminary 
information was obtained by measuring the recovery of 1.88ng 
(3.4pmole) dTTP standard applied in triplicate to a QAE A25 column 
and collected in fractions for the RIA in the same way as for the 
dUTP assay (Section 3.2.8.2). Recoveries were 99.8, 80.9 and 73.2%
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(mean = 84.6%, S.D. = 13.7), using G/S/1524 IIB, unpurified IgG.
3.3.7 Extraction of dTTP from cells followed the same protocol 
as for dUTP (Section 3.2.7).
3.3.8 Pre-RIA Treatment of Cell Extracts. It was intended to 
treat extracts for dTTP assay exactly as those for dUTP, so that a 
valid comparison of their relative concentrations following 
thymidylate synthase inhibition could be made. The same pre-RIA 
treatment was required as it transpired because of similar cross­
reactivity problems. Cross-reaction with UTP was sufficiently high 
(0.3%) to make NalO^/CH^NI^ degradation of this compound necessary 
prior to quantification of dTTP.
Chromatography was also necessary because of the cross­
reactivity of G/S/1524 antiserum with dTDP. It was found that 
using the chromatography conditions optimised for dUTP, dTTP was 
well separated from dTDP (Figure 3.21) but that it co-eluted with 
dUTP (results not shown). Thus, if dTTP was to be assayed in the 
same fractions as dUTP, the collection of large volume fractions 
(800jil, Section 3.2.8.2) which could be split into aliquots for the 
two different RIAs was necessary. Samples 215, 235 and 239 referred 
to in Section 3.3.2.5 were assayed in this way.
The recovery of standard dTTP applied to QAE A25 columns has 
been referred to in Section 3.3.6.
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3.3.9 dTTP RIA - Discussion
This RIA requires further validation before reliable results
can be obtained from samples, particularly those containing dUTP.
The problem of cross-reactivity with dUTP has been partly overcome
by affinity purification of G/S/1524 antiserum, but the low affinity
9
of the purified IgG (K = 1.72 x 10 litres/mole) led to a reduction 
in assay sensitivity. 480pg of dTTP caused a 50% inhibition of zero 
binding using purified IgG, as contrasted with 180pg for unpurified 
antiserum. The shallow nature of the top (more sensitive) end of 
the standard curve also made results read off this part of the curve 
unreliable. However, large volumes of antiserum are available for 
purification, and provided sufficiently concentrated samples are 
applied to the chromatography column for fractionation, useful 
information regarding dTTP levels in cells treated with antifolates 
or thymidylate synthase blockers can be obtained using this assay, 
although doubt may remain as to whether some dUTP is being measured 
as dTTP. Possibly other attempts at affinity purification of 
G/S/1524 IgG will be more successful than that described above. It 
is also hoped that the newly immunised rabbits will produce 
antiserum which is more specific for dTTP.
Chapter Four
Radioimmunoassay for dUTP and dTTP
Chapter 4
RADIOIMMUNOASSAYS FOR dCTP AND ARA CTP
"... several D-arabinosyl nucleosides have exhibited some 
striking biological activities in the treatment of certain virus
infections and leukaemias in laboratory animals and in man ....
it is now clear that they will keep many research workers occupied
for a few years...... "
Seymour Cohen
Progress in Nucleic Acids Research 
and Molecular Biology 
(1966) Vol.5, pp 2-3.
Radioimmunoassays for dCTP and ara.CTP were developed to 
enable measurements of the active form of the nucleoside analogue 
ara.C and its endogenous competitor dCTP to be made in the small 
numbers of cells which might be available in vivo e.g. from bone
marrow biopsies. It has been shown that there is a strong
correlation between ara.CTP concentrations in leukaemic cells and 
the clinical effectiveness of ara.C (Plunkett et al., 1983; Estey 
et_ al_., 1987) and it has been suggested that dCTP has a role to play 
in some forms of resistance to ara.C (Liliemark & Plunkett, 1986). 
The structures of ara.C and ara.CTP are shown schematically in 
Figure 4.1.
4.1 The Clinical Use and Pharmacology of Ara.C
Ara.C was first described as having anti-tumour activity by
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Figure 4.1. The Structure of Ara.C and Ara.CTP
Evans et al., in 1961. Since then it has been tested clinically
against a wide range of tumour types, but has been found to be most
effective against leukaemias and some lymphomas. It is now almost
entirely used in the treatment of these two types of disease, and
has an essential place in chemotherapy protocols for these neoplasms
(Freireich, 1987). However, some recent studies have found that in
combination with cis-platin, ara.C shows promise against glioma and
ar
following intracavit^ administration, against refractory ovarian 
carcinoma (Stewart ejt al_., 1987; Markman & Howell, 1987).
Ara.C is used in widely varying dosages, depending partly on
the disease under treatment and partly on the experience of
2
individual institutions. Low doses of 20mg/m /24 hours have been
reported effective in pre-leukaemic conditions such as
myelodyoplastic syndrome (Cheson & Simon, 1987), and in elderly AML
patients (Castaigne et al., 1983). So-called "conventional" dosages 
2
of 100-200mg/m /24 hours are widely used against AML (Lister et^  al^.,
2
1987) and high doses of l-3g/m /24 hours have been used in cases of 
refractory leukaemias (Iacobini et al., 1986; Barnett et al.,
1987). These treatments, especially at the conventional and high 
doses, are of only a few days duration as they are limited by the 
major toxic side-effects of ara.C, which are severe myelosuppression 
and vomiting (Lister & Rohatiner, 1982), and for high-dose regimes, 
CNS dysfunctions which are dose and age related (Herzig et al.,
1987).
Ara.C is generally used in combination with other cytotoxic 
agents, such as the anthracyclines adriamycin or mitoxantrone, and a
purine analogue such as 6-thioguanine (Brito-Babapulle et al.,
1987; Lister et al., 1987), although given alone in very high doses 
of 3g/m /12 hours for six days, it has recently been reported to 
give a high remission rate in AML patients (Curtis et al», 1987). 
However, the duration of remission in these patients was not 
increased following this treatment, and there is some evidence to 
suggest that high-dose ara.C may give rise to ara.C resistant 
populations of leukaemic cells (Kees, 1987).
The pathway of ara.C metabolism is shown in Figure 4.2. 
Deamination to ara.U by cytidine deaminase is a major route of 
inactivation, as ara.U is virtually ineffective as a cytotoxic agent 
(Muller & Zahn, 1979). Cytidine deaminase, present in all human 
blood cells, as well as in the plasma and in high concentrations in 
the liver (Chabner et_ al, 1974), was reported by Steuart & Burke 
(1971) to be elevated in ara.C-resistant cells, an observation 
unconfirmed by others. Because of the high activity of cytidine 
deaminase in humans, the disappearance of ara.C from the plasma when 
given by an i.v. or s.c. bolus injection is rapid, with a bi­
exponential disappearance, showing an a half-life (t%) of 
2-15 minutes, and a S th of 20-200 minutes (Ho & Frei, 1971;
Harris et al., 1979), although Slevin et al., (1981), using a 
sensitive RIA, showed a tri-exponential disappearance curve, with a 
long y th of from \\ to 8 hours. Ara.U appears rapidly in the 
plasma in high concentrations and is eliminated in the urine (Ho & 
Frei, 1971). To maintain a plasma level of ara.C over a period of 
time which would be effective for this S-phase specific drug, it is 
frequently given as an i v. or s c .  infusion for from 3 to 12 hours.
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kinase AR A.CM P
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deaminase
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FIGURE ^.2. The Metabolic Conversion of Ara.C
Slow release depot formulations such as liposome encapsulated ara.C, 
have also been tried (Hong & Mayhew, 1988), in order to mimic the 
effects of an infusion. Although there is considerable interpatient 
variation in ara.C plasma concentrations, no correlation has been 
found between these concentrations and response to ara.C. This may 
be because no correlation has been found between plasma ara.C levels 
and intracellular levels of the active metabolite ara.CTP (Liliemark 
et al., 1985).
Ara.CTP is the product of successive phosphorylation reactions 
utilising the pyrimidine phosphate kinases, but the rate-limiting 
step in its production appears to be the initial phosphorylation of 
ara.C to ara.CMP by deoxycytidine kinase (Plagemann et al., 1978; 
Plunkett et al., 1987). This enzyme is inhibited to some extent by 
ara.CTP and is very strongly inhibited by dCTP (Liliemark &
Plunkett, 1986). The cellular accumulation and retention of ara.CTP 
in cells in vitro and in vivo are both factors that have been shown 
to correlate with its effectiveness (Rustum & Preisler, 1979; Estey 
et al., 1987), although no correlation of these parameters with 
clinical outcome was found by Ochs et al., (1984). This may be 
explained by the contention of Kufe et al., (1984) that it was the 
amount of ara.C incorporated into DNA that correlated best with cell 
kill, and that cellular ara.CTP accumulation, although of great 
importance as a determinant of sensitivity, is not the ultimate 
parameter for correlation with clinical effectiveness. Resistance 
to ara.C has frequently been documented in cells with a deficiency 
of deoxycytidine kinase (Rogers et al., 1980; Hagenbeek et al., 
1987), and active dephosphorylation of ara.CTP has been shown in
resistant cells (Abe et al., 1982). Jamieson et al., (1987) showed 
that a major route of ara.C inactivation in human myeloblasts was 
the deamination of ara.CMP to ara.UMP by dCMP deaminase, which is 
activated by dCTP (Ellims et al., 1983A).
dCTP has been implicated in resistance to ara.C by virtue both 
of its potent feedback effects on ara.C metabolising enzymes and its 
direct competition with ara.CTP for DNA polymerase. High dCTP 
concentrations have been reported iji vitro in cell lines and in 
human leukaemic cells which were ara.C resistant (Momparler et al., 
1968; Tattersall et^  al., 1974; de Saint Vincent et al., 1980). As 
well as inhibiting anabolic and stimulating catabolic enzymes in the 
ara.C metabolic pathway, dCTP acts as a highly successful competing 
substrate for DNA polymerase - the Kj. of ara.CTP has approximately 
the same value as the of dCTP for this enzyme (Momparler, 1982). 
Moreover, Ohno et al., (1988) have shown that DNA strand elongation 
past ara.C incorporation sites was enhanced by increasing dCTP 
availability, and that where dCTP was present in a low ratio with 
ara.CTP, DNA strand elongation did not progress. Thus, an immediate 
toxic effect of ara.C - the interruption of DNA replication - could 
be overcome by a high dCTP:ara.CTP ratio.
The development of sensitive RIAs for measuring dCTP and 
ara.CTP was undertaken in order to further study the importance of 
ara.CTP accumulation and of ratios of the two compounds to cell 
sensitivity to ara.C in vivo.
4.2 The Development of a Sensitive RIA for dCTP
4.2.1 Standard dCTP was obtained from the Sigma Chemical
Company (catalogue number D4760), and was the sodium salt. Storage 
conditions used for crystalline standard and stock solutions were 
the same as those for the dUTP standard (Section 3.2.1).
4.2.2 Production of Antibodies to dCTP
4.2.2.1 Production of Immunogens. This was the first dNTP RIA
to be fully developed for this project, and four immunogens were
prepared utilizing three carrier proteins of a nature foreign to the 
animals to be immunised.
Three different haptens were also used in these preparations, 
the relatively stable dCMP and CMP being chosen, as well as dCTP, 
because it was thought that the latter might prove unstable during 
or after conjugation.
(a) dCTP-ovalbumin conjugates were made using the method of 
Halloran & Parker (1966). lOmg of dCTP were mixed with 30mg 
ovalbumin and 30mg EDC overnight at 4°C, in 1ml of 0.05M phosphate 
buffer, pH 7.4 After dialysis against two changes of 500ml water, 
the amount of free dCTP in the dialysates was calculated by 
measuring the absorbance at 280nm and comparing it with a 
calibration curve for dCTP at the same wavelength. The dCTP 
remaining was assumed to be conjugated to ovalbumin, and the degree 
of derivatisation obtained from eight preparations has been as
follows: 12.2, 12.4, 14.3, 14.9, 16.2, 17.2, 16.1, 14.0 moles
dCTP/mole ovalbumin. The conjugates were diluted to 5mg/ml of 
protein and were freeze-dried in 0.5ml aliquots for storage at 
-20°C.
(b) dCTP-chicken-y-globulin conjugates were also made by the 
carbodiimide method. lOmg dCTP, lOmg of chicken-Y -globulin and 
30mg EDO were stirred in l-2ml 0.05M phosphate buffer, pH 7.4, 
overnight at 4°C. The methods used for dialysis and the calculation 
of conjugated dCTP were the same as for dCTP-ovalbumin conjugates. 
The degree of derivatisation from four such preparations was 85.6, 
148, 162 and 178 moles dCTP/mole protein. The preparations were 
diluted, freeze-dried and stored as described above.
(c) dCMP-ovalbumin immunogens were also made by the method of 
Halloran & Parker (1966). lOmg dCMP (Sigma), 30mg ovalbumin and 
30mg EDC were mixed overnight at 4°C in 1ml phosphate buffer, 0.05M, 
pH 7.4. After dialysis and absorbance measurements at 280nm of free 
dCMP in the dialysates, the degree of derivatisation in two 
preparations was calculated to be 18.6 and 23.9 moles dCMP/mole 
ovalbumin.
(d) CMP-BSA were coupled by using the method of Erlanger & Beiser 
(1964) described in Section 2.4.4.2. lOOmg CMP (Sigma) was 
dissolved in 5ml 0.1M NalO^. Oxidation of the 2 f, 3 ’ hydroxyl 
groups then took place on standing the mixture at ambient 
temperature for 20 minutes. 0.3ml ethylene glycol was added to 
destroy excess NalO^, and the mixture was then added, while
stirring, to an aqueous solution of 28mg/ml BSA (Sigma, Fraction V) 
in 10ml water, pH 9.5. After stirring for 45 minutes with the pH 
maintained at 9.5 by the addition of l^CO^, 150mg NaBH^ in 10ml 
water was added to stabilise the hapten-protein linkage, and the 
reaction mixture was incubated for 1 hour at room temperature. The 
pH was adjusted to 8.5 with formic acid, followed by extensive 
dialysis of the mixture against two changes of 5 litres of distilled
water. The absorbance at 270nm of the conjugate diluted to 200pg
protein/ml was then compared with that shown by a BSA solution of 
the same concentration. After subtracting the absorbance shown by 
BSA alone from that shown by the conjugate, it was calculated that 
8.9 moles of CMP were conjugated/mole BSA. The conjugate was 
diluted, freeze-dried and stored in the same way as the dCTP- 
ovalbumin conjugate.
4.2.2.2 Immunisation Schedules
Six Soay and four Suffolk-cross sheep and three New Zealand 
and two Half-lop White rabbits were immunised with one of the 
conjugates described above, using the methods outlined for dUTP in 
Section 3.2.2.2.
4.2.2.3 Assessment of Antiserum Titre and Results of
Immunisation
The assay protocol for obtaining antiserum dilution curves and 
calculating antiserum titre was the same as that described in 
Section 3.2.2.3.
The results of immunisation are summarised in Table 4.1.
Table 4.1 Antibody Response to Immunisation with dCTP-, dCMP-
and CMP-Protein Conjugates
Conjugate A n t i b 
Non-responders
o d y R e  s p o 
Low Titre 
(Up to 1/10)
n s e
Suitable Titre 
for RIA
dCTP-ovalbumin 2 sheep 2 sheep
3 rabbits
2 rabbits
dCTP-chicken 
-Y*globulin
- 2 sheep -
dCMP-ovalbumin 2 sheep - -
CMP-BSA - 2 sheep -
Despite multiple boosts, the low antibody titre obtained in 
six sheep and three rabbits was not improved upon, and further 
immunisation was stopped. Two rabbits, G/R/3 and G/R/6, responded 
sufficiently well to dCTP-ovalbumin immunisation to merit full 
characterisation of their dCTP antiserum. The titres obtained are 
depicted in Figures 4.3 and 4.4.
4.2.2.4 Assessment of Antiserum Avidity and Specificity 
for dCTP, and RIA Sensitivity
The standard curve and sample assay protocol was the same as 
that described in Section 3.2.2.4. The non-specific binding was 
from 7 to 10% using fresh batches of radiolabel, with large 
increases to 15 up to over 20% when the label was deteriorating. 
Zero binding using a pre-determined titre was between 40 and 50% of 
total counts when using G/R/6 antiserum and between 20 and 35% with 
G/R/3 antiserum.
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Using the method of Muller (1980) for calculating mean 
antibody affinity in a polyclonal antiserum, the affinity constants 
for the two antisera from standard curve data were as follows:
G/R/3 : K 8
3(0.303 + 0.043) - 0.043
8 9
8.0 x 10 litres/mole1.038 - 0.043
G/R/6 : K 8
3(0.134 + 0.039) - 0.039
8
1.67 x 1 0 ^  litres/mole0.519 - 0.039
The standard curves are shown in Figure 4.5.
The theoretical sensitivity of the dCTP RIA using either 
antiserum was calculated using the method of Feldman & Rodbard 
(1971), described in Section 3.2.2.4. Ten zero binding tubes were 
set up for the calculation of S.D. at zero bound in each case.
For G/R/3, Pool IV, sensitivity = 2.758
2.051
For G/R/6, Pool II, sensitivity = 5.988 = 1.454pg added
4.118
1.345pg added 
2.24pg/ml 
4.8fmole/ml
2.42pg/ml 
5.7fmole/ml
The specificity of the two antisera for dCTP is summarised in 
Table 4.2 and cross-reactivity curves are shown in Figures 4.6 and 
4.7.
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Table 4.2 Cross-Reactivity of G/R/3 and G/R/6 Antisera
Compound
Amount required to 
displace 50% of zero binding
Percentage
cross-reactivity
G/R/3 G/R/6 G/R/3 G/R/6
dCTP 30pg 13.5pg 100 100
CTP 50pg 500pg 60 2.7
dCDP 44pg 190pg 67 7.1
dCMP 390 ng 650pg 0.079 2.1
dCd > 10pg > lOug <0.0003 < 0.00014
dUTP > l/ig > 500ng <0.003 <0.03
dTTP > lOOng <0.003 <0.013
ara.CTP 68pg 10.3ng 44 0.13
dUMP > iMg > 10pg <0.003 <0.00014
dATP > Ipg — <0.003 —
dGTP > 1/ig <0.003
The specificity of G/R/6 antiserum for dCTP is clearly greater
than that of G/R/3. The high (44%) cross-reaction shown by G/R/3 
antibody for ara.CTP precluded its use for extracts of ara.C treated 
cells, while the low (0.13%) cross-reaction of G/R/6 antiserum with 
ara.CTP made it suitable for this purpose. Cross-reactivity with 
dCMP and dCDP was thought to be low enough in the case of G/R/6 
(2.1% and 7.1% respectively) not to merit chromatographic separation 
of these compounds from dCTP, although using G/R/3 antiserum the 
high (67%) cross-reaction with dCDP would necessitate this.
Cross-reactivity with CTP, which could be present in one 
hundred-fold or greater concentrations than dCTP, was sufficiently 
high (60% for G/R/3, 2.7% for G/R/6) to require that it be removed 
from cell extracts prior to dCTP quantification by either of the 
antisera. The procedures used are described in Section 4.2.8.
4.2.3. Radiolabel
The radiolabelled dCTP routinely used for this assay was 
3
[l’- 2 ’- 5 ’- H] dCTP (TRK 625) obtained from Amersham International.
It had an average between-batch specific activity of 60Ci/mmole. It
3
was stored and dilutions were made as described for [ H] dUTP in 
Section 3.2.3. The total counts tubes contained approximately 2500
3
counts per minute, which represented 18pg of [ H] dCTP (38.5fmole) 
added in lOOjil. The stock label stored well for between 6  and 18 
months, depending on the batch, and the sub-stock, from which 
working dilutions were made, was made up fresh every one to two 
months.
Iodinated dCTP was evaluated as a possible radiolabel early on
125
in the development of this assay. 5[ I] Iodo 2 ’-deoxycytidine 5 ’-
triphosphate (specific activity 1500Ci/mmole) was purchased from
Amersham International, (IM5103). G/R/3 antiserum (the best
antiserum available at the time) was screened, and standard and
cross-reactivity curves were constructed using this label. Very low
titres were obtained, even when very low dilutions of the label were 
125
used (130fg [ I] dCTP added), and maximum binding (30% of total)
was achieved when the antisera were diluted to 1 / 1 0  or 1 /2 0 , whereas 
3
with the [ H] label titres were over 1/100.
Figure 4.8 shows cross-reactivity data obtained using the
125
[ I] label. Antisera from all the animals immunised were also 
125
screened with [ I] dCTP in case their binding characteristics were 
more favourable with this label, but they showed either nil or very
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low binding. It was decided not to continue work with [ I] dCTP, 
because of the unsatisfactory low degree of binding obtained with 
G/R/3 and other antisera.
4.2.4 Other RIA Components
4.2.4.1 Assay Diluent. Initial work in developing the dCTP RIA
utilised phosphate buffers pH 7.4, 0.05M either with or without 1% 
(w/v) gelatine added. This medium had been used previously for all 
RIA work (Piall et al., 1979). However, such high NSB (up to 30% of 
total) and such low specific binding for antisera on screening were 
obtained, that other diluents were tried in the hope of overcoming 
these difficulties. The only antiserum available to work with early 
on was from a sheep - G/S/1106 - and results obtained with this 
antiserum, using lO^il DCC for phase separation, are summarised in 
Table 4.3
Table 4.3 NSB and Specific Binding of G/S/1106 Serum 
in Different RIA Diluents
% o f  T o t a l  B o u n d
Diluent NSB Pre-Immunisation 
Serum (titre)
Post Boost 
Serum (titre)
0.05M KH 2 P0 4 /Na2 HP0 4  21.7 
pH 7.4
0.05M PBSG 
pH 7.4
0.1M Tris HC1 
pH 8.0
0.2M Borate 
pH 8.2
0.4M NH,H?P0, 
pH 3.3
0.2M KHoP0._ 2 4
pH 5.5
32.5
14.0
13.0
11.0
8.0
33.7 (1/5) 
39 (1/5)
16 (1/5)
17 (1/5)
16.8 (1/5)
6 . 0  (1 /1 0 ) 
28.0 (1 /1 0 ) 
0  (1 /1 0 ) 
1 0  (1 /1 0 )
G/R/3 meanwhile responded to immunisations, and its serum was 
also screened in different diluents to compare results, which are 
shown in Table 4.4. Another sheep antiserum, from G/S/18, showed 
50% binding of total at a titre of 1/150 in tetraborate diluent, but 
only 1/20 in the acetate diluent. By this time it was thought that 
because of problems of cross-reactivity, samples would require 
either pre-RIA HPLC or some form of borate-affinity chromatography 
(Section 4.2.8) and the diluents tried were possible chromatography 
eluants such as NH^^PO^, K^PO^, NH^HB^Oy and CH^COONH^.
Table 4.4 NSB and Specific Binding of G/R/3 Antiserum 
in Different RIA Diluents
% o f T o t a l  B o u n d
Diluent NSB (Titre)
0.05M P0, 
pH 6.0
24.0 45.8 (1/40)
0.1M NH,HB,0? 
pH 6.2
18.0 35.0 (1/130)
1M CH.COONH, 
pH 879
21.5 38.0 (1/120)
Because borate complexing with elution by 1M CH^COONH^, was 
decided upon as the pre-RIA form of sample treatment using G/R/3 
antiserum, this diluent was used for further RIA development. G/R / 6  
antiserum, obtained later, was also found to have good binding and 
displacement characteristics in CH^COONH^, so that although borate 
complexing was not necessary with this antiserum (Section 4.2.8) the 
diluent was retained.
The optimum pH of the borate complexing step was 8.9, but it 
was found that reduction of the pH to 6.2 by the addition of 20jil of 
50% CHgCOOH (v/v with water) to all assay tubes reduced the NSB from 
2 1 % to 8 % this increasing the zero-bound count rate, so that the 
assay diluent finally chosen was 0.1M CH^COONH^, pH 6.2.
4.2.4.2. Assay Incubation Conditions. dCTP RIAs were set up in 
ice and incubated for 1 hour. Early work with G/R/3 attempted to 
increase the sensitivity of the assay by using dis-equilibrium 
conditions during incubation, e.g. by incubating the antiserum and 
standard together for varying periods of time before adding the 
label, and then continuing the incubation for a short time before 
phase separation. This was found to increase the sensitivity of the 
standard curve, and the best result was obtained with 3 hours 
incubation with antiserum alone, followed by 1  hour with label 
added. The comparison of results from this and an equilibrium curve 
incubated for 4 hours is shown in Figure 4.9. Because it was later 
found that the disequilibrium curve was too sensitive for practical 
use with samples, equilibrium conditions were adopted.
4.2.4.3 Separation of Free from Antibody Bound Antigen
lOOpl DCC was used for work with G/R/3 and G/R / 6  as described 
for the dUTP assay in Section 3.2.4.3. to separate the bound and 
free fractions. However, a comparison of phase separation methods 
was made at the beginning of developmental work in order to improve 
on the poor results then being obtained from antibody binding 
experiments. G/S/1106 antiserum was used, with precipitation of the 
antibody bound fraction by either 50% (w/v) (NH^^SO^, or by "double 
antibody" (donkey anti-sheep IgG) being compared with 100 or 20^jul 
DCC. The results are shown in Table 4.5.
FIGURE 4.9. dCTP Standard Curves Using G/R/3
Antiserum and 4 hour Equilibrium 
or 3 hour + 1  hour with Label,
%B Disequilibrium Conditions
/Bo
100
90
3h + lh
80
0 - 0  4h
70
60
50
40
30
20
10
10 20 30 40 50 60 70 - 80 90 100
pg dCTP added
Table 4.5 Comparison of NSB and Specific Binding Obtained from
G/S/1106 Antiserum Using Different Phase Separation 
Methods
Method
% o f  
NSB
T o t a l  B o u n d  
G/S/1106 (1/5)
DCC - lOOjil 32.5 39
DCC - 200jil 14.9 16.9
50% (w/v) (NH4 )2 S04 3.8 5.4
"Double antibody" 3.6 6 . 1
On the occasion of the experiment, the NSB with lOOjil DCC was 
very high (32.5%) but the specific binding was still - even after 
subtraction of NSB - substantially elevated over that obtained using 
the other methods of phase separation. Because of the ease, low 
cost and speed of using DCC combined with satisfactory results, this 
method was used throughout.
4.2.4.4. Liquid Scintillation Counting
Because of difficulties in the efficient scintillation 
counting of samples with a high salt content, such as those 
resulting from this assay, a comparison of scintillants was made to 
find one which gave high efficiency combined with stability over a 
long period of time (Section 3.2.4.4). Four commercially available 
scintillants recommended for counting high salt samples were 
compared and the results are shown in Table 4.6.
3
Table 4.6 Comparison of Counting Efficiency of 5nCi [ H] dCTP
in 500 l^1 Assay Diluent and 4ml of Scintillation 
Counting "Cocktails"
"Cocktail" Counts per 
Minute
Appearance 
of Samples
Counting
Efficiency
RIA Luma 2702 2  phases
(LKB) 2533
2527
2456
2579
Clear 23.3%
Monofluor 4441 1  phase
(National
Diagnostics)
4443
4438
4666
4385
Clear 40.7%
Ultrafluor 5487 1  phase
(National
Diagnostics)
5390
5335
5460
5298
Clear 49.0%
Fluorodyne 1217 2  phases
(National
Diagnostics)
1258
1197
1 2 2 1
1083
Clear 10.9%
Counting efficiency, as a percentage of the disintegrations
3 3
per minute for 5nCi of [ H], (5 x 2.2 x 10 dpm) was calculated and
is shown in the Table. Samples in Monofluor and Ultrafluor were re­
counted the next day to check on stability, and the efficiency after 
24 hours was 37.1% and 49.3% respectively. On the basis of these 
results, Ultrafluor was used for all dNTP RIA scintillation 
counting.
4.2.5 Assay Precision
Inter-assay variation using G/R/ 6  and G/R/3 antiserum is shown 
in Tables 4.7 and 4.8 respectively.
Table 4.7 Inter-Assay Variation Using G/R / 6  (Pool II) Antiserum 
for 5 Consecutive Standard Curves
0  1 0  
(% B/T)
2 0 30
% B/Bo 
50
at Amount dCTP added (pg)
70 100 150 200 300 500
47. 6 81.1 64.4 55.1 41.7 35.2 29.1 18.8 16.3 12.4 7.8
52. 6 81.0 65.1 53.1 40.9 31.6 27.0 18.7 13.5 9.8 6 . 8
56. 8 85.9 67.9 56.9 44.9 34.0 29.1 23.4 19.7 14.0 8.9
49. 0 83.2 69.5 57.6 46.8 35.5 28.4 19.0 13.4 1 2 . 0 9.8
50. 2 80.5 66.9 55.9 43.9 33.9 28.4 19.4 16.5 1 0 . 0 8.7
Mean
51. 2 82.3 66.7 55.7 43.6 34.0 28.4 19.9 15.9 11.64 8.4
S.D .
3.61 2.24 2.07 1.75 2.39 1.53 0.85 1.99 2.59 1.76 1.14
c.v 7• to
7.0 2.7 3.1 3.1 5.5 4.5 3.0 1 0 . 0 16.3 15.0 13.6
Table 4. 8  Inter-Assay Variation Using G/R/3 Antiserum for
5 Consecutive Standard Curves
0
(% B/T)
1 0 2 0
% B/Bo at Amount dCTP added (pg) 
30 50 70 100 200 300 500 1 0 0 0
28.0 91.4 80.1 6 6 . 8 60.3 49.0 36.6 25.9 4.5 15.1
27.8 1 0 0 82.4 76.5 64.1 54.4 46.0 29.2 - 1 2 . 6 1 1 . 6
23.1 94.0 85.1 74.1 65.1 58.3 46.0 30.2 22.3 1 1 . 1 3.0
36.4 86.9 82.0 74.1 61.4 55.9 44.7 27.3 18.6 11.7 5.2
31.9 91.7 81.6 73.6 57.5 47.8 35.0 2 0 . 6 16.2 1 1 . 8 8.4
Mean
29.4 92.8 82.2 74.5 62.9 55.3 44.3 28.8 2 0 . 8 10.3 8.7
S.D.
4.99 4.78 1.82 1.30 3.64 4.82 5.09 5.75 4.25 3.3 4.85
c.v%
16.9 5.1 2 . 2 1 . 8 5.8 8.7 11.5 2 0 . 0 20.5 31.9 56.0
Precision between assays using G/R/3 antiserum was very poor 
as can be seen from the high c.v. at zero binding (16.9%) and at the 
lower end of the curve. The reason for this was probably the low 
count rate obtained using such a low zero binding (29% of total). 
Intra-assay precision using G/R/3 was better, however, and results 
are shown in Table 4.9.
Table 4.9 Intra-Assay Variation Using G/R/3 Antiserum
0
% (B/T)
1 0 2 0
% B/Bo at 
30 50
Amount dCTP 
70 100
Added
2 0 0
(pg)
300 500 1 0 0 0
34.9 8 6 . 1 75.3 70.3 57.3 48.8 37.4 25.5 14.6 7.4 5.5
35.1 84.7 77.6 65.1 53.1 44.1 34.7 22.9 14.9 13.8 9.4
35.2 83.9 76.1 6 6 . 0 53.5 48.5 39.6 2 1 . 0 16.8 1 1 . 0 5.9
33.4 89.7 77.7 73.0 59.2 49.5 36.2 26.2 25.3 15.7 7.4
31.9 91.7 81.6 73.6 57.5 47.8 35.6 2 0 . 6 16.2 1 1 . 8 8.4
Mean
34.1 87.2 77.7 69.6 56.1 47.7 36.7 23.2 17.6 11.9 7.3
S.D.
1.43 3.34 2.42 3.91 2 . 6 8 2 . 1 2 1.89 2.54 4.42 3.12 1.64
c.v.%
4.1 3.8 3.1 5.6 4.7 4.4 5.1 10.9 25.1 26.2 22.5
4.2.6 Assay Accuracy was assessed by the recovery of dCTP
through the entire assay procedure, and is described in 
Section 4.2.9.
4.2.7 Extraction of dCTP from cells was achieved using the
procedure of Bagnara & Finch (1972) outlined in Section 3.2.7.
4.2.8. Pre-RIA Treatment of Cell Extracts
4.2.8.1 Borate Affinity Chromatography
Cross-reaction with CTP was the most significant factor when 
considering treatment of extracts before RIA quantification (Section 
4.2.2.4). G/R/3 antiserum, available first, had a high
cross-reaction with CTP (60%). Although NalO^. oxidation and CH^NI^ 
degradation was known to be effective in the degradation of 
ribotides such as CTP in standard mixtures, it had been reported 
that in biological samples the degradation was not always complete 
(Ritter & Bruce, 1979). Thus, borate-affinity complexing of 
ribotides in samples was considered necessary when using G/R/3 
antiserum in order to effect complete removal of CTP (Section 
2 .3.2 .2 ).
Two commercially available boronate affinity gels were tried - 
Bio Rad Laboratories' "Affi-Gel 601" and Pierce's "Immobilised 
Boronic Acid". Both proved unsatisfactory although used as 
recommended, as they could not retain enough CTP (5jig) (approx­
imately lOnmole) unless very long, expensive and slow-running 
columns were used. It was decided to make a highly derivatised 
boronic-acid gel, starting with fine mesh (200-400) polyacrylamide 
gel beads, and using methods described by Inman & Dintzis (1969) and 
Gehrke et al., (1978).
lOg of Bio-gel (Bio Rad Laboratories) was placed in a 100ml 
silanized round-bottomed, stoppered flask with 1 0 0 ml distilled water
and was left to swell for 2 days. Approximately 50ml of the water 
was removed, and the gel was warmed for 1 hour in a 48°C water bath. 
In the fume cupboard, 24ml of pre-warmed hydrazine hydrate (6 M final 
dilution; Sigma) was added to the gel, and the mixture was stirred 
at 48°C for 5 hours with a "Quickfit" paddle attached to a stirring 
rod and stirrer, the whole system being closed by a sealing 
connector containing paraffin oil as shown in Figure 4.10 and kept 
in the fume cupboard. The carboxamide side groups on the 
hydrocarbon skeleton of the beads were thus converted to the more 
reactive hydrazo-derivative (Figure 4.11). The gel was washed 
thoroughly four times with 80ml of 0.1M NaCl on a Buchner funnel 
under gentle vacuum. It was suspended in 300ml 0.1M NaCl in a 
plastic beaker, and 3g of succinic anhydride (Sigma) was added in 
ten approximately equal portions over 90 minutes, with the pH 
constantly adjusted to 4.0 with 1M NaOH. Stirring continued 
overnight at ambient temperature, after which the gel was washed 
using gentle vacuum on a Buchner funnel with 500ml of 0.1M NaCl. It 
was suspended in 100ml 0.1M NaCl and coupled to 2.46g m-amino-phenyl 
boronic acid (Aldrich Chemical Co) in the presence of EDC at pH 7.0 
while stirring in an ice bath. For this reaction the pH was 
adjusted to 7.0 with 1M NaOH and maintained while three additions of 
EDC were made: 2.58g at the beginning, 0.24g after 3 hours and 1.4g
after a further 2 hours. Stirring was continued overnight in the 
cold (4°C cold room), and the product was washed on a Buchner funnel 
with 800ml of 0.1M NaCl. The gel was stored in 0.1M NaCl containing 
0.1% sodium azide at 4°C and was found to have no deterioration in 
performance with frequent use over a period of 18 months.
Stirrer
Glass stirring rod
Quickfit” fitting
Paraffin oil sealant
Quickfit” adaptor
Reaction mixture
Paddle
48° Water 
bath
FIGURE 4.10. Apparatus used in the Activation of
Polyacrylamide Gel by Hydrazine Hydrate
-C O N K
NH_NH0 
2  2
CONHNH„ 
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CONHNHCO(CH) COOH
2  2
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FIGURE it. 11. Activation of Polyacrylamide Gel with 
Hydrazine Hydrate and Succinic Anhydride, 
Followed by the Coupling on of m-amino 
phenylboronic Acid in the Presence of 
Carbodiimide
(from Bergold & Scouten, 1983)
The successfully derivatised gel had a creamy appearance, and 
it was found that if the m-amino-phenyl boronic acid was degraded, 
the gel had an orange appearance, and was unable to retain 
ribotides. A fresh batch of acid was thus purchased for each 
preparation. The degree of derivatisation of the gel was determined 
by the absorbance at 293nm of unreacted m-amino-phenyl boronic acid 
in the supernatant fluid of the reaction mixture. It was found to 
average 1.10m equivalent of boronate per gram of dry gel. The 
derivatisation is depicted schematically in Figure 4.11.
Before use, the gel was equilibrated in 5 vol of 1M CH^COONH^, 
with the pH adjusted to 8.9 with ammonia. This pH and ionic 
strength had been shown to be optimum for the retention of NTPs by 
immobilised boronates (Bergold & Scouten, 1983). 10ml of gel 
(2g dry gel) were poured into plastic K9/15 columns (Pharmacia) 
filled with the equilibrating buffer. Cell extracts were applied to 
the gel in 0.5 vol 3M CH^COONH^, pH 8.9, and elution of dCTP was 
with 15ml 1M CH^COONH^, pH 8.9, The void volume was discarded and 
then twenty 0.4ml fractions (9 drops each) were collected in plastic 
LP4 tubes (Luckham Ltd) using an LKB "Redirac" 2112 fraction 
collector. The fractions were either assayed by the RIA on the same 
day or were stored at -40°C. The RIA was performed directly on the 
fractions after adjustment of the pH to 6.2 by the addition of 20jil 
50% CHgCOOH (v/v with water).
To disassociate complexed ribotides the gel was washed with 10 
vol of distilled water on a Buchner funnel under gentle vacuum, and 
then was re-equilibrated on the Buchner funnel with 5 vol of 1M 
CH^COONH^, pH 8.9, and re-poured ready for application of the next 
extract.
The flow-rate of the columns was approximately 1.7ml/minute, 
and each sample took 20 minutes to chromatograph. Up to 5^ ig of CTP
was retained by the column.*
The recovery of dCTP applied to the column was 84.3 and 83.0% 
for 300pg applied, and 82.3 and 84.5% for 400pg applied, using G/R/3 
antiserum in the RIA. Blank fractions were collected for assessment 
of their effects on NSB and zero binding in the RIA, and these, when 
calculated as a percentage of the total counts, were found to be
negligible (RIA NSB = 12.8%; column blank NSB = 13.6%;
RIA zero = 24.1%; column blank zero = 21.3%).
The elution position of dCMP and dCDP from the boronate gel 
columns was ascertained by applying 500pg dCDP or 5jig dCMP, and 
collecting fractions in the usual way. The results of these as well 
as a typical elution pattern for dCTP standard and immunoreactive 
fractions from a cell extract are shown in Figure 4.12. It will be 
seen that, as they are not retained on the gel, dCMP, dCDP and dCTP 
elute together.
*0.02% of CTP applied eluted as dCTP; this was assumed to be an 
impurity in the CTP standard as ten blank fractions preceded it, 
showing that it was a compound distinct from CTP.
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4.2.8.2 Periodate-Amine Treatment of Extracts
NalO^/CH^NI^ degradation of CTP was used when antiserum from 
G/R / 6  was obtained, with its relatively low cross-reaction with CTP 
(2.7%). 0.5ml of extract was treated by the addition of 20jil of
0.5M sodium periodate followed after 5 minutes by 25jil of 4M CH^NH^, 
(pH adjusted to 7.5 by the slow addition of concentrated PCA while 
in ice). After vortex-mixing, the samples were incubated at 37°C 
for 30 minutes. The extracts were then ready for quantification,
10, 20 or 50ul aliquots being removed into a total volume of 40^ul 
with assay diluent for RIA.
The recovery of CTP and dCTP by the RIA after the treatment 
described above was as follows; 0.09% CTP recovered from ljig added; 
100.9% and 112% from 500pg and lng respectively of dCTP added. It 
was concluded that the conditions used, and described by Garrett & 
Santi (1979) as optimal, were suitable for this assay.
The effects of the addition of aliquots of extracts treated in
this way to the RIA when using G/R/ 6  antiserum were investigated by
the addition of suitable aliquots of blank NalO^/CH^N^ treated
"extracts" to the standard curve, NSB and zero binding tubes. The 
results are summarised in Table 4.10 and are shown in Figure 4.13.
Table 4.10 The Effect of Aliquots of NalO^/CH^NH^, Treated Blank 
"Extract" on the dCTP RIA when using 6 /r/ 6  Antiserum
Amount of Treated % B/Total
Blank "Extract" Added NSB Zero
13.3 62.4
15.2 56.7
17.2 56.7
22.7 51.0
27.7 45.6
None
20^1
50pl
I00p.l
2 0 foil
FIGURE 4.13. The Effect of the Addition of Different
Aliquots of NalO/j Treated "Blank" Extract 
on dCTP Standard Curves Using G/R/6 
Antiserum.
^Bo
100
No extract 
♦ ”♦ 200^ il extract
0— 0 lOOjil extract
4_4 50jil extract
□— n 20ul extract
20
10 100 1000
pg dCTP added
Because the NSB was unacceptably high when lOOjil or more of 
"extract" was added, it was decided to set up dCTP RIAs with a 
maximum of 50jil aliquots from the extract. The assay sensitivity 
using G/R / 6  antibody was such that this was possible.
4.2.8 .3 Anion Exchange Chromatography
Cross-reaction of G/R / 6  antiserum (which became the routinely
used reagent) with dCDP and dCMP was considered low enough (7.1% and
2 .1 % respectively) not to require chromatographic separation of
these two compounds from dCTP in the extracts to be assayed.
However, if required, anion exchange chromatographic separation of
these deoxycytidylates can be achieved in the same way as described
in Section 3.2.8 .2. The RIA would then need re-development in the
new diluent, namely 0.7M KH^PO^, and it has been shown that both
3
G/R/3 and G/R/ 6  antisera bind [ H] dCTP at adequate titres in this 
medium, but no displacement curves have been attempted.
4.2.9 Summary of dCTP Assay and Recoveries Through the
Entire Procedure
The dCTP assay is summarised in Figure 4.14.
Where extracts are from cells exposed to ara.C, G/R / 6  
antiserum must be used, its low cross-reactivity with ara.CTP 
(0.13%) making it more suitable than G/R/3 antiserum, which cross- 
reacts with ara.CTP by 44%. Ara.CTP can neither be immobilised on 
a boronate affinity column nor be oxidised by NalO^, due to its 
possession of trans-hydroxyl groups at 2 ’, 3 ’ (Khym & Cohn, 1961; 
Bergold & Scouten, 1983). It also co-elutes with dCTP in anion 
exchange systems and these difficulties of separation make antibody 
specificity for dCTP over ara.CTP of critical importance when 
dealing with ara.C treated cell extracts.
Figure 4.14 dCTP Assay Procedure
EXTRACTION
Procedure as for 
dUTP (Figure 3.12)
NaIO,/CH»NHp degradation 
of CTP (G/R/ 6  antiserum)
BORONATE 
AFFINITY 
CHROMATOGRAPHY 
(G/R/3 antiserum)
Procedure as for dUTP 
(Figure 3.12) - but 
incubation can be up to 
30 min, 37°C
1 0 ml boronate gel 
columns in 1M
ch3 coonh4. pH 8.9
2 0  fractions 
collected after 
void volume 
discarded
RIA
(G/R/3 or - if cells were 
exposed to ara.c - 
G/R / 6  antiserum)
Recovery of lng dCTP standard ”extracted” from water and taken 
through the assay procedure either via boronate chromatography or 
via NalO^ oxidation, and assayed using G/R/ 6  antiserum, gave the 
results shown in Table 4.11.
Table 4.11 Recovery of lng (2.14pmole) Standard dCTP Taken Through 
the Entire Assay Procedure
% dCTP recovered following:
Boronate chromatography NaI04 oxidation
(n = 7) (n = 8 )
6 6 .0 , 
73.6,
80.3, 96.4, 71.6, 
81.5, 63,0
88.4,
87.1,
92.6, 107.8, 96.3 
88.1, 97.4
Mean 76.06 92.43
S.D. 11.25 8.06
c.v% 14.78 8.72
Recovery of extracted dCTP was more reproducible and 
quantitative following NalO^ oxidation than after boronate 
chromatography. dCTP applied directly to the boronate column,
i.e. not extracted into PCA, showed similar recovery data to the 
extracted material, so that most losses were on the boronate 
chromatography column.
4.2.10 Results of Sample Assay
The assay was used to measure dCTP levels in 3 strains of 
L5178Y mouse lymphoma cells cultured by Dr A Lehman, at the MRC Cell 
Mutation Unit, University of Sussex. These strains and their 
sensitivity to ara.C had been described by Rogers et al.,(1980).
The wild type retained its sensitivity to ara.C, while the two 
mutants - induced by exposure to EMS - both showed resistance to 
ara.C. L5178Y EB 192-03A which showed a three thousand-fold 
resistance to ara.C over the wild type, was known to be dCd kinase 
deficient, but L5178Y 192-8, with a twenty-fold resistance to ara.C, 
showed only a minor reduction in dCd kinase activity. The cells, 
sent as a frozen pellet, were extracted whilst frozen and assayed 
following the protocol in Figure 4.14, with boronate chromatography 
as the pre-RIA treatment using G/R/ 6  antiserum. Results shown in 
Table 4.12, were from duplicate or triplicate assays of the same 
sample.
Table 4.12 dCTP Concentration in Three Strains of Mouse 
Lymphoma Cells
Cell Type
£
dCTP pmole/10 cells
L5178Y wild type 22.0, 27.3, 28.4
L5178Y 192-8 87.8, 79.2
L5178Y EB 192-03A 1.34, 1.26
The presence of the high dCTP level in the 192-8 strain could 
explain the resistance this line showed to ara.C, either by virtue 
of the inhibitory action of dCTP on dCd kinase (which was reduced in 
activity in these cells, Rogers et^  al., 1980) and hence on ara.C 
anabolism, or by direct competition between dCTP and ara.CTP for DNA 
polymerase. The dCd kinase deficient cells - EB 192-03A - had the 
very low dCTP levels expected.
dCTP was also measured in human fibroblasts cultured by Dr 
Lehman. These cells grew in monolayers until confluence, when cell 
division ceased due to contact inhibition. Fibroblasts from a 
normal individual were sent from different days during this growth 
cycle, as were fibroblasts from an immunodeficient patient (46 BR). 
46 BR cells were sensitive to a range of mutagens and had a defect 
in DNA ligation. It was thought possible that they might have 
imbalanced nucleotide pools. Results of dCTP assay on the 
fibroblasts are shown in Table 4.13. The cells were assayed using 
G/R / 6  antiserum after either boronate affinity chromatography or 
periodate treatment of the extract.
Table 4.13 dCTP Concentration in Human Fibroblasts from a Normal 
and an Immunodeficient Individual (46 BR) Throughout
their Growth Cycle
Cell Type dCTP (pmole 
Following 
chromatography
/1 0 ^ cells) 
Following 
NaI0 4 /CH3 NH 2
Normal human fibroblast Day 1 34.2, 28.4 30.8
Day 2 22.5, 18.3 18.4
Day 3 5.6 6.7
Day 7 1.3 0.89
Human fibroblast 46 BR Day 1 21.9 25.8
Day 2 5.5, 5.6 7.4
Day 3 3.4, 5.5 5.4
Day 7 3.3 2.7, 4.7
Note: Where more than 1 result is given this denotes assays done
on different days.
There was a reduction of dCTP in the cells as they went 
through their growth cycle as would be expected, but there was no 
significant difference between results from the two types of 
fibroblast.
It can also be seen that the two types of pre-RIA treatment 
received by these cells gave very similar results by RIA when using 
G/R / 6  antiserum, and results after fifteen different cell extracts 
were compared in this way and analysed by linear regression analysis 
(Figure 4.15). A good correlation was obtained (r = 0.9879) and it 
was concluded that when using G/R/ 6  antiserum with its low cross­
reaction with CTP (2.7%) NalO^/CH^NI^ degradation of this ribotide 
was sufficiently complete for any remaining NTP not to interfere 
with dCTP measurement.
This assay has also been used to measure dCTP in cell lines 
derived from a patient with ALL who developed resistance to ara.C 
after receiving high-doses of the drug (Kees, 1987). Three cell 
lines have been derived from this patient, and they were sent by Dr 
Kees as frozen pellets for dCTP assay. These lines differed in 
their sensitivity to ara.C; PER-164 was resistant to ara.C 
following in vivo exposure in the patient; PER-163, also ara.C 
resistant, has been exposed to ara.C in culture, while PER-145, 
established in culture from the same patient before high-dose ara.C 
therapy, was sensitive to ara.C. All these cell lines were 
identical with respect to surface markers, morphology, cytochemical 
stains and requirements for growth in vitro.
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FIGURE 4.15. Comparison of Results Obtained Following
Chromatographic (Method A); and NaI0i| 
(Method B) pre-RIA Treatment of Sample 
Extracts Using G/R / 6  Antiserum
0  2  4 6 1 2  14 1 6  1 8
METHOD A
2 0  2 2  24 2 6
pmole/ 1 0 ^ cells
Linear regression analysis of the data shows: slope = 1 .0 0 3 9 9 ;
mean of x values = 8.647; mean of y values = 9 .1 0 3 ; 
intercept =0.422; correlation coefficient = 0 .9 8 7 9 ; p^ 0 . 0 5
Studies were made in the three lines by Dr Kees on drug
uptake, and dCd kinase and Cd deaminase activity, as well as 
3
incorporation of [ H] ara.C into the DNA.
The rate of ara.C uptake by the three lines was identical, but
dCd kinase activity was virtually absent in PER-163 and much reduced
in PER-164. This was reflected in the level of ara.CTP in the
cells, which was practically undetectable in PER-163, and much
reduced in PER-164 compared with PER-145. Cytidine deaminase
activity was practically undetectable in all three lines.
3
Incorporation of [ H] ara.C into DNA reflected the ara.CTP levels, 
being the lowest in PER-163, and the highest in PER-145 (Kees et 
al., submitted to Cancer Research). The results of the assay of 
dCTP in the three cell lines are shown in Table 4.14. They were 
obtained by assaying each sample, with G/R / 6  antiserum, on two 
occasions and at three dilutions in the RIA on each occasion.
Table 4.14 Results of dCTP Assay on Three Leukaemic Cell Lines
Cell line
pmole/ 1 0  cells
dCTP .
t /i
Mean S.D
PER-145-86-1 52.3, 49.9, 47.3, 53.6, 52.1 3.02
54.5, 55.2
PER-163-ara.C 31.0, 35.7, 30.9, 27.1, 30.3 5.42
32.7, 34.2
PER-164 45.5, 53.1, 48.6, 47.6, 49.7 4.21
47.0, 56.5
Applying the unpaired t-test to the results shown in Table 
4.14, there was a significant difference (p =< 0.0001 degrees of 
freedom = 10) between dCTP results from PER-163 and PER-164, and 
PER-163 and PER-145. There was however no significant difference 
between dCTP levels in PER-145 and PER-164 (p = 0.336).
4.2.11 dCTP Assay - Discussion
dCTP conjugates did not prove to be very immunogenic, although 
there was a low-grade response from several animals (Table 4.1).
One conjugate (dCMP-ovalbumin) elicited no antibodies capable 
3
of binding [ H] dCTP, and the dCTP-ovalbumin was the msot 
successful. However, the small number of animals immunised with 
each conjugate prevented firm conclusions from being drawn as to the 
relative immunogenicity of each conjugate.
The successful use of different assay diluents was of 
interest, as it demonstrated that where samples are to undergo 
extraction or chromatographic treatments before RIA quantification, 
and are therefore no longer in a physiological medium themselves, 
antibody-antigen binding can be successfully achieved, and 
displaced, in extremely unphysiological media if this is convenient 
to the overall assay design. The use of a rapid degradative method 
such as NalO^/CHglTC^ treatment was shown to be adequate for the 
removal of interfering ribotides, provided the antibody used in the 
subsequent RIA cross-reacted by a low percentage with these 
ribotides.
The assay is sufficiently sensitive to measure dCTP in small
£
numbers of cells, e.g. 1 0  or less, which may be available from in 
vitro experiments, such as those outlined above, or from biopsy 
material.
The high degree of cross-reactivity shown by G/R/3 antiserum
for CTP (60%) could be utilized to study the effect of UMP synthase
inhibitors, such as pyrazofurin, on CTP levels. CTP can be readily
eluted from boronate affinity columns by a reduction in the pH of
the eluant (Bergold & Scouten, 1983), and it has been shown in
preliminary experiments (results not shown) that G/R/3 antibody 
3
binds well to [ H] dCTP even in 0.1M CH^COOH. This is however, a 
cumbersome procedure, and HPLC is probably best suited to studies of 
this kind.
Initial applications of this assay to cell extracts have shown 
dCTP concentrations fluctuating within human fibroblasts throughout 
the cell cycle, being at their highest during their most active 
growth phase. Where resistance to ara.C was being investigated, the 
L5178Y cells which were dCd kinase deficient showed an extremely low 
dCTP concentration, while the human leukaemia cell line PER-163, 
also deficient in this salvage enzyme, still maintained - presumably 
through a very active d£ novo synthetic pathway - a fairly high 
level of dCTP. The PER-164 line, also ara.C-resistant, did not have 
a dCTP level significantly different from that in the ara.C- 
sensitive PER-145 line. Thus in these cases of ara.C resistance, 
dCTP appeared to play no part in the resistant mechanism, which was 
much more likely to be due to reduced ability to phosphorylate ara.C 
to its active form (Kees et al., submitted to Cancer Research).
4.3 Ara.CTP RIA
This assay has been only partially developed and is not fully 
validated, so that a brief description of work to date will be 
given.
4.3.1 Standard Ara.CTP was obtained from Sigma, and was the 
sodium salt (catalogue number C8779), with a stated purity of 98%. 
Storage of the crystalline and stock standard solutions was under 
the same conditions used for dUTP standards (Section 3.2.1).
4.3.2 Production of Antibodies to Ara.CTP
Antibodies used in the development of this assay were raised 
originally as a reagent for an ara.C RIA. They have been used 
extensively for the latter purpose and the ara.C RIA has been 
described (Piall et al., 1979). The antibody was raised in a Soay 
sheep (G/S/747) to a conjugate of ara.CMP and ovalbumin, made using 
the method of Halloran & Parker (1966). 30mg of ara.CMP, lOOmg 
ovalbumin and lOOmg EDC were stirred together overnight in 1ml of 
0.1M phosphate buffer, pH 7.5. Dialysis was against 2 changes of 
one litre of distilled water, and the absorbance at 260nm of 
unconjugated ara.CMP in the dialysates was compared with a 
calibration curve for ara.CMP at that wavelength in order to 
calculate the amount assumed conjugated. The degree of 
derivatisation was from 29 to 50 moles ara.CMP/mole ovalbumin in 
different preparations. This conjugate was used to immunise seven 
Soay and nine Suffolk-cross sheep and ten New Zealand White rabbits.
The immunisation schedule used was similar to that described for 
dUTP in Section 3.2.2.2. Antibody response was obtained in only 
*one animal (G/S/747) in sufficient titre to merit antibody 
characterisation.
In the attempt to raise ara.C antibody a total of eighteen 
sheep and twelve rabbits were immunised with this ara.CMP-ovalbumin 
conjugate or with a conjugate of Cd to BSA, made using the method of 
Erlanger & Beiser (1964) described in Section 4.2.2.1.. Cd-BSA 
failed to elicit any significant response.
4.3.3 Assessment of Antiserum Titre, Avidity and Specificity
Antiserum titre was measured in the same way described in 
Section 3.2.2.. The response of G/S/747 to 26 successive boosts 
over 9 years was varied, but generally resulted after 9 - 1 4  days in 
antiserum with a titre of 1/60. On two occasions the titre rose to 
1/120 and 1/150 respectively, and the last two boosts were with an 
ara.CTP-ovalbumin conjugate made using the method of Halloran & 
Parker (1966). Following immunisation with this conjugate, titres 
rose as high as 1/380 for 4 weeks after boosting. The sheep then 
expired. Despite the low titres generally obtained, the antiserum 
produced good results in the ara.C RIA, (Piall i^t al., 1979), and 
was available in large volumes.
*A recent attempt to raise more ara.C antibody, following the demise 
of G/S/747, succeeded. Three sheep were immunised with a conjugate 
of ara.CTP to ovalbumin, made using the carbodiimide condensation 
method of Halloran & Parker (1966) and one responded with suitable 
titre antiserum. Ara.CTP had not been used as a hapten before, and 
the apparently improved immunogenicity of this conjugate over that 
of ara.CMP-ovalbumin may have been only the result of the chance 
immunisation of a "good responder".
The avidity of the antiserum for ara.CTP could not be
3
calculated, as the radiolabelled antigen used for the RIA was [ H] 
ara.C (Moravek Biochemicals Inc.), tritiated ara.CTP not being 
available. The reactivity of these two compounds with the antibody 
was different (see later this Section under "Specificity"). Chard 
(1971) has shown that the same degree of reactivity with the 
antibody must be shown by the two species of antigen, in order that 
a valid application of an equation derived from the Law of Mass 
Action equation can be made to standard curve data, and Muller 
(1980) has supported this conclusion.
Standard curves were set up and calculated in the same way as 
described for dUTP in Section 3.2.2.4. A typical standard curve is 
shown in Figure 4.16.
3
The specificity of G/S/747 antiserum using the [ H] ara.C 
label was described by Piall et al., (1979) in developing an RIA for 
ara.C, and is shown below in Table 4.15. The assay diluent used to 
obtain these results was PBSG, 0.05M, pH 7.4.
Table 4.15 Cross-reactivity of G/S/747 Antiserum with Ara.C 
and Structurally Related Compounds
Compound % cross-reactivity at 50% 
inhibition of zero binding
ara.C 100
*ara.CMP 125
ara.CTP 109
ara.U < 0.01
dCd; Cd; < 0.19
dCMP
*ara.CDP has been unavailable. It has been assumed that 
it would also cross-react by 100% or more.
FI
GU
RE
 
4.
16
. 
St
an
da
rd
 
Cu
rv
e 
fo
r 
Ar
a.
CT
P 
Us
in
g 
G/
S/
74
7 
A
n
t
i
s
e
r
u
m
 
(M
ea
n 
of
 
5 
cu
rv
es
 
pe
rf
or
me
d 
on
 
th
e 
sa
me
 
da
y 
S.
D.
oCQ
OO
CO
o
CM
oo
CO
o omoo
o
m
ON
LOvovo
LP\
o--=r
in
0 0
C\l
O
ON
rH
CO
■=t
LO
OV
CO
ON
1— I
pg 
ad
de
d
The ability of the antiserum to bind ara.CTP was exploited for 
the purposes of this assay. Its cross-reaction with CTP, dCTP and 
dTTP when in 0.7M Kt^PO^, pH 4.5 (chromatography medium, Section 
4.3.9.), was compared with its binding to ara.CTP in that medium.
The results are shown in Table 4.16.
Table 4.16 Cross-reactivity of G/S/747 Antiserum with Ara.CTP 
and Structurally Related Compounds
Compound % cross-reactivity at 50% 
inhibition of zero binding
ara.CTP 100
CTP < 0.01
dCTP < 0.01
dTTP < 1.26
It was apparent from the cross-reactivity of the antibody 
with ara.C and ara.CMP and its assumed cross-reaction with ara.CDP, 
that chromatography would be necessary to separate these compounds 
from ara.CTP. However, cross-reaction with dCTP, which would co­
elute with ara.CTP in most ion exchange systems, was insignificant.
4.3.4 Radiolabel used, due to the unavailability of
3
radiolabelled ara.CTP, was [5,6- H] cytosine arabinoside, average 
specific activity 26Ci/mmole, obtained from Moravek Biochemicals 
Inc, California, USA. Tritiated ara.C from Amersham International 
had been found to give rise to problems of increasing NSB and 
reduction in zero binding on storage for a short period of time.
The Moravek label has proved to be extremely stable over long (up to 
2 year) periods, when stored as recommended at -20°C. Sub-stock and
working dilutions were made up and stored as described in Section
3.2.3. The label was diluted in water for RIA, so that total counts 
were approximately 2500 counts per minute, and 2.18pg (1.9fmole) 
ara.C were added per assay tube in lOOjil.
4.3.5 Other RIA Components
4.3.5.1 Assay Diluents tried in developmental work for this
assay have been 1M CH^COONH^, pH 8.9, (for quantifying ara.CTP in 
fractions from a boronate affinity column); 0.4M IQ^PO^, pH 4.5, 
(for quantification following HPLC); and 0.7M KH^PO^, pH 4.5 (for 
quantification following LC).
All three diluents gave good results and standard curves for 
ara.CTP in these three media are shown in Figure 4.17. 0.7M IQ^PO^
will be used for future work with cell extracts.
4.3.5.2 Assay Incubation Conditions
The assay was set up and incubated for 1-2 hours in ice under 
equilibrium conditions. No comparison was made with other 
incubation conditions, except where CH^COONH^ was used as a 
diluent, when an equilibrium curve, incubated for 2 hours, was 
compared with a disequilibrium curve. In the latter, the standard 
was incubated with antiserum alone for l\ hours, when label was 
added, and a further \ hour incubation was allowed. The 
disequilibrium curve was significantly steeper (Figure 4.18).
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FIGURE 4.18. Standard Curves for Ara.CTP in 1M
CH^COONHzi, pH 6.2, Using G/S/747 
Antiserum and Equllibrium and ■ 
Disequilibrium Conditions
® Equilibrium (2 hours)
100 □ P]
Disequilibrium (1 1/2 hours 
with antiserum + ara.CTP, then 
+ 1/2 hour with label 
added)
20
10
100 10005020 50010
pg ara.CTP added
4.3.5.3 Separation of Antibody-Bound and Free Antigen was 
achieved by the use of lOOjil of DCC, made as described in Section
3.2.4.3. Results were sufficiently satisfactory for no comparisons 
to be made with other methods.
4.3.5.4 Liquid Scintillation Counting was accomplished in the 
same way as described in Section 3.2.4.4, using Ultrafluor 
scintillant..
4.3.6 Assay Precision has been evaluated both between and
within assays using 0.7M Kl^PO^ as assay diluent. The results from 
7 consecutive standard curves performed on different days are shown 
in Table 4.17, and from 5 curves performed on the same day in Table 
4.18.
It can be seen from the poor results for c.v. between assays 
that more work is needed on this RIA to improve the reproducibility. 
A wide standard curve range of this type is useful in assaying 
fractions from chromatography, which themselves might range very 
widely in concentration, but to improve reproducibility, it may be 
necessary to increase the count rate by adding more label, thus 
probably losing the top (more sensitive) part of the curve.
Table 4.17 Inter-Assay Variation Shown by Ara.CTP Standard
Curves in 0.7M KHoP0. -------------------2— 4
% B/Bo at Amount Ara.CTP Added (pg)
0 19 48 95 143 190 285 475 950 1900
(% B/T)
48.5 92.1 83.5 64.9 51.5 40.9 29.8 21.0 8.7 4.7
32.4 83.6 66.5 50.5 34.6 27.3 18.8 10.0 3.8 1.6
42.6 89.8 76.0 58.0 47.6 36.9 24.1 13.5 6.0 0.7
48.8 87.9 75.1 58.4 43.9 34.6 22.5 13.7 6.6 3.8
39.2 88.1 78.0 59.5 45.5 35.4 26.3 16.9 7.4 2.2
44.6 85.2 79.2 58.8 - 34.8 19.9 9.0 6.5 3.2
44.3 87.9 78.6 67.3 - 47.1 37.8 24.9 8.8 -
Mean
42.9 87.8 76.6 59.6 44.6 36.7 25.6 15.6 6.8 2.7
S.D.
5.70 2.79 5.57 5.39 6.26 6.10 6.56 5.78 1.72 1.48
c.v.%
13.3 3.2 7.3 9.1 14.0 16.6 25.6 37.0 25.2 54.7
Table 4.18 Intra-Assay Variation Shown by Ara.CTP Standard 
Curves in 0.7M KI^PO^
% B/Bo at Amount ara.CTP Added (pg)
0
(% B/T)
19 48 95 143 190 285 475 665 950
45.5 92.3 74.8 59.1 48.8 36.6 26.1 14.7 11.1 7.3
43.1 92.8 80.0 61.1 50.9 39.1 26.7 15.0 11.9 7.6
43.1 92.9 81.5 61.4 47.7 38.0 26.4 16.1 12.7 8.4
42.7 94.1 79.5 61.9 47.2 39.1 25.8 15.8 12.0 7.1
42.6 91.8 82.2 59.7 47.0 32.3 22.8 13.5 10.1 5.9
Mean
43.4 92.8 79.6 60.6 48.3 37.0 25.5 15.0 11.5 7.2
S.D.
1.19 0.86 2.89 1.18 1.60 2.83 1.57 1.02 0.99 0.90
c.v.%
2.8 0.92 3.6 1.9 3.3 7.6 6.1 6.8 8.6 12.5
4.3.7 Assay Accuracy has only been evaluated for the recovery
of ara.CTP applied to the LC column, collected in fractions and 
quantified by the RIA. 4.7ng (10 pmole) ara.CTP was 
chromatographed, and 64.5, 69.0 and 65.2% was recovered. More work 
is needed to establish that the results of recovery are reproducible 
over a range of standard values, and recoveries from extraction 
through the entire procedure should also be evaluated.
4.3.8 Extraction of Ara.CTP
It is intended to use the PCA extraction technique described 
by Bagnara & Finch (1972) and used for other dNTP assays (Section 
3.2.7.).
4.3.9 Pre-RIA Treatment of Cell Extracts
Because of high cross-reactivity with ara.C, ara.CMP and, it 
is presumed, ara.CDP, chromatographic separation of these three 
compounds from ara.CTP was a necessary requirement before RIA 
quantification. It has been shown that ara.CMP and ara.CDP are 
present in cultured human myeloblasts and in leukaemic cells in vivo 
in a total concentration of 10% or less of ara.CTP, following 
exposure to ara.C (Jamieson et al., 1987; Plunkett et^  al., 1987). 
However, separation of ara.C, which could be present in high 
concentrations was essential, and the two metabolites could be 
easily removed at the same time using chromatography.
HPLC was used for a short time before mechanical difficulties 
became too severe. An isocratic eluting buffer, 0.4M KI^PO^, 
pH 4.5, was used with a 25cm x 4.6mm Partisil 10 SAX anion exchange 
column (Whatman). A Varian 5000 LC, fitted with a Rheodyne loop 
injector was used with a flow rate of 2ml/minute, 80 atmospheres 
pressure. Ara.C eluted from the column with the solvent front, 
ara.CMP was retained for 2 minutes and ara.CTP for 11 minutes. 
Fractions containing ara.CTP were collected into plastic LP4 tubes 
(Luckham Ltd) in an. LKB "Redirac" 2112 fraction collector.
Fractions were removed into ice before measurement by the RIA, or 
were frozen at -40°C. Preliminary work with recoveries from this 
system gave 98.8 and 99.6% (lng applied), and 80.4 and 90.9% (2ng 
applied) recovery of ara.CTP.
LC was used later as it was more reliable than HPLC. QAE A25 
Sephadex was used as described for the dUTP assay in Section 
3.2.8.2, except that initial elution was with only 30ml of 0.3M
Fractions were collected from an extract of cells exposed 
to ara.C and were assayed by the RIA. The elution pattern of 
immunoreactive fractions from the sample is shown in Figure 4.19, as 
well as results obtained when it was "spiked" with ara.CMP and 
ara.CTP standard. The first peak from the sample fractions was 
probably ara.C as well as ara.CMP, as neither of these compounds 
would be retained on an anion exchange column with this high 
molarity (0.3M) buffer. The second, ill-defined peak, is probably 
ara.CDP, and ara.CTP eluted after increasing the molarity of the 
buffer to 0.7M. The great enhancement of the second (probable 
ara.CDP) peak when ara.CTP and ara.CMP standards were added, can
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only lead to the assumption that these preparations contain a high 
degree of contaminating ara.CDP. The ara.CTP peak was well 
separated from the other compounds using this system.
4.3.10 Ara.CTP Assay - Discussion
This assay requires further optimisation, particularly to 
improve the RIA precision and the use of disequilibrium conditions 
may be necessary. The addition of more radiolabel to de-sensitise 
the curve and probably lose the top point (19pg added), but increase 
the count rate and improve the bottom half of the curve, would also 
be a first practical manipulation to attempt. More information 
regarding recovery of ara.CTP from extraction through the assay 
procedure is also required. The presence of an apparently high 
degree of impurity in standard material is of great concern, and a 
new source of standard should be considered. Once received, new 
standards should he chromatographed to check the percentage 
impurity, using the RIA for quantification, followed by any 
necessary purification.
Cells from leukaemic patients receiving a liposomal 
preparation of ara.C by iv. bolus, which it was hoped would give a
prolonged t\ of ara.CTP, await assay by this method. The patients 
also received "free" ara.C by both an iv. bolus and a 
12 hour continuous iv. infusion for comparison of ara.CTP 
accumulation after these different ways of giving the drug. This
assay, it is hoped, will thus be of direct use in clinical 
situations. The assay could also be used to measure individual 
patient's response to ara.C, so that pharmacologically directed 
doses of this drug could be given (Estey et al_., 1987).
Chapter Five
Discussion
Chapter 5
DISCUSSION
The development of fully validated assays for dUTP and dCTP 
with quantification by RIA, has been described, together with their 
application to studies on drug action and drug resistance. The 
assay for dTTP is well advanced in development, requiring some final 
validation, and that for ara.CTP is in need of optimisation of RIA 
conditions to achieve better reproducibility, before validation can 
be completed.
5.1 The Need for dNTP Assays is evident from the considerable 
effort already expended on their development and refinement (Hunting 
& Henderson, 1982). The broad range of studies in which dNTP 
measurements find their place includes biochemical studies on 
metabolic pathways and cellular growth and division, which are of 
special interest in different tissues and species and in disease 
states such as cancer. The dNTP concentrations in normal as well as 
in neoplastic tissues are of importance for comparative purposes. 
Differences in DNA precursor pathways between species are also 
important to ascertain, especially where animal models are to be 
used to test experimental antimetabolites for use in the clinic.
The occurrence of many abnormalities in purine and pyrimidine 
pathway enzymes in neoplastic tissues was described in Section 1.3. 
The large amount of work already carried out on enzyme abnormalities 
has not so far been matched by work on dNTP concentrations in these
tissues. This is probably partly due to the technical difficulty of 
measuring these compounds in what is often the small number of cells 
available from cultures or biopsy material. Because of their 
inhibitory or stimulatory roles, the measurement of substrates made 
at the same time as estimations of appropriate enzyme levels and 
activities would give a better understanding of pathway 
abnormalities, rather than enzyme studies done in isolation. Since 
the advent of HPLC as an effective method of measuring NTP levels, 
there has been a notable increase in reports of the concentrations 
of these compounds in both normal and neoplastic tissues (McKeag, 
1984), but dNTP measurements are still infrequent.
Almost all the work referred to in Section 1.2 on the effects 
of dNTP pool imbalance in inducing mutagenic changes or reductions 
in the efficiency of DNA repair mechanisms, has been reported 
without measurement of the effects of the various treatments used on 
actual dNTP pool sizes in the experimental cells. The assumed pool 
imbalances were brought about either by the use of drugs inhibiting 
dNTP pathway enzymes, by adding an excess of one dNTP, or by making 
use of genetic lesions to block specific steps in dNTP biosynthesis 
(Haynes, 1985). Unknown side effects from drugs or exogenous 
precursors, and pleiotropies in the case of genetic lesions, were 
not ascertained. Different effects on dNTPs in different cell types 
were also not considered, so that a treatment used to bring about 
change in dNTP pool size in one cell type was assumed to have the 
same effect in another.
The compartmentalisation of dNTPs in different parts of the 
cell is not taken into account by most published methods, or by the 
assays described in this thesis. The changes occurring in dNTP 
distribution in different parts of the cell throughout the cycle are 
of importance to cellular function (Harrap & Renshaw, 1980; Keppler 
& Holstege, 1982) and the separation of cellular components for 
comparative analysis of dNTP concentrations might yield further 
useful information on the role of dNTPs in DNA replication.
The changes in dNTP concentrations known to occur throughout 
the cell cycle make necessary the use of cells in the same part of 
the cycle from in vitro experiments so that the results of dNTP 
assay reflect the dNTP concentration in the entire cell sample.
Thus, sub-confluent, actively dividing cells have been used for the 
work on CB3717 described in Chapter 3 (Section 3.2.10). In biopsies 
of solid tumours, normal cells such as blood or interstitial cells 
would be mixed with neoplastic tissue (Whitehouse, 1984). Thus dNTP 
measurements would reflect the levels in these normal cells as well 
as those in the cancer cells. Many of the cancer cells might also 
not be undergoing cell division. In vivo leukaemic cells, readily 
separated from normal blood cells by the Ficoll layering technique 
(Section 2.1), lend themselves better to studies of this kind, as 
they can also be easily checked for the percentage in S-phase by the 
use of flow cytometry.
Pharmacological studies of the effects of exogenous agents 
(e.g. chemotherapeutic, toxic or carcinogenic) on cells, are another 
important area where dNTP assays can give valuable information on 
cellular reactions to these agents. In the area of chemotherapy,
and in particular in the use of antimetabolites, dNTP assays can
fulfil useful functions. Where new drugs are under assessment, the
use of iii vitro experiments to establish dose response curves for
drug exposure against effect on dNTPs can assist in dosage and
scheduling protocols for in vivo work. The mode of action of the
drug, as far as DNA precursors are concerned, can also be elucidated
(Jackson jet al., 1983). The very high levels of dUTP found in A549
cells after exposure to CB3717 (Section 3.2.10) has, for example,
indicated that uracil incorporation into DNA may be a major toxic
effect of this drug. Even the use of clinically well-estabished
drugs can benefit from measurements of dNTPs and of the active tri-
phosphorylated form of the pro-drug where it competes with an
endogenous dNTP, e.g. ara.CTP and dCTP measured in the same cell
extracts (Liliemark & Plunkett, 1986). The use of an ara.CTP assay
to monitor the individual patient’s response to high-dose ara.C
treatment, and thus to give pharmacologically dictated doses of
ara.C, is carried out frequently at one institution (Estey et al.,
1987). This has led to the discontinuation of extremely high-dose 
2
ara.C (3g/m /12h) in favour of a lower, less toxic, and equally
2
effective dose (0.5g/m /12h) as ara.CTP levels in patients cells 
were found to be saturated at the latter dose (Plunkett et^  al.,
1987).
When drug resistance is encountered a possible mode of action 
due to competition from high levels of endogenous dNTPs can be 
ascertained or discounted by the use of appropriate assays, e.g. the 
dCTP assay where ara.C resistance is encountered, (Sections 4.1 and 
4.2.10). Low endogenous dNTP levels indicate decreased enzyme
activity and/or substrate level in the purine/pyrimidine pathways. 
Such findings might have implications for suitable changes of the 
drug protocol. However, the multifactorial systems involved in 
maintaining these pathways are such, that knowledge of key metabolic 
pools and enzyme activities would be required before a full 
interpretation of such abnormalities could be made.
Drug synergy and the biochemical modulation of drug action 
has been referred to in Section 1.4.5 and this is an area of 
considerable interest and possible clinical importance in cancer 
chemotherapy (Leyland-Jones & 0 ’Dwyer, 1986). In vitro and animal 
studies have given encouraging results, which have not however often 
translated well to the clinic (0’Dwyer, 1987). It seems possible 
that the subtleties of many of these drug modulating protocols are 
difficult to reproduce in the heavily pre-treated patients included 
in Phase I and II trials. Biological variation and variations in 
physiological state coupled with tumour heterogeneity within and 
between patients (Section 1.3), all combine to make successful 
biochemical modulation in vivo a difficult proposition. It appears 
possible that a modulating effect such as the use of a blocker of 
nucleoside-efflux and nucleoside salvage, e.g. dipyridamole 
(Section 3.2.10), may give rise to more successful results than 
modulations involving manipulations of the purine/pyrimidine 
pathways using combinations of antimetabolites. Whatever the type 
of modulating protocol tried however, this is another area where 
dNTP assays could be of use in measuring effects on DNA precursors.
It has been noted (Section 1.2) that abnormal pool ratios of
dNTPs may be of great importance in their effects on DNA synthesis
inhibition or on base misincorporation (Newman & Miller, 1985;
Kunz, 1982), and because of the importance of balanced dNTP ratios 
to normal cell function and to the replicational fidelity of DNA, 
the measurement of all four normal precursors in the same extract 
would be of advantage in interpreting drug actions, synergies and 
attempts to modulate drug action. Thus the fibroblasts from the 
immunodeficient patient (46BR) which were assayed for dCTP and found 
to be normal for this compound, might have had dNTP pool imbalances,
as the other dNTPs were not measured (Section 4.2.10.).
The development of RIAs for the purine DNA precursors, dATP 
and dGTP, would be of interest, but is not planned at present.
5.2 Advantages and Disadvantages of RIA Compared with Other 
Methods for Measuring dNTPs.
5.2.1 HPLC. The great advantage of HPLC over other analytical
methods is its ability to resolve a large number of structurally 
related compounds at one time. Its limitation however is the low 
sensitivity of the "on-line" quantification method most frequently 
used, i.e. UV (Section 2.4.3). For the measurement of dNTPs by this 
method, large numbers of cells (in excess of 10^) are required.
Such large numbers are not always readily available even from cell 
cultures, and cannot be obtained from biopsies such as a single 
needle-biopsy. For the separation and quantification of NTPs,
present in concentrations of nmoles/10 cells, HPLC-UV is an 
excellent and frequently used method but difficulties of resolution 
as well as detection are encountered when measuring dNTPs by this 
method (McKeag, 1984).
The pre-analytical column removal of interfering ribotides is 
required for good HPLC resolution of dNTPs, and procedures such as 
NalO^ oxidation are usually used (Section 2.3). Even then, there is 
interference in the UV trace from breakdown products of this 
reaction with e.g. the dCTP peak (W Plunkett, personal 
communication).
The resolution of dNTPs by HPLC prior to RIA is potentially a 
powerful combination of techniques, and was tried with some success 
(Section 3.2.8.2) until excessive and expensive technical 
difficulties made the use of HPLC impractical for this project.
5.2.2 The DNA Polymerase Assay is capable of great sensitivity
(Section 2.4.2) but there are considerable difficulties connected 
with the purity of commercial reagents such as the polymerase 
itself, or the polymers used as primer/templates, and also with 
interference from cell extracts with certain assays, such as that 
for dCTP (Tyrsted, 1985; Booth, 1985).
Added to these technical problems, the inability of the 
polymerase to distinguish between dUTP and dTTP (Bessman et al.,
1958; Harrap & Renshaw, 1980), makes this method unacceptable for 
the measurement of these compounds in extracts from anti-folate or 
thymidylate synthase-treated cells.
5.2.3 Miscellaneous Methods. It was noted that much of
the published literature reporting dNTP work, particularly that on
dUTP, used methodologies which were not validated for recovery or
reproducibility and no reference sources for the methods used were
given. Goulian et^  al., (1980), reporting on the presence of dUTP in
cells exposed to MTX, did refer to the recovery of added radioactive
dUTP, and this varied from 10-40%. The method used took over a week
to perform, so that the time taken by this procedure probably
resulted in the degradation of dUTP. Sedwick et al., (1981)
reporting large amounts of dUDP in cells exposed to DDMP, admitted
that its presence might be due to the breakdown of dUTP, but did not
attempt to recover unlabelled dUTP standard material taken through
their assay procedure. This group calculated their results from a
3
residual count rate of as low as 12 cpm [ H] for some samples, and 
these counts represent background in most scintillation counters.
No reproducibility data was given by these authors. Jackson et al., 
(1983) also gave no recovery or reproducibility data, and 
disappointingly did not show any cell extract traces from the HPLC 
separations used in their report on the presence of dUTP following 
exposure to CB3717.
5.2.4 RIA. It was the great potential sensitivity of this
technique which made it an attractive one to apply to dNTP 
measurement. High specific activity radiolabels and standard NTPs 
and dNTPs were readily available commercially, leaving the 
requirement of antisera for the development of the assays.
RIA rather than an ELISA was chosen as the type of immunoassay 
to be developed, for several practical reasons. At the
start of this project, the sensitivity that could be achieved with 
ELISA was rarely as great as that desired for measuring dNTPs, and 
because of the commercial availability of high specificity activity 
radiolabels, it was clearly possible to attain the required 
sensitivity with RIA. It was also realized that complete antibody 
specificity for the antigen would be impossible to achieve (see 
"Antibody Specificity" later this Section), so that pre­
quantification treatment of cell extracts to remove cross-reactants 
would be necessary. It was anticipated that this would leave the 
sample for immunoassay in a medium unsuitable for ELISA.
RIA is unable to quantify more than one compound at a time - a 
disadvantage compared with HPLC - and a different antiserum must be 
raised for each compound. Because of the difficulties of eliciting 
an antibody response to some immunogens, and the antibody 
characterisation involved, this factor presents a further 
disadvantage to the use of RIA unless a good commercial source of 
antibody is available.
5.2.4.1 Antiserum of sufficiently high affinity to start
developmental work on the RIAs was difficult to raise in two cases 
(ara.CTP and dCTP) but was quickly obtained in the cases of dUTP and 
dTTP (Sections 3.2.2, 3.3.2, 4.2.2 and 4.3.2). The reasons for 
these differences are unknown. The successful conjugates used for 
three of the four compounds (dCTP, dUTP and dTTP) were all made by 
coupling the respective dNTP to ovalbumin, using the same 
carbodiimide reaction, and the immunisation protocols were also all
essentially identical, so that the differences may have lain only in 
the immunised animals themselves. It is well known that individuals 
vary greatly in the responsiveness of their immune systems to a 
specific challenge, and that such variation is genetically 
controlled (Roitt, 1986). Thus biological variation was probably 
the reason for the differences observed.
Many immunised animals showed early responses of low titre 
antibody, which it was not possible to boost, and which in some 
animals disappeared altogether on further boosting. G/S/1524, the 
producer of dTTP antiserum, at one time had a titre of 1/500, which 
on further boosts fell to 1/200 (Figure 3.15). G/R/3 and G/R/6
antiserum titres to dCTP both fell after several boosts (Figures 4.3 
and 4.4). It can be speculated that a second set of antibodies was 
produced against those to the dNTPs, forming an immune complex with 
them and thus making them unavailable. It has been shown that such 
antibodies (anti-idiotypic antibodies) can be produced to the first 
antibodies’ variable and hypervariable regions, which act as 
antigenic determinants and are known as idiotopes (Roitt, 1986).
IgM antibodies enhance this kind of response most frequently, and 
the early responses which quickly disappeared were most likely IgM 
antibodies. Another explanation, particularly for the results in 
G/R/3, G/R/6 and G/S/1524, is that the animals had developed 
immunological tolerance to the antigens, although this appears to 
have been only incomplete, reducing the quantity of the antibody 
(Roitt, 1986). Thus infrequent boosts e.g. at six monthly 
intervals, or possibly even longer, are probably advantageous.
Antibody specificity was not expected to be good enough for 
the direct RIA of untreated extracts. Because of the antigenic 
determinants shared with the mono- and di-phosphorylated forms of 
each of the compounds, it was anticipated that chromatographic 
separation of each dNTP from these forms would be necessary. In the 
cases of dCTP and dUTP the corresponding ribotide cross-reacted, 
again because of a number of shared antigenic determinants.
The difference in the cross-reactivity of G/R/3 and G/R/6 
antisera with ara.CTP was notable (44% for G/R/3 and only 0.13% for 
G/R/6, Table 4.2, Section 4.2.2.4). G/R/6 antiserum was more
specific altogether, however, and individual variation must be again 
put forward as the reason for these differences, as the immunisation 
procedure and conjugates used were the same for these two rabbits.
G/S/747 antibody, used for the ara.CTP assay, was raised 
against an ara.CMP conjugate, but interestingly failed to cross- 
react significantly with dCMP (0.19%, Table 4.14) or with dCTP 
(^0.01%, Table 4.15, Section 4.3.3.). The ara.CMP : protein 
conjugate was made using the carbodiimide condensation reaction of 
Halloran & Parker (1966) (Section 2.4.4.2), which made highly 
probable the masking of the difference between ara.CMP and dCMP at 
the 2 f-position, so that this structural difference is unlikely to 
be the cause of the specificity shown by G/S/747 antiserum for 
ara.CTP over the endogenous cytidylates. The converse effect of 
greater specificity for dCTP over ara.CTP shown by G/R/6 antiserum 
(0.13%, Table 4.2, Section 4.2.2.4) was again the result of an 
immune response to a dNTP : protein conjugate made with the probable
masking of the 2 ’-position. It can be speculated therefore that the 
difference in the three-dimensional structure of these furanoid and 
arabinoid nucleotides has been a strong antigenic determinant. The 
rotation of the ara.C molecule around the N-glycosidic bond is 
markedly different to that shown by dCd (Emerson et al., 1967), and 
as three-dimensional shapes are thought to be recognised by 
antibodies (Roitt et al., 1986; Section 2.4.4.3) it seems likely 
that it is this characteristic that has conferred this particular 
aspect of specificity on both the G/R/6 and G/S/747 antisera.
It has been shown by others (Humayun & Jacob, 1973; Stollar, 
1980) that conjugates of nucleic acid components to proteins can 
elicit antibodies of great specificity. Humayun & Jacob (1973), in 
discussing the characteristics of antibodies raised to a dAMP-BSA 
conjugate, made by the carbodiimide method, noted that specificity 
was strongest for the base, followed by the sugar and was least for 
the phosphate groups. In general this has been borne out by the 
results described in Chapters 3 and 4, although there was a 
disappointing degree of cross-reactivity of the dUTP antiserum for 
dTTP (about 4%), and vice versa. Neither of these antisera cross- 
reacts with dCTP to a significant degree (<0.2%; Tables 3.4 and 
3.14), presumably because of the differences on the base rings 
between this compound and dUTP at position 4 or at 5 for dTTP, (see 
Figure 1.1). dTTP and dUTP differ from one another by only one base 
ring substituent, namely the possession by dTTP of a methyl group at 
5. It was hoped that this latter difference, left unmasked by 
conjugation procedures, would confer to the antibody elicited a 
specificity for dUTP or dTTP such as that shown for dCTP. To
support this expection for antibody specificity for the base ring 
substituents even further, G/R/3 and G/R/6 antisera to dCTP had not 
displayed any significant cross-reaction with either dUTP or dTTP 
(<0.1%; Table 4.2).
There are two possible explanations for these high cross­
reactions by G/R/9 and G/S/1524 antisera with dTTP and dUTP 
respectively. One possibility is that both the dTTP and dUTP 
standards are cross-contaminated. This is likely in view of the 
difficulty of separating these compounds completely, although the 
technical department of the supplier used in later work (Pharmacia) 
has stated that methods of dUTP and dTTP synthesis preclude any such 
contamination. The other possibility, that in both G/R/9 and 
G/S/1524, the immune response has produced IgG most of which 
recognises both dTTP and dUTP, appears to be borne out by the 
results of affinity chromatography of the IgG from these animals.
In both antisera, the attempted removal of cross-reacting antibody 
left very low concentrations of "specific" IgG behind, unbound to 
the cross-reactant. This "specific" IgG also still showed somewhat 
equivocal results for cross-reaction with the unwanted cross­
reactant (Section 3.2.2.4 and Table 3.14, Section 3.3.2.5.). It 
appears likely therefore that most of the IgG is capable of 
recognising either compound. In view the lack of recognition shown 
by these antisera for dCTP, it must be conjectured that the 
substituent at position 4 on the base ring which is shared by dUTP 
and dTTP is a strong antigenic determinant. It can then be further 
reflected that DNA polymerase cannot distinguish between dUTP and 
dTTP, and this lack of specificity is repeated in the immune system.
The culture of monoclonal antibodies for dNTPs was not 
considered, for two reasons. The first was the practical one of a 
lack of sufficient time and facilities. Also a rapid screening 
method for the antibodies would have been needed from the beginning, 
and this was not available. A further factor against attempting to 
raise monoclonal, and therefore possibly more specific, antibodies, 
was that there have been reports of a loss of the high affinity 
antibodies required for very sensitive assays, in some monoclonal 
cultures. There is, however, evidence that if bovine or ovine 
circulating lymphocytes are used in the fusion process rather than 
murine cells, the resultant monclonal lines retain a high affinity 
(Morris, 1988). Also monoclonal antibodies, which can show great 
specificty, are not yet shown to be of advantage in this regard over 
polyclonal antibodies when they are raised against small molecular 
weight antigens whose antigenic determinants are close together, as 
are those of the dNTPs.
5.2.4.2 Other assay reagents were all commercially available.
The development of the RIAs using different diluents and conditions 
was greatly assisted by the ability of the dNTP antigen-antibody 
reactions described in Chapters 3 and 4 to take place in high 
molarity salt solutions, often at a low pH. This meant that post­
chromatography fractions could all be quantified directly. Some 
early work with dCTP had shown that if dCTP was in a medium such as 
CH^COONHg and was then lyophilised in order to re-solubilise it for 
RIA in a more physiological medium, a very high (can exceed 50%) and 
variable percentage was lost by degradation during the process.
Thus for these unstable compounds a reduction in the number of steps 
undertaken in their assay is highly advantageous.
5.3 The Future of RIA for dNTP Assay. It is not expected that 
many laboratories will attempt to develop their own RIAs for dNTPs 
due to the difficulties encountered in raising antisera, for which 
large numbers of animals are required. However, expertise in RIA is 
present in many laboratories world-wide, and antisera such as those 
described for dTTP and dUTP (from G/S/1524 and G/R/9 respectively) 
are available in sufficient quantities to supply other groups. Even 
following the considerable loss of titre experienced on affinity 
purification of these antisera, enough IgG remains available for the 
assay of several million tubes by the methods described for these 
nucleotides. The successful development of these assays also shows 
that there is another alternative to methods previously available, 
which either did not provide the sensitivity or the specificity 
required. The dUTP assay in particular provides a unique 
combination of specificity and sensitivity in a fully validated 
assay.
They are fairly laborious assays taking all the steps into 
account, but the most time consuming and tedious step - that of LC 
chromatography - need be performed only once to provide fractions 
for the assay of several dNTPs. Twenty samples can be 
chromatographed in one day, and aliquots from all the fractions can 
then be readily quantified by RIA for one dNTP on the next day.
The affinity purification of the dUTP and dTTP IgG can be 
performed using large batches of IgG, and the antibodies store well 
even in the low dilution in which they come off the affinity column.
Once developed, these assays have the great advantage of 
requiring simple equipment, found in most research laboratories, 
which does not require frequent maintenance or expenditure. The 
high affinity of the antisera also makes the RIAs "robust", so that 
they need not be performed by very highly trained individuals, 
although careful and precise work is required.
The publication of the validated methods for dCTP and dUTP has 
been undertaken (Piall jelt al., 1986; Piall et al., submitted to 
Analytical Biochemistry), and it is hoped that these papers will 
shortly be followed by published reports of the dTTP and ara.CTP 
assays. Thus fully validated assays for these four pyrimidine 
nucleotides, representing the novel application of immunoassay to 
dNTP measurement, and providing specificity and sensitivity, will be 
available to investigate drug or genetically induced changes in 
these precursors of the so-called "dead-end" of DNA synthesis 
referred to at the beginning of this thesis.
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Abstract
A radioimmunoassay (RIA) for dUTP, with a sensitivity of 3.78fmol, has been 
developed. The antibody cross-reacted with dTTP so that affinity purification of the 
IgG fraction was required before its use in the RIA. Cross-reactivity with UTP and 
with mono- and di-phosphodeoxyuridylates has necessitated respectively sodium 
periodate oxidation, and anion exchange chromatography of cell extracts, prior to RIA 
quantitation of dUTP directly in fractions from the chromatography column. Mean 
recovery ra te  of a range of concentrations of extracted dUTP standard taken through 
the entire procedure is 63.7% (7.8-31.3 pmol dUTP) although at a lower concentration 
(3.l i p  mol) the recovery was only 36.2%. Results are reproducible with CV values of 
between 3.1 and 9.3%. The assay has been used to assess the presence of dUTP in 
A549 human lung carcinoma cells exposed to the TS inhibitor CB3717. The high 
sensitivity of the quantitation step has made it possible to measure dUTP in relatively 
small numbers (10^) of cells.
dNTPs have proved difficult to quantitate due to their presence in cells in low 
concentrations (pmoles 10^ cells), and to the simultaneous presence of 100 to 1000- 
fold concentrations of the corresponding NTPs. The importance of dNTP pool changes 
in understanding the action of anti-metabolites in trea ted  cells has led to effo rts  to 
improve methods for their quantitation, and the most frequently employed methods at 
present are HPLC and variations of the DNA polymerase assay (1). A fter NTP 
removal by periodate oxidation, HPLC offers potentially excellent resolution of 
dNTPs, but the standard detection method of UV absorbance lacks the sensitivity 
required to quantitate these compounds except in ex tracts  from large numbers of cells 
(107 or greater). The DNA polymerase assay is capable of great sensitivity (<lpmol), 
but besides presenting some difficulties in performance, it is not specific for dUTP due 
to the inability of DNA polymerase to distinguish between dUTP and dTTP (2, 3). 
dUTP, undetectable to date in untreated cells has been shown to be present a f te r  
exposure to some drugs belonging to the clinically important group of antim etabolites 
causing inhibition of thymidylate synthase eg. MTX and DDMP (4,3) while Ingraham e t 
al (6) have shown the fluorinated analogue, 5FdUTP, to be present in cells a f te r  
treatm ent with 5FU. It is possible tha t the presence of dUTP in TS-inhibited cells may 
explain - a t  any ra te , partially, - the mode of action of this type of drug. Cell death 
could follow the incorporation of uracil into DNA in the presence of reduced 
thymidylate, thus leading to instability and the fragmentation of newly-forming 
strands (7,8). The role of dUTP in TS-inhibited cell death is however, not yet clear, 
and no sensitive and fully validated method for the quantitation of dUTP has so far 
appeared in the literature.
We required such a method to quantitate low pmol amounts of dUTP in the 
presence of dTTP, in cells exposed to the TS inhibitor, CB3717 (9). dUTP has been 
shown by Jackson et al. (10) using relatively large numbers of cells (107) or more to be 
present in human lymphoblastoid cells a fte r  trea tm en t with this new TS inhibitor. We 
anticipated using only relatively small numbers of cells in each experiment (10^ or
less), and wished to de tec t  any small increments in dUTP concentration tha t might 
occur with dose escalation or modulation of culture conditions, so tha t the 
development of a highly sensitive RIA, similar to tha t described by Piall e t al., for 
dCTP (11), was undertaken. We report on immunological method for quantitating 
dUTP which uniquely combines sensitivity with specificity when measuring this 
compound.
Materials and Methods
A549 human lung carcinoma cells were grown in monolayers in multi-dish trays 
(Falcon, Becton-Dickinson, Oxford, England) in RPMI 1640 (Northumbria Biologicals, 
Northumberland, England), supplemented with 10% heat inactivated foetal bovine 
serum (Gibco, Paisley, Scotland), 500i.u/ml penicillin and 500pg/ml streptomycin. 
When the desired density was reached, the medium was replaced with medium 
containing CB3717 (ICI, Macclesfield, England) in concentrations of IpM, 3pM, lOpM 
and 30pM. Each dose level was run in triplicated wells, and control wells with no drug 
were run in trip licate  with each experiment. A fter incubation for 24h a t  37°C, the 
medium was removed by aspiration, the dish immediately placed on ice, and the 
monolayers flooded with 1ml 0.4M ice cold PCA. They were detached from the dish 
with a cell scraper and the suspension was transferred to chilled centrifuge tubes, 
vigorously vortex-mixed and stood on ice for 30 minutes. After centrifugation for 20 
minutes at 4°C and 1500g, the supernatant was carefully decanted, the volume 
measured and neutralised with 0.5vol of ice-cold 0.72M KOH in 0.16M KHCOy A fter 
vortexing, the ex tracts  were kept in ice for lh , then centrifuged as before. The 
supernatant was aliquoted in duplicate and stood frozen in liquid nitrogen.
Sodium Periodate T reatm ent of Extracts
20pl of 0.3M sodium periodate was added to 0.5ml extract, vortex-mixed and 
followed a f te r  5 minutes at ambient tem perature  by the addition of 25pl of 4M
4methylamirie, pH7.5 (12). After incubation for 15 minutes at 37°C, the ex trac ts  were 
plunged into ice while awaiting chromatography.
Chromatography of Extracts
QAE A25 Sephadex (Pharmacia) was kept swollen in 0.3M Kb^PO^, pH4.4, 
containing 0.002% (w/v) chlorhexidine (Aldrich Chemical Company) as preservative. 
5ml (2 g) was poured into a plastic K9/15 column (Pharmacia) filled with the same 
buffer. A suitable aliquot (50 to 500 yl depending on the degree of exposure of the 
cells to CB 3717) of ex trac t was applied to the column, and a f te r  the passage of 10 
column volumes of 0.3M Kb^PO^, a change to 0.7M Kb^PO^, pH4.4 was made. A fte r 
discarding the void volume (approx. 3 ml), 0.4ml or 0.8ml fractions were collected, 
removed immediately into ice, and either stored frozen a t -40°C or assayed the same 
day by the RIA. The RIA was performed directly on the 0.4ml fractions, or on aliquots 
from the 0.8ml fractions made up to 0.4ml with 0.7M Kb^PO^.
Radioimmunoassay
Standard nucleotides were purchased from the Sigma Chemical Company, or 
from Pharmacia. They were stored aliquoted in lOOyg/ml solutions in b^O  a t  -40°C. 
The assay diluent was 0.7M KH^PO^, pH4.4. deoxyuridine 5'-triphosphate (TRK
351, specific activity 22Ci/mmol) was obtained from Amersham International and 
diluted in water for each assay so that 53.2pg (O.llpmol) of £ dUTP was added to 
all assay tubes.
dUTP antibody was raised in a New Zealand white rabbit in response to a prime 
and one boost with a conjugate of dUTP: ovalbumin made by the carbodiimide 
condensation method (13), and following the immunisation schedule already described 
by Piall e t  al. (11), except that a fter the first 3-monthly booster, injections were given 
at 6-monthly intervals, and the rabbit was bled a t  intervals from 9 days to 35 days 
following each boost.
Removal of antibodies binding dTTP was carried out by affinity purification of 
the antiserum. IgG was precipitated by the gradual addition of 50% (v/v) of saturated 
(N H ^ S O ^  to the antiserum while stirring. A fter centrifugation at lOOOg for 30 
minutes a t  4°C, the pellet was solubilised in 0.1M Na2HCOy pH8.0.
A conjugate of dTTP to thyroglobulin (416 moles dTTP/mole of protein dimer as 
calculated by absorbance of conjugate dialysates a t  280 nm) was made by the 
carbodiimide condensation method (13) and lOmg (protein) of this conjugate was 
coupled to 5g Activated CH-Sepharose 4B (Pharmacia). This was accomplished by 
following the suppliers' instructions for the initial preparation of this Sepharose and 
then by mixing it with the conjugate in 0.1M NaHCOy pH8.0 for lh  at ambient 
temperature on a roller mixer. A fter alternating acid and neutral washes with 0.1 M 
sodium acetate/CH^COOH acid in 0.5M NaCl, pH4.0 and 0.1M Tris/HCl in 0.5M NaCl, 
pH8.0 the immobilised ligand was ready for use, or could be stored for up to two weeks 
at 4°C in 0.1M NaHCO^ with 0.1% sodium azide as preservative.
A 3ml plastic column was filled with the immobilised ligand, and solubilised IgG 
equivalent to approximately 60 mg protein (concentration ascertained by U.V. 
absorbance at 280nm) was applied. A fter discarding the void volume, purified antibody 
was collected in the eluant, and in a column wash of 3ml 0.1M NaHCOy 0.1% sodium 
azide was added, and the antibody was stored a t 4°C. Immobilised antibodies binding 
to the ligand were eluted with 10ml 0.05M glycine/HCl, pH2.2, and the Sepharose was 
then re-equilibrated with NaHCOy for re-use.
The antibody was diluted in water just prior to each assay and added to all assay 
tubes except for to ta l count and non-specific binding tubes. Standard dUTP 
(Pharmacia) was made up as a lOOug/ml solution in water, aliquoted, and stored a t - 
40°C until required. It was diluted in 0.7 M Kh^PO^ for the RIA and was dispened 
using a Dilutrend (Boehringer). The standard curves, set up in duplicate in plastic
tubes (LP3 tubes, Luckham Limited, England), covered a range from 22pg (0.047pmol) 
to 1103pg (2.356pmol) of dUTP added. Zero standard binding tubes containing 
radiolabel and antiserum, but no dUTP were also set up as well as "total" and "non­
specific binding" tubes containing only assay diluent and radiolabel. A fter vortex- 
mixing, the tubes were incubated for 2-3 h in ice. Antibody bound and free ligand 
were then separated by the addition of ice-cold dextran-coated charcoal (2.5g% w/v 
activated charcoal (Sigma) coated with 0.25g% (w/v) Dextran T-70 (Pharmacia) to all 
except the "total" tubes. A fter mixing and standing in ice for 15 min, centrifugation 
was carried out at 1500g and 4°C for 10 minutes and aliquots of supernatant were 
taken for scintillation counting in 'Ultrafluor' (National Diagnostics, Aylesbury, 
England). The dUTP concentration in the fractions was calculated from the standard 
curve by on line data reduction. Using a smoothed spline fitting procedure (LKB- 
Pharmacia) A fter taking dilution factors of the assay into account, results were 
expressed as pmol dUTP/10^ cells.
Details of the protocol are shown in Table I .   ------------------------ -----  ---------------
Results and Discussion
Calculating from the absorbance of conjugate dialysates at 280nm, the dUTP; 
ovalbumin conjugation procedure yielded a conjugate with 9.58mole dUTP coupled per 
mol of protein. Six rabbits and three sheep have been immunised with this conjugate, 
and antibodies binding £ hP j  dUTP were obtained from seven animals. However, only 
in the antiserum from one rabbit (G/R/9) described here, were the t i tre  and affinity of 
the antibodies suitable for use in an RIA. Booster injections were given to G/R/9 a t  6- 
monthly ra ther than 3-monthly intervals as it was found tha t the more frequent boosts 
resulted in antiserum with a lower ti tre  and affinity than that resulting from 6 
monthly boosts. The titres  obtained from G/R/9 a f te r  boosting have ranged from 
1/1200 to 1/2800, maintaining a high plateau level for four to five weeks. The mean
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affinity constant (K) of the antiserum as determined by the method of Muller (14) for 
polyclonal antisera was 7.97 x 10^1itres/mol, and the sensitivity of the standard curve 
calculated by the method of Albano and Ekins (15) was 3.78fmol (Figure 1).
The specificity of the unpurified antiserum for dUTP is shown in Table 2 , 
Although the cross-reactivity with UTP was low (2.6%), the high concentrations of this 
NTP present relative to dUTP made essential the degradation of UTP by NalO^ in the 
cell ex tracts  lOng. (approx. 20 pmol) of standard UTP was added to RIA tubes and 
incubated with periodate and methylamine as described above. On quantitation with 
purified G/R/9 IgG, no immunoreactivity was detectable in these tubes, indicating 
satisfactory degradation of this ribotide under these conditions. The degree of cross- 
reactivity  shown by the antibody to dUMP and dUDP also demanded that separation of 
these compounds be made from dUTP before quantitation. Early work with HPLC 
separation, using an anion exchange column, resulted in so much 'down-time' tha t 
simple LC columns were used instead. The time taken for each separation run using 
LC was approximately lh , but several LC columns could be run at one time. The 
resolution with LC was however, found to be such that a long immunoreactive 'tail' 
from high concentrations of dUDP standard (lOOpmol) overlapped with the dUTP peak 
unless the elution volume of 10 column volumes of 0.3M KH^PO^ described here was 
employed. dUDP is not found in high concentrations in some normal or untreated 
cells, but it has been reported that a level of 7pmol/10^ control cells rose to 170 and 
185pmol/10^ cells, respectively, following trea tm ent with the anti-folate MTX and 
with CB3717 (10). The elution pattern of dUMP, dUDP and dUTP from the QAE A25 
columns is shown in Figure 2, as well as the profile of immunoreactive fractions from 
an ex trac t  FoF CB3717 trea ted  cells.
The early eluting peak from the cell extract, coming off the column immediately 
a fter the void volume, probably represents dUMP. It can be seen however tha t there is 
no evidence of a dUDP immunoreactive peak of fractions from this extract, and three 
other similar ex tracts  have shown the same absence of dUDP immunoreactivity. It is 
possible therefore  tha t A549 cells in contrast to the human lymphoblastoid cells used 
by Jackson e t  al (10), do not have significant pool sizes of dUDP a fte r  trea tm en t with 
TS inhibitors.
Although the process of coupling a protein to the small hapten molecule of any 
NTP or dNTP will unavoidably mask one or more sites on the hapten, giving rise to 
unwanted cross-reactions, the high degree of cross-reactivity with dTTP was an 
unexpected and unwelcome finding. It was thought tha t the protein in the conjugate 
was attached to dUTP via the phosphate groups and/or the 3'-OH group (13), thus 
leaving all substituents of the pyrimidine ring of dUTP to be clearly recognised by the 
antibody. Indeed, G/R/9 antibody does not significantly cross-react with dCTP which 
differs from dUTP only by the possession of an amino group a t  the 4 position on the 
base ring. It was noted tha t cross-reaction with dTTP increased with successive 
boosts, and it was suspected tha t a dTTP impurity in the standard dUTP used to make 
the conjugate may have caused this. The source of dUTP was changed, a new 
conjugate was made, and cross-reactivity of subsequent batches of G/R/9 antiserum 
with dTTP declined with the use of this conjugate from 12% to a minimum of 4.3%. 
Following affinity purification of one such antibody batch, cross-reactivity with dTTP 
fell from 5.9% to <0.027% (Table 3). This low degree of cross-reactivity was essential, 
as dTTP could be present in normal actively dividing cells in concentrations of 50pmol 
or more/10^ cells (10), while dUTP has been reported to be present as less than
0.3fmol/10^ normal cells (4), and has been undetectable in normal cells by methods 
available to date. The complete separation of dUTP from dTTP by chromatography 
was known to be difficult to accomplish, and using the LC method described above, 
dTTP and dUTP co-elute. Using purified antiserum however, no immunoreactive 
fractions were detected following chromatography of extracts of untreated sub­
confluent cells.
The inter-assay reproducibility of the standard curve using purified IgG is shown 
in Table 4, the results being obtained from six consecutive standard curves performed 
on different days. The affinity contant (K) for the purified IgG was calculated to be 
7.99 x 10 litres/mol and was thus remarkably unchanged from the value for the 
unpurified antiserum.
The standard curve sensitivity using purified IgG also remained as shown in 
Figure 1 when using whole antiserum. The RIA could very successfully be run in the 
column eluent (0.7M, KH^PO^), so tha t quantitation could be carried out directly on 
chromatography column fractions. The use of w ater to dilute the radiolabel and the 
antiserum for use in the RIA, thus lowering the molarity of the RIA diluent, was 
however found to result in a more sensitive standard curve than when these reagents 
were added diluted in 0.7M KH^PO^. Repetition of sample chromatography due to an 
"overload" of the RIA could be avoided by collecting the larger 0.8ml fractions and 
quantitating a range of aliquots from each fraction. Parallelism with the standard 
curve was shown by aliquots assayed in this way.
Recovery of a range of dUTP standard concentrations in w ater "extracted" into 
PCA and taken through the entire assay procedure, is shown in Table 5. A low 
recovery ra te  (36.2%) was found for the lowest concentration tested  (3.11pmol) and at 
no concentration were recoveries quantitative. However, there was good 
reproducibility a t all concentrations. It is not known with certain ty  where the losses 
occur. Standards of 3.11 and 7.84pmol dUTP applied directly to the chromatography 
column and quantitated by the RIA in aliquots from 0.8 ml fractions gave mean 
recoveries of 68.1% and 86.9% respectively (n=3), so it is probable tha t there is a small 
loss at each step of the procedure. Reproducibility of the assay was tested  in two 
extracts  of CB3717-treated cells, each being chromatographed and quantitated  five 
times on one day, and once on two other occasions. Good reproducibility was obtained 
both within and between assays, and the results are shown in Table 6.
Results of dUTP assays in A549 cells exposed for 24 h to 3 d ifferent 
concentrations of CB3717 are shown in Figure 3. A dose-response curve is clearly 
demonstrated, and further work is underway to assess the importance of dUTP and 
uracil incorporation into DNA in contributing to 'thymineless death' in cells exposed to 
CB3717 and other thymidylate synthase inhibitors and anti-folates, (4,5,6,10,16).
In summary, we describe the development and initial application of a sensitive 
assay for the measurement of dUTP in cell extracts! dUTP has proved particularly, 
difficult to measure to date, due to its low concentration, even in thymidylate 
synthase inhibited or anti-folate trea ted  cells, and to the difficulties of resolution of 
dUTP from dTTP by chromatography or by enzymic incorporation.
This work also serves to support an earlier observation, made with regard to 
dCTP (5), tha t  the immunogenicity of dNTPs coupled to proteins can stimulate the 
production of antibodies suitable for highly sensitive RIA quantitation of these 
compounds in the relatively small numbers of cells available from cultures or biopsies 
and tha t  RIA is a suitable procedure for the measurement of a NTPs. Difficulties of 
specificity due to cross reacting antibodies can be adequately resolved by chemical or 
chromatographic means, including affinity purification of the antiserum.
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Abbreviations Used
RIA Radioimmunoassay
TS Thymidylate Synthase
dNTPs Deoxyribonucleoside Triphosphates
NTPs Ribonucleoside Triphosphates
HPLC High Pressure Liquid Chromatography
PCA Perchloric Acid
CB3717 N-(4-(N-(2-amino-4-hydroxy-6-quinazolynyl)methyl)
prop-2-ynylamino)benzoyl)-L-glutamic acid 
LC Liquid Chromatography
MTX Methotrexate
DDMP Metoprine
5FdUTP 5-Fluorodeoxyuridine triphosphate
5FU 5-Fluorouracil
T able 1. dUTP RIA P rotocol.
Volume added to RIA tube (pi)
Reagent Total Non-specific 
binding
Zero
binding
Standard on 
Sample
Diluent 
(0.7M KhLPO, 
pH 4.4) Z 4
600 500 400 400 (containing 
standard or 
sample)
Radiolabel 100 100 100 100
Standard - - (Up to 400pl 
contained in 
diluent)
Antiserum - 100 100
Vortex-mix. Incubate in ice 2-3h.
Dextran-
coated
charcoal
- 100 100 100
Vortex-mix. Incubate for 15 min in ice.
Centifuge at 4°C for 10 min a t 1500g.
Remove 500pl of supernatant for liquid scintillation counting
"Ultrafluor"
scintillant
4000 4000 4000 4000
Table 2. Cross Reactivity  of G/R/9 Antiserum Before Affinity 
Purification
Compound Amount required to displace 
50% of zero binding
Percentage
cross-reactivity
dUTP 76 pg 100
UTP 2.5 ng 3.04
dUMP > 2 ng < 3.8
dUDP 180 pg 42.2
dTTP 635 pg 12.0
dCTP > 100 ng < 0.076
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Table 3 / Comparison of the Cross Reactivity of a Batch of G/R/9
IgG (Pool IV) with dUTP and dTTPi Before and After 
Affinity Purification.
Compound Amount required to displace 50% of Percentage cross-
zero binding using: reactivity  using:
Unpurified Purified Unpurified Purified
IgG IgG IgG IgG
dUTP 130pg 90pg 100 100
dTT.P 2.2ng 32.5ng 5.9 0.027
Tabled . Interassay Variation of dUTP Standard Curves Using
Purified G/R/9 Antibody (n=6).
Amount of dUTP added, pg (pmol)
22 51 74 147 221 367 514 1103
% B/BO
(0.047) (0.109) (0.158) (0.314) (0.472) (0.784) (1.098) (2.356)
Mean 84.2 74.0 67.4 47.2 38.9 26.9 21.1 11.7
S.D. 2.10 3.00 3.07 1.09 2.65 2.35 2.17 2.32
CV% 2.5 4.1 4.6. 2.3 6.8 8.7 10.2 19.8
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Table 5. Recovery of Standard dUTP Extracted, NalO /CH^Nh^
Treated, Chromatographed and Quantitated by KIA.
ng dUTP (pmol dUTP) % recovered mean S.D. C.V.%
1.46 (3.11) 37.1, 32.8, 38.9 36.2 3.13 8.65
3.67 (7.84) 69.9, 64.9, 73.9 69.6 4.51 6.47
7.33 (15.66) 59.8, 57.5, 61.7 59.7 2.10 3.50
14.66 (31.32) 62.6, 61.0, 62.5 61.1 1.80 3.10
Mean % recovery of a range of dUTP standard concentrations from
7.84 - 31.32 pmol = 63.7%
Table 6.
18
Reproducibility of dUTP Assay in Two Extracts  of CB3717 
Treated A549 Cells.
Sample Day of dUTP Evaluation of assay
number assay pmol/ml ex trac t results from Day 1
235 1 145.2, 122.8, 130.7, 123.3, 112.4 Mean = 126.8 S.D. =
2 126.7 12.13 C.V. = 9.5%
3 108.7
239 1 90.3, 93.0, 84.4, 86.9, 85.1 Mean = 87.95, S.D. =
2 80.1 3.65 C.V. = 4.1%
3 72.6
Figure 1
Figure 2
Figure 3
Standard Curve for dUTP Using G /R /9  Antiserum
Elution Profiles of Immunoreactive Fractions from a 5ml QAE A23 
Sephadex Column,
A, Separation of dUMP, dUDP and dUTP standards
B. Extract from Cells Exposed to 30pM CB3717 for 24h
dUTP Pools in A549 Cells Exposed to CB 3717 for 24 h, Figures represent 
means and error bars represent the standard deviations of duplicate 
samples from 4 experiments. No corrections were made for recovery.
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The Quantitative Determination of 2'-Deoxycytidine-5'-triphosphate 
in Cell Extracts by Radioimmunoassay
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A radioimmunoassay (RIA) capable of quantitating dCTP in femtomolar amounts in cell extracts 
has been developed, and applied to human fibroblast cell lines and L5178Y mouse lymphoma 
lines. Cross reactivity of the antibody with CTP, though low (2.7%) has necessitated pre-RIA 
removal of CTP by either boronate affinity gel chromatography or sodium periodate oxidation. 
Fractions from the boronate gel column or aliquots of NaI04-treated cell extract are quantitated 
directly by the RIA. Recovery of extracted dCTP standard taken through the entire procedure is 
quantitative and results are reproducible. Due to the high sensitivity of the quantitation step, 
dCTP can be accurately measured in relatively small numbers of cells—about 104 cells. © 1986
Academic Press, Inc.
Key W ords: radioimmune assay; affinity chromatography; nucleotides; cell extracts; anti­
metabolites; drug resistance.
dNTP concentrations are of great impor­
tance as indicators of antimetabolite drug ac­
tion and other perturbations in intracellular 
nucleotide pools. The pyrimidine deoxyribo- 
nucleoside triphosphates such as dCTP have 
proved difficult to quantitate due to their low 
concentrations and the presence, in 1 0 0 -fold 
or greater concentrations, of compounds of 
closely related molecular structure, such as 
CTP. The DNA polymerase assay of Solter 
and Handschumacher (1) has suitable sensi­
tivity but presents difficulties in performance. 
The other currently important method for 
measuring nucleotides, HPLC,1 has the ad­
vantage of measuring a large number of com­
pounds at one time, but dCTP does not resolve 
well from other nucleotides, and moreover its 
low concentration is difficult to measure ac­
curately by UV absorbance, which is the stan­
dard detection method.
1 Abbreviations used: RIA, radioimmunoassay; dNTPs, 
deoxyribonucleoside triphosphates; HPLC, high-pressure 
liquid chromatography; ara.c, cytosine arabinoside; PBS, 
phosphate-buffered saline; PCA, perchloric acid; BCG, 
Bacilli Calmette-Guerin.
We required a highly sensitive quantitation 
step for dCTP, because of our interest in the 
implication of this nucleotide in resistance to 
the antileukaemic agent, cytosine arabinoside 
(ara.c). The RIA developed to meet this re­
quirement is reported in this paper.
MATERIALS AND METHODS
Two types of cells, L 5178Y mouse lym­
phoma cells and human skin fibroblasts, were 
extracted for dCTP quantitation. The growth 
and preparation of these cells was carried out 
by Dr. Alan Lehmann at the M.R.C. Cell Mu­
tation Research Unit, University of Sussex, 
England. Three L 5178 Y lines were used, wild 
type and two ara.c. resistant lines, EB 192- 
03A (known to be deoxycytidine kinase defi­
cient) and 192-8 (2). Two human fibroblast 
lines, 1BR and 46 BR, were studied through­
out their growth cycle. 1BR was from a nor­
mal individual and 46BR from an immuno- 
deficient individual. 46BR cells were sensitive 
to a variety of mutagens and have a defect in 
DNA ligation. It is conceivable that the prop­
0003-2697/86 $3.00
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erties of this cell strain result from a distur­
bance in nucleotide metabolism. Cells grown 
in suspension culture (L5178Y) were centri­
fuged, washed once in cold PBS and recentri­
fuged. Fibroblasts, grown in monolayers, were 
harvested by removal of the medium, and 
trypsinization, followed by one cold PBS wash, 
and centrifugation. The cell pellets were frozen 
down at —70°C until extraction. Aliquots of 
each cell sample were taken for counting in a 
haemocytometer. The frozen cell pellet was 
extracted into ice-cold 0.4 M  PCA and vor- 
texed vigorously so that the pellet was thor­
oughly broken up. The extract was stood in 
ice for 30 min, then centrifuged at 4°C for 20 
min at 1500g. Aliquots of supernatant were 
taken into tubes containing 0.5 vol of ice-cold 
0.73 M  KOH in 0.16 M  KHCO3 . After vor- 
texing, the extracts were kept in ice for 1 h 
then centrifuged as before. Aliquots of super­
natant were then treated by boronate affinity 
chromatography or by NaI04 oxidation to 
remove ribotides prior to quantitation by 
the RIA.
Affinity chromatography of extracts. Boron­
ate affinity gel was made following the meth­
ods of Inman and Dintzis (3) and of Gehrke 
et al. (4). Bio-Gel P2, 200-400 mesh (Bio-Rad 
Laboratories Ltd.), was activated with hydra­
zine hydrate and succinylated with succinic 
anhydride; then m-amino-phenyl boronic acid 
(Aldrich Chemicals Co. Ltd., Dorset, England) 
was coupled on to the gel in the presence of 
EDC (1 -ethyl-3-(3-dimethylamino-propyl)- 
carbodiimide, Sigma Chemical Co.). The 
derivatized gel was stored in plastic containers 
at 4°C, in 0.1 M  NaCl with 0.1% sodium azide. 
Prior to use it was equilibrated with 5 vol 1 M 
ammonium acetate, pH 8.9, and 10 ml (2 g 
dry gel) was poured into a plastic K9/15 col­
umn (Pharmacia) filled with the same buffer. 
Extracts were applied to the column in 0.5 vol 
3 M  CH3COONH4 , pH 8.9. Fractions were 
collected and were either assayed the same day 
or stored at —70°C. The RIA was performed 
directly on the fractions after adjustment of 
the pH to 6.2 with acetic acid. To dissociate 
complexed ribotides the gel was washed with
10 vol of distilled water on a Buchner funnel 
under gentle vacuum, then reequilibrated on 
the Buchner funnel with 5 vol of 1 M 
CH3COONH4, pH 8.9, and repoured ready 
for the next extract.
Sodium periodate treatment of extracts. A 
0.5-ml extract was treated by the addition of 
20 /A of 0.5 M  sodium periodate followed after 
5 min by 25 jil of 4 M  methylamine, pH 7.5 
(5). After 30 min incubation at 37°C, 10 /il of 
1 M  rhamnose was added to remove excess 
periodate and quantitation of treated extract 
was performed by the addition of 1 0 , 2 0 , or 
50 n 1 aliquots of RIA assay diluent.
Radioimmunoassay. Standard nucleosides 
and nucleotides were purchased from Sigma, 
and were stored aliquoted in 100 Mg/ml so­
lutions at —70°C. Assay diluent was 1 M  
CH3COONH4 brought to pH 6.2 with acetic 
acid. [3H]Deoxycytidine-5-triphosphate (NET 
601, specific activity 60 Ci/mmol) was pur­
chased from the New England Nuclear Com­
pany, and was diluted for each assay so that 
18 pg (38.5 fM) of [3H]dCTP was added to all 
assay tubes.
dCTP antibody was raised in a Half-lop 
rabbit in response to a prime and one boost 
with a conjugate of dCTP:ovalbumin made 
by the carbodiimide condensation method of 
Halloran and Parker (6 ). The rabbit was 
primed with 2.5 mg of conjugate and 100 /xl 
BCG (Glaxo Laboratories, England) in normal 
saline, emulsified with 2  parts of mineral oil. 
Four intramuscular and four subcutaneous 
injections were made in the backlegs and 
across the neck. Booster injections, given at 3 
monthly intervals, omitted the BCG. The rab­
bit was bled at 9 and 14 days after injection 
of conjugate.
The antibody was diluted 1:90 and added 
to all assay tubes except for total count and 
nonspecific binding tubes. The standard curve 
was set up in duplicate in plastic tubes (LP3 
tubes, Luckham Ltd, England) and covered a 
range from 5 pg (10.7 fM) to 300 pg (642 fM) 
of dCTP added. Zero standard binding tubes 
containing radiolabel and antiserum, but no 
dCTP, were also set up. Incubation was for 1
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h, in ice, after which antibody bound and free 
ligand were separated by the addition of ice- 
cold dextran-coated charcoal (2.5% (w/v), ac­
tivated charcoal (Sigma) coated with 0.25 g% 
w/v Dextran T-70 (Pharmacia)). After centri­
fuging at 4°C for 10 min at 1500& aliquots of 
the supernatant were taken for liquid scintil­
lation counting in “Ultrafluor” (National Di­
agnostics, Aylesbury, England). The concen­
tration of samples was calculated from the 
standard curve, and after dilution factors were 
taken into account, the results were expressed 
in picomolar amounts of dCTP/106 cells.
RESULTS AND DISCUSSION
The dCTP:ovalbumin conjugation proce­
dure yielded a conjugate with 15 mol dCTP 
coupled per mol of ovalbumin. This was cal­
culated from the UV absorbance of the con­
jugate dialysates at 280 nm. Of five rabbits 
and six sheep immunized with the conjugate, 
nine animals responded by producing anti­
bodies which bound to [3H]dCTP, but titers 
and affinity were too low to allow assay de-
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Fig. 1. Standard curve for dCTP using G/R/6 antiserum.
TABLE 1
Cross-reactivity of 2 dCTP Rabbit Antisera: 
G/R/3 and G/R/6
Compound
Amount required 
to displace 50% 
of zero binding
Percentage
Cross-reactivity
G/R/3 G/R/6 G/R/3 G/R/6
dCTP 30 pg 13.5 pg 100 100
CTP 50 pg 500 pg 60 2.7
dCDP 44 pg 190 pg 67 7.1
dCMP 390 pg 650 pg 0.079 2.1
dCyd >10 Mg >10 ^ <0.0003 <0.00014
Ara.CTP 68 ng 10.3 ng 44 0.13
dUTP >1 Mg >500 ng <0.003 <0.03
dTTP >1 Mg >100 ng <0.003 <0.013
dUMP >1 Mg >10 Mg <0.003 <0.00014
dATP >1 Mg — <0.003 —
dGTP >1 Mg — <0.003 —
velopment except in two rabbits, G/R/3 and 
G/R/6 . Initial titer of G/R/3 antiserum was 
1:150, the affinity constant (K ) as determined 
by a Scatchard plot was 7.083 X 1010 liters/ 
mol and sensitivity of the standard curve, cal­
culated by the method of Albano and Ekins 
(7) was 40 fM. Initial titer of G/R/ 6  antiserum 
was 1:90, K  = 4.178 X 1011 liters/mol and 
standard curve sensitivity was 5.78 fM (Fig. 1). 
The specificity of these antisera for dCTP 
compared with structurally similar com­
pounds is shown in Table 1. The high-cross 
reactivity shown by G/R/3 antiserum with 
CTP (60%) can be utilized in measuring this 
compound after suitable separation from 
dCTP, but because of its better affinity and 
specificity, G/R/ 6  antiserum has been used to 
obtain the results described here.
The reproducibility of the standard curve is 
shown in Table 2, which summarizes data ob­
tained from seven consecutive standard curves 
performed on different days.
The chromatography eluant 1 M  CH3- 
COONH4, was used to set up the standard 
curve, as it was found that the RIA worked 
well in this unusual diluent, and that therefore 
chromatography column fractions needed no 
treatment before quantitation except adjust­
ment of pH. The standard curve was signifi­
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TABLE 2
Interassay Variation of dCTP Standard Curves U sing G/R/6 Antibody (n = 7) 
%B/bo = %Bound/%Bound at Zero
Amount of dCTP added, pg (pM)
10 20 30 50 70 100 150 300
(0.021) (0.042) (0.064) (0.107) (0.149) (0.214) (0.321) (0.642)
Mean 81.9 66.8 55.9 43.3 33.5 28.1 20.1 11.7
SD 1.99 1.71 1.71 2.11 1.67 1.11 1.73 1.58
CV(%) 2.43 2.56 3.06 4.88 4.99 3.95 8.61 13.5
cantly improved, with increased sensitivity, 
when the pH was altered from 8.9 (pH of the 
column eluant) to pH 6.2.
Although cross-reactivity of G/R/ 6  antise­
rum with CTP was only 2.7%, it was still too 
high to allow dCTP concentrations in cell ex­
tracts to be quantitated directly by the RIA. 
The choice of method for pre-RIA removal of 
CTP lay between boronate affinity chroma­
tography and NaI0 4  oxidation followed by 
amine cleavage of the product with CH3NH2. 
While the latter method was easier and much 
quicker to perform, it was noted that in the 
experience of some workers (8 ) NaI04/ 
CH3NH2 treatment of biological samples did 
not consistently destroy all the ribotides, al­
though in standard mixtures degradation was 
always complete. Boronate affinity chroma­
tography was therefore a more certain way of 
moving all endogenous ribotides provided that 
the gel used was sufficiently highly derivatized 
with phenylboronic acid and that optimal 
conditions of pH and ionic composition and 
strength were employed (9). The gel made by 
us was much cheaper than similar commer­
cially available gels, and took only a few hours 
spread over 3 days to make. Derivatization 
was 1 . 1 0  meq of boronate per gram of dry gel 
as determined by the absorbance at 293 nm 
of unreacted m-amino-phenylboronic acid in 
the supernatant fluid of the reaction mixture. 
This gel has been used frequently over a period 
of 1 year with no apparent deterioration. Two 
grams (=10 ml wet gel) retained up to 5 ng
(0.01 juM) of CTP using our conditions. Typ­
ical elution patterns of immunoreactive frac­
tions collected from a 1 0 -ml gel column after 
application of cell extracts are shown in Fig.
2. Each sample takes approximately 20 min
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Fig. 2. Typical elution patterns o f immunoreactive 
fractions from the boronate affinity gel column. (A) 46 
BR, Day 7; (B) 500 pg standard dCTP applied directly to 
the column; (C) 46 BR, Day 1. (i) Change from 
C H 3 C O O N H 4  to H 2 0 .
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to chromatograph, and the process is much 
slower and more cumbersome than Nal04 
oxidation.
It was found that the addition of up to 50 
p\ ofNaI04/CH3NH2 treated blank “extract” 
to the standard curve did not affect the zero 
standard binding or alter the shape of the 
curve. When 50, 20, and 10 p\ of sample ex­
tract were assayed, they were found to dilute 
out parallel to the standard curve. However, 
the addition of 100 pi or more of NaI04/  
CH3NH2-treated blank changed the zero 
binding and nonspecific binding as well as the 
shape of the standard curve, and samples did 
not dilute out parallel to the standard curve, 
even when a curve was set up containing the 
appropriate amount of blank-treated extract.
Results obtained when comparing these two 
methods of pre-RIA treatment of 15 cell ex­
tracts are shown in Fig. 3, and this shows a 
good correlation between results obtained us­
ing these two methods of ribotide removal in 
these samples. It is probable that even if 
NaI04/CH3NH2 degradation of CTP does not 
go to completion in every sample, because of 
the low cross-reactivity of G/R/6 antiserum
PM /10
C ells
P M /1 0
C e l l sMETHOD A
Fig. 3. Comparison of results obtained following chro­
matographic (Method A) and NaI04 (Method B) pre-RIA 
treatment of sample extracts. Linear regression analysis of 
the data shows: slope = 1.00399; mean of x  values = 8.647; 
mean of y  values = 9.103; intercept = 0.422; correlation 
coefficient = 0.9879; p  >  0.05.
TABLE 3
Recovery of 1 ng (2.14 pM) Standard dCTP Taken 
THROUGH THE ENTIRE ASSAY PROCEDURE
% dCTP recovered following:
Boronate
chromatography NaI04 oxidation
80.3, 96.4, 71.6, 88.4, 92.6, 107.8,
73.6, 81.5, 63.0, 96.3, 87.1, 88.1,
66.0 97.4
n 7 8
Mean 76.06 92.43
SD 11.25 8.06
CV (%) 14.78 8.72
with CTP the quicker oxidation method can 
be used routinely for pre-RIA treatment of ex­
tracts.
Recovery of 1 ng (2.14 pM) of dCTP “ex­
tracted” from water into PCA and quantitated 
after affinity chromatography or NAI04 oxi­
dation is shown in Table 3. Recovery was 
higher and more reproducible following 
NaI04/CH3NH2 treatment than after chro­
matography, and it had been notable that re­
covery of standard dCTP directly applied to 
the boronate column, i.e., not subjected to ex­
traction into PCA, had shown similar unsat­
isfactory recovery data. The reason for this is 
not known.
Results of dCTP assay in L5178Y cells and 
human fibroblasts are shown in Table 4. The 
two mutant strains of L5178Y cells, 192-8 and 
EB 192-03A, described by Rogers et al. (2), 
were grown in suspension culture with expo­
nential kinetics for several generations. The 
two mutant strains described here were har­
vested at the same time as the wild type. The 
deoxycytidine kinase deficient line EB192- 
03A, as would be expected had a significantly 
lower dCTP concentration (1.3 pM/106 cells), 
whereas the 192-8 strain, known to be normal 
as regards deoxycytidine kinase level and ac­
tivity, but still resistant to ara-c, showed a 
greatly increased dCTP concentration (83.5 
pmol/106 cells). The presence in 192-8 cells of
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TABLE 4
dCTP Concentration in Three Strains of M ouse 
Lymphoma Cells and in Human Fibroblasts
THROUGHOUT THE GROWTH CYCLE
dCTP pM/1*0® cells
Cell type
Following
chromatography
Following
NaIO„/CH3NH2
L5178Y wild type 22.0, 27.3, 28.4 _
L5178Y 192-8 87.8, 79.2 —
L5178Y EB 192-03A 1.34, 1.26 —
Human fibroblast 1 
BR
Day 1 34.2, 28.4 30.8
2 22.5, 18.3 18.4
3 5.6 6.7
7 1.3 0.89
Human fibroblast 46 
BR
Day 1 21.9 25.8
2 5.5, 5.6 7.4
3 3.4, 5.5 5.4
7 3.3 2.7, 4.7
Note. Where more than one result is given, this indicates assays 
done on different days.
this high dCTP pool could account for their 
resistance to ara-c which, in its triphosphate 
form, competes with dCTP for incorporation 
into DNA (10). The human fibroblasts grow 
as monolayers until they reach confluence, 
when division ceases due to contact inhibition, 
thus the proportion of cells undergoing divi­
sion declines as cultures approach confluence. 
This is reflected by the reduction in dCTP 
concentrations through the growth cycle (Ta­
ble 4). These preliminary experiments do not 
reveal any significant differences in the dCTP 
concentrations between cells from a normal 
individual and mutagen sensitive cells from 
an immunodeficient patient (46BR).
In summary, we describe a highly sensitive 
method for measuring dCTP in cell extracts, 
and have shown that the immunogenicity of 
dCTP, when coupled to a protein carrier, is 
such that the principle of RIA can be applied 
to other dNTPs which are difficult to quanti­
tate by HPLC. This particularly applies to the 
pyrimidine dNTPs, dUTP and dTTP, also of 
great interest in the study of antimetabolite 
drug action and mechanisms of drug resis­
tance.
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